thmo20200930

0001437749-20-023634.txt : 20201112 0001437749-20-023634.hdr.sgml : 20201112 20201112162208 ACCESSION NUMBER: 0001437749-20-023634 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 53 CONFORMED PERIOD OF REPORT: 20200930 FILED AS OF DATE: 20201112 DATE AS OF CHANGE: 20201112 FILER: COMPANY DATA: COMPANY CONFORMED NAME: ThermoGenesis Holdings, Inc. CENTRAL INDEX KEY: 0000811212 STANDARD INDUSTRIAL CLASSIFICATION: LABORATORY APPARATUS & FURNITURE [3821] IRS NUMBER: 943018487 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 333-82900 FILM NUMBER: 201307063 BUSINESS ADDRESS: STREET 1: 2711 CITRUS ROAD CITY: RANCHO CORDOVA STATE: CA ZIP: 95742 BUSINESS PHONE: 9168585100 MAIL ADDRESS: STREET 1: 2711 CITRUS ROAD CITY: RANCHO CORDOVA STATE: CA ZIP: 95742 FORMER COMPANY: FORMER CONFORMED NAME: CESCA THERAPEUTICS INC. DATE OF NAME CHANGE: 20140221 FORMER COMPANY: FORMER CONFORMED NAME: THERMOGENESIS CORP DATE OF NAME CHANGE: 19951117 FORMER COMPANY: FORMER CONFORMED NAME: INSTA COOL INC OF NORTH AMERICA DATE OF NAME CHANGE: 19920703 10-Q 1 thmo20200930_10q.htm FORM 10-Q thmo20200930_10q.htm

Table of Contents

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington D.C. 20549

FORM 10-Q

☒	Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the quarterly period ended September 30, 2020.

☐	Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the transition from _____________ to _______________.

Commission File Number: 333-82900

ThermoGenesis Holdings, Inc.

(Exact name of registrant as specified in its charter)

Delaware

(State of incorporation)

94-3018487

(I.R.S. Employer Identification No.)

2711 Citrus Road

Rancho Cordova, California 95742

(Address of principal executive offices) (Zip Code)

(916) 858-5100

(Registrant’s telephone number, including area code)

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading symbol(s)	Name of each exchange on which registered
Common Stock, $.001 par value	THMO	Nasdaq Capital Market

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.

Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).

Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer ☐ Accelerated filer ☐ Non-accelerated filer ☒ Smaller reporting company ☒ Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).

Yes ☐ No ☒

Indicate the number of shares outstanding of each of the issuer’s classes of common stock, as of the latest practicable date.

Class		Outstanding at November 10, 2020
Common stock, $.001 par value		7,796,170

Table of Contents

ThermoGenesis Holdings, Inc.

INDEX

		Page Number
Part I Financial Information

Item 1.	Financial Statements	1

Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	22

Item 3.	Quantitative and Qualitative Disclosures about Market Risk	30

Item 4.	Controls and Procedures	30

Part II Other Information

Item 1.	Legal Proceedings	31
Item 1A.	Risk Factors	31
Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds	32
Item 3.	Defaults upon Senior Securities	32
Item 4.	Mine Safety Disclosure	32
Item 5.	Other Information	32
Item 6.	Exhibits	33

Signatures		34

Table of Contents

PART I - FINANCIAL INFORMATION

Item 1. Financial Statements

ThermoGenesis Holdings, Inc.

Condensed Consolidated Balance Sheets

	September 30, 2020			December 31, 2019
	(Unaudited)
ASSETS
Current assets:
Cash and cash equivalents	$	4,436,000		$	3,157,000
Restricted cash		--			1,000,000
Accounts receivable, net of allowance for doubtful accounts of $220,000 ($226,000 at December 31, 2019)		1,698,000			1,278,000
Inventories, net of reserves of $755,000 ($350,000 at December 31, 2019)		5,876,000			3,824,000
Prepaid expenses and other current assets		766,000			602,000
Total current assets		12,776,000			9,861,000

Equipment and leasehold improvements, net		1,537,000			2,028,000
Right-of-use operating lease assets, net		765,000			859,000
Goodwill		781,000			781,000
Intangible assets, net		1,382,000			1,467,000
Other assets		48,000			218,000
Total assets	$	17,289,000		$	15,214,000

LIABILITIES AND STOCKHOLDERS’ EQUITY
Current liabilities:
Accounts payable	$	1,661,000		$	1,447,000
Accrued payroll and related expenses		513,000			288,000
Deferred revenue – short-term		700,000			620,000
Interest payable – related party		1,519,000			1,869,000
Note payable – short-term		235,000			--
Other current liabilities		1,092,000			2,461,000
Total current liabilities		5,720,000			6,685,000

Convertible promissory note – related party, less debt discount of $4,893,000 ($5,195,000 at December 31, 2019)		5,107,000			3,518,000
Convertible promissory notes, less debt discount of $588,000 (plus debt premium of $46,000 at December 31, 2019)		412,000			413,000
Note payable		411,000			1,000,000
Operating lease obligations – long-term		648,000			761,000
Deferred revenue – long-term		1,669,000			1,901,000
Other noncurrent liabilities		20,000			20,000
Total liabilities		13,987,000			14,298,000

Commitments and contingencies

Stockholders’ equity:
Preferred stock, $0.001 par value; 2,000,000 shares authorized, none outstanding		--			--
Common stock, $0.001 par value; 350,000,000 shares authorized; 6,832,040 issued and outstanding (2,843,601 at December 31, 2019)		7,000			3,000
Additional paid in capital		253,537,000			237,313,000
Accumulated deficit		(250,434,000	)		(236,932,000	)
Accumulated other comprehensive loss		22,000			2,000
Total ThermoGenesis Holdings, Inc. stockholders’ equity		3,132,000			386,000

Noncontrolling interests		170,000			530,000
Total equity		3,302,000			916,000
Total liabilities and equity	$	17,289,000		$	15,214,000

See accompanying notes.

Table of Contents

ThermoGenesis Holdings, Inc.

Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited)

	Three Months Ended September 30,						Nine Months Ended September 30,
	2020			2019			2020			2019

Net revenues	$	2,355,000		$	4,058,000		$	7,797,000		$	11,325,000
Cost of revenues		844,000			2,163,000			7,426,000			6,220,000

Gross profit		1,511,000			1,895,000			371,000			5,105,000

Expenses:

Sales and marketing		539,000			502,000			1,424,000			1,227,000
Research and development		750,000			584,000			1,937,000			1,758,000
General and administrative		1,305,000			1,139,000			4,489,000			3,617,000

Total operating expenses		2,594,000			2,225,000			7,850,000			6,602,000

Loss from operations		(1,083,000	)		(330,000	)		(7,479,000	)		(1,497,000	)

Other income (expenses):
Interest expense		(1,531,000	)		(1,188,000	)		(6,377,000	)		(3,531,000	)
Loss on equity method investments		--			--			(13,000	)		--
Loss on extinguishment of debt		--			(840,000	)		--			(840,000	)
Other income (expense)		5,000			(15,000	)		7,000			(27,000	)

Total other expense		(1,526,000	)		(2,043,000	)		(6,383,000	)		(4,398,000	)

Net loss		(2,609,000	)		(2,373,000	)		(13,862,000	)		(5,895,000	)

Loss attributable to noncontrolling interests		(146,000	)		(91,000	)		(360,000	)		(445,000	)
Net loss attributable to common stockholders	$	(2,463,000	)	$	(2,282,000	)	$	(13,502,000	)	$	(5,450,000	)

COMPREHENSIVE LOSS
Net loss		(2,609,000	)		(2,373,000	)		(13,862,000	)		(5,895,000	)
Other comprehensive loss:
Foreign currency translation adjustments gain (loss)		(19,000	)		16,000			20,000			9,000
Comprehensive loss		(2,628,000	)		(2,357,000	)		(13,842,000	)		(5,886,000	)

Comprehensive loss attributable to noncontrolling interests		(146,000	)		(91,000	)		(360,000	)		(445,000	)
Comprehensive loss attributable to common stockholders	$	(2,482,000	)	$	(2,266,000	)	$	(13,482,000	)	$	(5,441,000	)

Per share data:

Basic and diluted net loss per common share	$	(0.37	)	$	(0.78	)	$	(2.36	)	$	(2.00	)

Weighted average common shares outstanding basic and diluted		6,711,664			2,913,198			5,728,105			2,720,502

See accompanying notes.

Table of Contents

ThermoGenesis Holdings, Inc.

Condensed Consolidated Statements of Equity (Unaudited)

For the Nine Months Ended September 30, 2020

	Shares		Common stock		Paid in capital in excess of par		Accumulated deficit			AOCL*			Non-controlling interests			Total equity
Balance at January 1, 2020		2,843,601	$	3,000	$	237,313,000	$	(236,932,000	)	$	2,000		$	530,000		$	916,000

Stock-based compensation expense		--		--		67,000		--			--			--			67,000
Exercise of pre-funded warrants		100,000		--		10,000		--			--			--			10,000
Exercise of warrants		7,866		--		47,000		--			--			--			47,000
Discount due to beneficial conversion features		--		--		1,869,000		--			--			--			1,869,000
Conversion of related party note payable to common stock		1,666,670		2,000		2,998,000		--			--			--			3,000,000
Conversion of note payable to common stock		100,000		--		180,000		--			--			--			180,000
Issuance of common stock, net		1,050,748		1,000		3,220,000		--			--			--			3,221,000
Foreign currency translation gain		--		--		--		--			38,000			--			38,000
Net loss		--		--		--		(4,602,000	)		--			(141,000	)		(4,743,000	)
Balance at March 31, 2020		5,768,885		6,000		245,704,000		(241,534,000	)		40,000			389,000			4,605,000

Stock-based compensation expense		--		--		314,000		--			--			--			314,000
Exercise of pre-funded warrants		224,445				22,000		--			--			--			22,000
Exercise of warrants		267,271		--		1,604,000		--			--			--			1,604,000
Discount due to beneficial conversion features		--		--		3,112,000		--			--			--			3,112,000
Conversion of note payable to common stock		104,445		1,000		188,000		--			--			--			189,000
Issuance of Common Stock, net		344,419		--		1,993,000		--			--			--			1,993,000
Foreign currency translation gain		--		--		--		--			1,000			--			1,000
Net loss		--		--		--		(6,437,000	)					(73,000	)		(6,510,000	)
Balance at June 30, 2020		6,709,465		7,000		252,937,000		(247,971,000	)		41,000			316,000			5,330,000

Stock-based compensation expense		--		--		234,000		--			--			--			234,000
Issuance of Common Stock, net		122,575		--		366,000		--			--			--			366,000
Foreign currency translation loss		--		--		--		--			(19,000	)		--			(19,000	)
Net loss		--		--		--		(2,463,000	)		--			(146,000	)		(2,609,000	)
Balance at September 30, 2020		6,832,040	$	7,000	$	253,537,000	$	(250,434,000	)	$	22,000		$	170,000		$	3,302,000

* Accumulated other comprehensive loss.

See accompanying notes.

Table of Contents

ThermoGenesis Holdings, Inc.

Condensed Consolidated Statements of Equity (Unaudited)

For the Nine Months Ended September 30, 2019

	Shares		Common stock		Paid in capital in excess of par			Accumulated deficit			AOCL*			Non-controlling interests			Total equity
Balance at January 1, 2019		2,168,337	$	2,000	$	235,888,000		$	(227,435,000	)	$	(13,000	)	$	(1,711,000	)	$	6,731,000

Stock-based compensation		--		--		81,000			--			--			--			81,000
Exercise of pre-funded warrants		50,000		--		5,000			--			--			--			5,000
Discount due to beneficial conversion features		--		--		1,513,000			--			--			--			1,513,000
Reorganization of subsidiary and related change in non-controlling interest		--		--		(2,843,000	)		--			--			2,843,000			--
Foreign currency translation loss		--		--		--			--			(4,000	)		--			(4,000	)
Net loss		--		--		--			(1,871,000	)		--			(176,000	)		(2,047,000	)
Balance at March 31, 2019		2,218,337		2,000		234,644,000			(229,306,000	)		(17,000	)		956,000			6,279,000

Stock-based compensation		--		--		125,000			--			-			--			125,000
Exercise of pre-funded warrants		150,000		--		18,000			--			--			--			18,000
Discount due to beneficial conversion features		--		--		800,000			--			--			--			800,000
Issuance of pre-funded warrants in financing, net of offering costs		--		--		756,000			--			--			--			756,000
Foreign currency translation		--		--		--			--			(3,000	)		--			(3,000	)
Net loss		--		--		--			(1,297,000	)		--			(178,000	)		(1,475,000	)
Balance at June 30, 2019		2,368,337		2,000		236,343,000			(230,603,000	)		(20,000	)		778,000			6,500,000

Stock-based compensation		--		--		253,000			--			--			--			253,000
Exercise of pre-funded warrants		216,500		1,000		18,000			--			--			--			19,000
Conversion of note payable to stock		120,000		--		216,000			--			--			--			216,000
Foreign currency translation gain		--		--		--			--			16,000						16,000
Net loss		--		--		--			(2,282,000	)		--			(91,000	)		(2,373,000	)
Balance at September 30, 2019		2,704,837	$	3,000	$	236,830,000		$	(232,885,000	)	$	(4,000	)	$	687,000		$	4,631,000

* Accumulated other comprehensive loss.

See accompanying notes.

Table of Contents

ThermoGenesis Holdings, Inc.

Condensed Consolidated Statements of Cash Flows (Unaudited)

	Nine Months Ended September 30,
	2020			2019
Cash flows from operating activities:
Net loss	$	(13,862,000	)	$	(5,895,000	)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization		569,000			604,000
Stock based compensation expense		615,000			459,000
Amortization of debt discount/premium, net		2,165,000			1,799,000
Amortization of accelerated debt discount due to conversion		2,486,000			--
Reserve for excess and slow-moving inventories		4,036,000			141,000
Reserve for bad debt expense		(6,000	)		(53,000	)
Change in fair value derivative		--			2,000
Loss on disposal of equipment		118,000			20,000
Loss on extinguishment of debt		--			840,000
Net change in operating assets and liabilities:
Accounts receivable		(414,000	)		(2,908,000	)
Inventories		(6,086,000	)		980,000
Prepaid expenses and other assets		6,000			(227,000	)
Accounts payable		223,000			(542,000	)
Interest payable - related party		(350,000	)		(116,000	)
Accrued payroll and related expenses		225,000			(298,000	)
Deferred revenue – short-term		80,000			354,000
Other current liabilities		(1,326,000	)		(145,000	)
Long-term deferred revenue and other noncurrent liabilities		(338,000	)		1,467,000
Net cash used in operating activities		(11,859,000	)		(3,518,000	)

Cash flows from investing activities:
Capital expenditures		(23,000	)		(178,000	)
Net cash used in investing activities		(23,000	)		(178,000	)

Cash flows from financing activities:
Proceeds from convertible promissory note-related party		4,287,000			1,513,000
Payments on financing lease obligations		(32,000	)		(15,000	)
Proceeds from issuance of common stock, net of expenses		5,580,000			756,000
Proceeds from exercise of options, warrants and pre-funded warrants		1,683,000			42,000
Proceeds from long-term debt		--			1,800,000
Proceeds from note payable		646,000			--
Net cash provided by financing activities		12,164,000			4,096,000

Effects of foreign currency rate changes on cash and cash equivalents		(3,000	)		--
Net increase (decrease) in cash, cash equivalents and restricted cash		279,000			400,000

Cash, cash equivalents and restricted cash at beginning of period		4,157,000			3,400,000
Cash, cash equivalents and restricted cash at end of period	$	4,436,000		$	3,800,000

Supplemental disclosures of cash flow information:
Cash paid for interest	$	2,094,000		$	1,613,000
Supplemental non-cash financing and investing information:
Recording of beneficial conversion feature on debt	$	4,981,000		$	2,313,000
Right-to-use asset acquired under operating lease	$	--		$	966,000
Related party promissory note converted to common stock	$	3,000,000		$	--
Fair value of amended convertible note issued in connection with the extinguishment of original convertible note	$	--		$	1,473,000
Convertible promissory note converted to common stock	$	369,000		$	216,000
Transfer of equipment to inventories	$	--		$	33,000

See accompanying notes.

Table of Contents

ThermoGenesis Holdings, Inc.

Notes to Condensed Consolidated Financial Statements

(Unaudited)

1. DESCRIPTION OF BUSINESS, BASIS OF PRESENTATION AND GOING CONCERN

Organization and Basis of Presentation

ThermoGenesis Holdings, Inc. (“ThermoGenesis Holdings,” the “Company,” “we,” “our,” “us”) develops, commercializes and markets a range of automated technologies for CAR-T and other cell-based therapies. The Company currently markets a full suite of solutions for automated clinical biobanking, point-of-care applications, and automation for immuno-oncology, including its semi-automated, functionally closed CAR-TXpress™ platform, which streamlines the manufacturing process for the emerging CAR-T immunotherapy market. The Company was founded in 1986 and is registered in the State of Delaware and headquartered in Rancho Cordova, CA.

The Company previously had two reportable segments, a Device Segment and a Clinical Development Segment. Due to the winding down of the Clinical Development Segment in 2019, the Company no longer has any material revenues or expenses in that segment. As a result, the Company’s chief operating decision maker no longer reviews unconsolidated operating results and the Company no longer reports in two segments. The Company provides the AutoXpress^® and BioArchive^® platforms for automated clinical bio-banking, PXP^® platform for point-of-care cell-based therapies and CAR-TXpress™ platform under development for bio-manufacturing for immuno-oncology applications. The Company and its subsidiaries currently manufacture and market the following products:

Clinical Bio-Banking Applications:

●

AXP^®Automated Cell Separation System – an automated, fully closed cell separation system for isolating and retrieving stem and progenitor cells from umbilical cord blood.

●

BioArchive^® Automated Cryopreservation System – an automated, robotic, liquid nitrogen controlled-rate-freezing and cryogenic storage system for cord blood samples and cell therapeutic products used in clinical applications.

Point-of-Care Applications:

●

PXP^®Point-of-Care System – an automated, fully closed, sterile system allows for the rapid, automated processing of autologous peripheral blood or bone marrow aspirate derived stem cells at the point-of-care, such as surgical centers or clinics.

Large Scale Cell Processing and Biomanufacturing:

●

X-Series^® Products: X-Lab^® for cell isolation, X-Wash^® System for cell washing and reformulation, X-Mini^® for high efficiency small scale cell purification, and X-BACS™ System under development for large scale cell purification using our proprietary buoyance-activated cell sorting (“BACS”) technology.

●

CAR-TXpress™ Platform – a modular designed, functionally closed platform that addresses the critical unmet need for large scale cellular processing and chemistry, manufacturing and controls (“CMC”) needs for manufacturing chimeric antigen receptor (“CAR”) T cell therapies. CAR-TXpress Bio, Inc. (“CARTXpress Bio”) is owned and developed through a subsidiary in which we own 80% of the equity interest.

Table of Contents

COVID-19 Testing Kit:

●

Antibody Test – The ThermoGenesis SARS-CoV-2 IgM/IgG Antibody Test Kit is a single-use rapid immunochromatographic test for the qualitative detection and differentiation of Immunoglobulin M (IgM) and Immunoglobulin G (IgG) antibodies to SARS-CoV-2 in human serum, plasma (heparin, dipotassium EDTA, and sodium citrate), and venous whole blood (heparin, dipotassium EDTA, and sodium citrate).

On January 1, 2019, the Company entered into a reorganization of the business and equity ownership of its majority-owned ThermoGenesis Corp. subsidiary. Pursuant to the reorganization, the assets acquired by ThermoGenesis Corp. from SynGen Inc. in July 2017 were contributed to a newly formed Delaware subsidiary of ThermoGenesis Corp., CARTXpress Bio, and the 20% interest in ThermoGenesis Corp. held by a third party was exchanged for 20% interest in CARTXpress Bio. As a result, the Company holds an 80% equity interest in CARTXpress Bio and the Company has become the owner of 100% of ThermoGenesis Corp. The purpose of the reorganization was to allow CARTXpress Bio to focus on the development and commercialization of the newly launched CARTXpress Bio cellular manufacturing platform.

In the reorganization, the Company reacquired the non-controlling interest shares in ThermoGenesis Corp., which had an accumulated deficit of $1,711,000, in exchange for 20% equity interest in the newly formed subsidiary, CARTXpress Bio, which amounted to approximately $1,100,000. The total amount of $2,843,000 related to the reorganization of subsidiary and the related increase in non-controlling interest was partially offset by a charge to additional paid in capital in stockholders’ equity.

On November 26, 2019 the Company entered into a joint venture agreement with HealthBanks Biotech Inc. (“HealthBanks”), an affiliate of the Boyalife Group, to form a new company called ImmuneCyte, Inc. (“ImmuneCyte”) to commercialize the Company’s proprietary cell processing platform, CAR-TXpress™, for use in immune cell banking as well as for cell-based contract development and manufacturing services (CMO/CDMO). Under the terms of the JV Agreement, ImmuneCyte was initially owned 80% by HealthBanks and 20% by the Company. The Company currently owns 18.79% of the equity of ImmuneCyte.

ThermoGenesis Holdings is an affiliate of the Boyalife Group, a global diversified life science holding company that focuses on stem cell technology and cell-based therapeutics.

Reverse Stock Split

On June 4, 2019, the Company effected a one (1) for ten (10) reverse split of its issued and outstanding common stock. The total number of shares of common stock authorized for issuance by the Company of 350,000,000 shares did not change in connection with the reverse stock split. All historical share amounts disclosed herein have been retroactively restated to reflect the reverse split and subsequent resulting share exchange.

Going Concern

The Company has a Revolving Credit Agreement (“Credit Agreement”) with Boyalife Asset Holding II, Inc. (Refer to Note 3), allowing the Company to borrow up to $10,000,000 in principal amount outstanding at any time. As of September 30, 2020, the Company had drawn down the full amount available under the Credit Agreement and had an outstanding balance of $10,000,000. Boyalife Asset Holding II, Inc. is a wholly owned subsidiary of Boyalife Group Inc., which is owned and controlled by the Company’s Chief Executive Officer and Chairman of our Board of Directors.

Table of Contents

On April 21, 2020, the Company entered into a promissory note and received a loan (collectively, the “PPP Loan”) from Comerica Bank (“Comerica”) under the Paycheck Protection Program (“PPP”), which was established under the Coronavirus Aid, Relief, and Economic Security Act (“CARES Act”) administered by the U.S. Small Business Administration. The Company received net proceeds of $646,000 from the PPP Loan. The current portion of the PPP loan is $235,000 and the noncurrent portion is $411,000. The term of the PPP Loan is two years with an interest rate of 1.00% per annum, which shall be deferred for the first six months of the term of the loan or after an application is filed for loan forgiveness, whichever is later. Each monthly payment shall be in the amount which would fully amortize the principal balance outstanding under the PPP Loan. Pursuant to the terms of the CARES Act, the proceeds of the PPP Loan may be used for payroll costs, mortgage interest, rent or utility costs. The promissory note of the PPP Loan contains customary events of default relating to, among other things, payment defaults, breach of representations and warranties, or provisions of the promissory note. The occurrence of an event of default may result in a claim for the immediate repayment of the amount outstanding under the PPP Loan.

At September 30, 2020, the Company had cash and cash equivalents of $4,436,000 and working capital of $7,056,000. The Company has incurred recurring operating losses and as of September 30, 2020 had an accumulated deficit of $250,434,000. These recurring losses raise substantial doubt about the Company’s ability to continue as a going concern within one year from the filing of this report. The Company may need to raise additional capital to grow its business, fund operating expenses and make interest payments. The Company’s ability to fund its cash needs is subject to various risks, many of which are beyond its control. The Company may seek additional funding through debt borrowings, sales of debt or equity securities or strategic partnerships. The Company cannot guarantee that such funding will be available on a timely basis, in needed quantities or on terms favorable to the Company, if at all.

The accompanying condensed consolidated financial statements have been prepared assuming that the Company will continue as a going concern; however, the above conditions raise substantial doubt about the Company’s ability to do so. The condensed consolidated financial statements do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classifications of liabilities that may result should the Company be unable to continue as a going concern.

Principles of Consolidation

The consolidated financial statements include the accounts of ThermoGenesis Holdings and its wholly-owned subsidiaries, ThermoGenesis Corp. and TotipotentRX Cell Therapy, Pvt. Ltd and ThermoGenesis Corp’s majority-owned subsidiary, CARTXpress Bio. All significant intercompany accounts and transactions have been eliminated upon consolidation.

Non-controlling Interests

The 20% ownership interest of CARTXpress Bio that is not owned by ThermoGenesis Holdings is accounted for as a non-controlling interest as the Company has an 80% ownership interest in CARTXpress Bio. Earnings or losses attributable to other stockholders of a consolidated affiliated company are classified separately as "non-controlling interest" in the Company's consolidated statements of operations. Net loss attributable to non-controlling interests reflects only its share of the after-tax earnings or losses of an affiliated company. The Company's condensed consolidated balance sheets reflect non-controlling interests within the equity section.

Table of Contents

Interim Reporting

The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) for interim financial information and with the instructions to Form 10-Q and Article 8 of Regulation S-X. Accordingly, certain information and footnote disclosures normally included in annual financial statements prepared in accordance with U.S. GAAP have been condensed or omitted pursuant to such Securities and Exchange Commission (“SEC”) rules and regulations and accounting principles applicable for interim periods. In the opinion of management, all adjustments (consisting of normal recurring accruals) considered necessary for a fair presentation have been included. Events subsequent to the balance sheet date have been evaluated for inclusion in the accompanying condensed consolidated financial statements through the date of issuance. Operating results for the three and nine month periods ended September 30, 2020 are not necessarily indicative of the results that may be expected for the year ending December 31, 2020. These unaudited condensed consolidated financial statements should be read in conjunction with the consolidated financial statements and the notes thereto included in ThermoGenesis Holdings’ Annual Report on Form 10-K for the year ended December 31, 2019.

2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Recently Issued Accounting Standards

In August 2020, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2020-06 “Debt-Debt with Conversion and Other Options (“Subtopic 470-20”) and Derivatives and Hedging—Contracts in Entity’s Own Equity (“Subtopic 815-40”): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity,” which, among other things, provides guidance on how to account for contracts on an entity’s own equity. This ASU simplifies the accounting for certain financial instruments with characteristics of liabilities and equity. Specifically, the ASU eliminated the need for the Company to assess whether a contract on the entity’s own equity (1) permits settlement in unregistered shares, (2) whether counterparty rights rank higher than shareholder’s rights, and (3) whether collateral is required. In addition, the ASU requires incremental disclosure related to contracts on the entity’s own equity and clarifies the treatment of certain financial instruments accounted for under this ASU on earnings per share. This ASU may be applied on a full retrospective of modified retrospective basis. This ASU is effective January 1, 2022 and interim periods presented. Early adoption of the ASU is permitted by the Company effective January 1, 2021. The Company is in the process of assessing the impact of the adoption of the ASU on the Company’s financial statements.

In December 2019, FASB issued ASU 2019-12 “Income Taxes (“Topic 740”): Simplifying the Accounting of Income Taxes,” which is intended to simplify various aspects related to accounting for income taxes. ASU 2019-12 removes certain exceptions to the general principles in Topic 740 and also clarifies and amends existing guidance to improve consistent application. This guidance is effective for fiscal years and interim periods within those fiscal years, beginning after December 15, 2020, with early adoption permitted. The Company doesn’t expect the adoption of the standard to have a material impact.

In June 2016, the FASB issued ASU 2016-13, “Financial Instruments - Credit Losses (“Topic 326”).” The ASU introduces a new accounting model, the Current Expected Credit Losses model (“CECL”), which requires earlier recognition of credit losses and additional disclosures related to credit risk. The CECL model utilizes a lifetime expected credit loss measurement objective for the recognition of credit losses at the time the financial asset is originated or acquired. ASU 2016-13 is effective for annual periods beginning after December 15, 2022, including interim reporting periods within those annual reporting periods. We expect that the impact of adoption will not have a material impact.

Table of Contents

Recently Adopted Accounting Standards

In August 2018, the FASB issued ASU 2018-13, “Fair Value Measurement (“Topic 820”): Disclosure Framework-Changes to the Disclosure Requirements for Fair Value Measurement.” This ASU eliminates, adds and modifies certain disclosure requirements for fair value measurements as part of its disclosure framework project. The standard was adopted and did not have a material impact on the Company’s financial statements.

Revenue Recognition

Revenue is recognized based on the five-step process outlined in Accounting Standards Codification (“ASC”) 606.

The following tables summarize the revenues by product line:

	Three Months Ended September 30, 2020
	Device Revenue		Service Revenue		Other Revenue		Total Revenue
AXP	$	1,137,000	$	32,000	$	--	$	1,169,000
BioArchive		337,000		282,000		--		619,000
CAR-TXpress		332,000		22,000		71,000		425,000
Manual Disposables		100,000		--		--		100,000
Other		26,000		--		16,000		42,000
Total	$	1,932,000	$	336,000	$	87,000	$	2,355,000

	Nine Months Ended September 30, 2020
	Device Revenue		Service Revenue		Other Revenue		Total Revenue
AXP	$	4,009,000	$	103,000	$	--	$	4,112,000
BioArchive		675,000		900,000		--		1,575,000
CAR-TXpress		1,035,000		47,000		214,000		1,296,000
Manual Disposables		499,000		--		--		499,000
Other		276,000		--		39,000		315,000
Total	$	6,494,000	$	1,050,000	$	253,000	$	7,797,000

	Three Months Ended September 30, 2019
	Device Revenue		Service Revenue		Other Revenue		Total Revenue
AXP	$	2,255,000	$	51,000	$	--	$	2,306,000
BioArchive		243,000		351,000		--		594,000
Manual Disposables		221,000		--		--		221,000
CAR-TXpress		875,000		10,000		33,000		918,000
Other		--		--		19,000		19,000
Total	$	3,594,000	$	412,000	$	52,000	$	4,058,000

	Nine Months Ended September 30, 2019
	Device Revenue		Service Revenue		Other Revenue		Total Revenue
AXP	$	6,550,000	$	160,000	$	--	$	6,710,000
BioArchive		1,274,000		1,117,000		--		2,391,000
Manual Disposables		764,000		--		--		764,000
CAR-TXpress		1,365,000		6,000		33,000		1,404,000
Other		5,000		11,000		40,000		56,000
Total	$	9,958,000	$	1,294,000	$	73,000	$	11,325,000

Table of Contents

Contract Balances

Generally, all sales are contract sales (with either an underlying contract or purchase order). The Company does not have any material contract assets. When invoicing occurs prior to revenue recognition, a contract liability is recorded (as deferred revenue on the consolidated balance sheet). Revenues recognized during the three and nine months ended September 30, 2020 that were included in the beginning balance of deferred revenue were $115,000 and $547,000, respectively. Short-term deferred revenues increased from $620,000 to $700,000 and long-term deferred revenues decreased from $1,901,000 to $1,669,000 during the nine months ended September 30, 2020, respectively.

Exclusivity Fee

On August 30, 2019, the Company entered into a Supply Agreement with Corning Incorporated (the “Supply Agreement”). The Supply Agreement has an initial term of five years with automatic two-year renewal terms, unless terminated by either party in accordance with the terms of the Supply Agreement (collectively, the “Term”). Pursuant to the Supply Agreement, the Company has granted to Corning exclusive worldwide distribution rights for substantially all X-Series^® products under the CAR-TXpress™ platform (the “Products”) manufactured by its subsidiary, ThermoGenesis Corp., for the duration of the Term, subject to certain geographical and other exceptions. As consideration for the exclusive worldwide distribution rights for the Products, Corning paid a $2,000,000 exclusivity fee, in addition to any amounts payable throughout the Term for the Products.

The Company performed an evaluation of the revenue recognition of the $2,000,000 fee under ASC 606. It determined that the $2,000,000 will be recognized over time, based on the term of the contract. It was determined that the most likely outcome is the agreement is extended for one additional two-year term after the initial five-year contract is complete. Consequently, the term to recognize the exclusivity fee is over seven years. The Company will allocate the upfront fee evenly to each daily performance obligation of providing exclusivity and recognize the revenue ratably over the seven-year period. As each day passes, the Company will recognize the portion of the exclusivity fee allocated to that day. For the three and nine months ended September 30, 2020, the Company recorded revenue of $71,000 and $214,000, respectively, related to the exclusivity fee. The remaining balance of the $2,000,000 payment of $1,690,000 was recorded to deferred revenue, with $286,000 in short-term deferred revenue and $1,404,000 recorded in long-term deferred revenue.

Backlog of Remaining Customer Performance Obligations

The following table includes revenue expected to be recognized and recorded as sales in the future from the backlog of performance obligations that are unsatisfied (or partially unsatisfied) at the end of the reporting period.

	Remainder of 2020		2021		2022		2023		2024 and beyond		Total
Service revenue	$	310,000	$	958,000	$	561,000	$	298,000	$	38,000	$	2,165,000
Clinical revenue		3,000		13,000		13,000		13,000		175,000		217,000
Exclusivity fee		71,000		286,000		286,000		286,000		761,000		1,690,000
Total	$	384,000	$	1,257,000	$	860,000	$	597,000	$	974,000	$	4,072,000

Revenues are net of normal discounts. Shipping and handling fees billed to customers are included in net revenues, while the related costs are included in cost of revenues.

Table of Contents

Fair Value Measurements

In accordance with ASC 820, “Fair Value Measurements and Disclosures,” fair value is defined as the exit price, or the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants as of the measurement date.

The guidance also establishes a hierarchy for inputs used in measuring fair value that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that the most observable inputs be used when available. Observable inputs are inputs that market participants would use in valuing the asset or liability and are developed based on market data obtained from sources independent of the Company. Unobservable inputs are inputs that reflect the Company’s assumptions about the factors that market participants would use in valuing the asset or liability. The guidance establishes three levels of inputs that may be used to measure fair value:

Level 1:

Quoted market prices in active markets for identical assets or liabilities.

Level 2:

Observable market-based inputs or unobservable inputs that are corroborated by market data.

Level 3:

Unobservable inputs which are supported by little or no market activity.

The carrying values of cash and cash equivalents, accounts receivable and accounts payable approximate fair value due to their short duration. The fair value of the Company’s derivative obligation liability is classified as Level 3 within the fair value hierarchy since the valuation model of the derivative obligation is based on unobservable inputs. The derivative obligation is not material to the financial statements of the Company. The impairment of goodwill and intangible assets is a non-recurring Level 3 fair value measurement.

Net Loss per Share

Net loss per share is computed by dividing the net loss by the weighted average number of common shares outstanding plus pre-funded warrants. For the purpose of calculating basic net loss per share, the additional shares of common stock that are issuable upon exercise of the pre-funded warrants have been included since the shares are issuable for a negligible consideration and have no vesting or other contingencies associated with them. As of September 30, 2020, all pre-funded warrants previously issued have been exercised and none are currently outstanding. The calculation of the basic and diluted earnings per share is the same for all periods presented, as the effect of the potential common stock equivalents noted below is anti-dilutive due to the Company’s net loss position for all periods presented. Anti-dilutive securities consisted of the following at September 30:

	2020		2019
Common stock equivalents of convertible promissory note and accrued interest		6,988,334		6,013,667
Vested Series A warrants		40,441		40,441
Unvested Series A warrants⁽¹⁾		69,853		69,853
Warrants – other		1,006,190		1,300,091
Stock options		892,149		296,029
Total		8,996,967		7,720,081

___________

(1)

The unvested Series A warrants were subject to vesting based upon the amount of funds actually received by the Company in the second close of the August 2015 financing which never occurred. The warrants will remain outstanding but unvested until they expire in February 2021.

Reclassifications

Certain prior period amounts have been reclassified to conform to the current period presentation. The reclassifications did not have an impact on net loss as previously reported.

Table of Contents

3. Related Party Transactions

HealthBanks Biotech (USA) Inc.

On November 26, 2019 the Company entered into a joint venture agreement with HealthBanks Biotech (USA) Inc. (the “JV Agreement”) to form a new company called ImmuneCyte, Inc. (“ImmuneCyte”) to commercialize the Company’s proprietary cell processing platform, CAR-TXpress™, for use in immune cell banking as well as for cell-based contract development and manufacturing services (CMO/CDMO). Under the terms of the JV Agreement, ImmuneCyte was initially owned 80% by HealthBanks Biotech and 20% by the Company. The Company currently owns 18.79% of the equity of ImmuneCyte. ImmuneCyte will be among the first immune cell banks in the U.S. and offer customers the ability to preserve younger, healthier and uncontaminated immune cells for future potential use in dendritic and chimeric antigen receptor (“CAR-T”) cell therapies in a GMP compliant processing environment. The Company’s principal contribution to ImmuneCyte was a supply agreement under which ImmuneCyte will have the exclusive right to purchase the Company’s proprietary cell processing equipment in the immune cell banking business and a non-exclusive right to purchase it for other cell-based contract development and manufacturing (“CMO/CDMO”) services at a price equal to 115% of the Company’s cost. The Company also contributed to ImmuneCyte intellectual property and trademarks relating to the Company’s clinical development assets, which were fully impaired by the Company in 2018 and had no book value. HealthBanks contributed to ImmuneCyte a paid-up, royalty free license to use its proprietary business management system, customer relationship management software, and laboratory information statement, and it will also make available a $1,000,000 unsecured, non-convertible line of credit to ImmuneCyte to provide initial operating capital. Healthbanks is a subsidiary of Boyalife Group, Inc. (USA), the owner of Boyalife Asset Holding II, Inc., which is the largest stockholder of the Company, and is owned by Dr. Xiaochun (Chris) Xu, the Company’s Chief Executive Officer and Chairman of our Board of Directors.

Between November 26, 2019 and September 30, 2020, ImmuneCyte closed $3,700,000 of equity investments with a private institution and qualified investors. ImmuneCyte issued 643,750 shares of Class A common stock at a price between $5.00 to $16.00 per share, representing a total of 6.05% ownership in the joint venture. As a result of these equity investments in ImmuneCyte, the Company’s equity in the joint venture is no longer subject to anti-dilution provisions. After these investments, ImmuneCyte is owned 75.16% by HealthBanks, 18.79% by the Company and 6.05% by the private investors.

The Company initially determined that ImmuneCyte would be considered a variable interest entity, as a result of the significant influence the Company has over operations and its’ lack of sufficient equity at inception. After the additional investment of $3,700,000, ImmuneCyte’s equity at risk was considered sufficient and the Company determined it would no longer be classified as a variable interest entity. The Company’s investment in ImmuneCyte will be accounted for under the equity method based on management’s conclusion that the Company can exercise significant influence over ImmuneCyte via its equity interest and the related Supply Agreement. The Company recorded the investment initially at the value of the nonfinancial assets contributed of $28,000, which consisted of the book value of certain assets contributed at the time of formation.

The Company entered into a supply agreement with ImmuneCyte with an effective date of April 22, 2020. The supply agreement, which related to the supply of COVID-19 antibody detection kits, has a term of one year from the effective date, thirty (30) day renewal terms and contains the Company’s standard supply contract provisions. The Company paid ImmuneCyte approximately $3,600,000 for kits during the nine months ended September 30, 2020. In August 2020, due to concerns over the consistency of performance of these kits, the Company voluntarily withdrew its application for an Emergency Use Authorization (“EUA”) with respect to the detection kits. After the EUA application was withdrawn, ImmuneCyte agreed to refund their mark-up on the purchased kits. That refund of approximately $800,000 was received in the quarter ended September 30, 2020. Additionally, ImmuneCyte and the Company agreed to work together to attempt to secure a refund from the original manufacturer for the remaining amount the Company paid for kits. If a refund is obtained, it will be recognized when received. For the nine months ended September 30, 2020, the Company recorded a loss to cost of goods sold for the remaining carrying amount of the testing kits in inventory as of September 30, 2020 of approximately $2,800,000. In order to continue to pursue its strategy to sell COVID-19 antibody detection test kits, the Company entered into a supply agreement in August 2020 with BioHit Healthcare (Hefei) Co., Ltd. for kits to be marketed under the ThermoGenesis brand.

Table of Contents

For the three and nine months ended September 30, 2020, the Company recorded a loss of $0 and $13,000, respectively, on its equity investment in ImmuneCyte as ImmuneCyte has recorded a cumulative loss since the Company made its investment. At September 30, 2020, the value of the Company’s investment in ImmuneCyte will remain at $0. For the three and nine months ended September 30, 2020, ImmuneCyte had net loss of $1,313,000 and $1,422,000, respectively. As of September 30, 2020, its current assets were $2,120,000 and current liabilities were $296,000.

Convertible Promissory Note and Revolving Credit Agreement

In March 2017, ThermoGenesis Holdings entered into a Credit Agreement with Boyalife Investment Fund II, Inc., which later merged into Boyalife Asset Holding II, Inc. (the “Lender”). The Lender is a wholly owned subsidiary of Boyalife Group Inc., which is owned and controlled by the Company’s Chief Executive Officer and Chairman of our Board of Directors. The Credit Agreement, as amended, grants to the Company the right to borrow up to $10,000,000 (the “Loan”) at any time prior to March 6, 2022 (the “Maturity Date”). In February 2020, the Company and the Lender completed a series of transactions in which the Company completed a draw down for $1,869,000 and the Lender converted a total of $3,000,000 of the outstanding balance of the convertible note into an aggregate of 1,666,670 shares of our common stock in two conversions. As a result of the conversions, the Company recorded a $2,486,000 charge to interest expense for the unamortized portion of the beneficial conversion feature related to the unamortized portion of the beneficial conversion feature of outstanding principal balance that was converted. On April 28, 2020, the Company borrowed an additional $2,418,000 under the Loan. Immediately after that draw down, the outstanding principal balance under the Loan was $10,000,000 and accrued but unpaid interest was $580,000. The principal purpose of the draw down was to provide working capital to fund the Company’s purchase of SARS-CoV-2 (COVID-19) IgM/IgG Antibody Fast Detection Kits from ImmuneCyte. As of September 30, 2020, the outstanding principal balance of the Loan was $10,000,000.

The Credit Agreement and the Convertible Promissory Note issued thereunder (the “Note”) provide that the principal and all accrued and unpaid interest under the Loan will be due and payable on the Maturity Date, with payments of interest-only due on the last day of each calendar year. The Loan bears interest at 22% per annum, simple interest. The Company has five business days after the Lender demands payment to pay the interest due before the Loan is considered in default. The Note can be prepaid in whole or in part by the Company at any time without penalty.

The Maturity Date of the Note is subject to acceleration at the option of the Lender upon customary events of default, which include; a breach of the Loan documents, termination of operations, or bankruptcy. The Lender’s obligation to make advances under the Loan is subject to the Company’s representations and warranties in the Credit Agreement continuing to be true at all times and there being no continuing event of default under the Note.

The Credit Agreement and Note were amended in April 2018. The amendment granted the Lender the right to convert, at any time, outstanding principal and accrued but unpaid interest into shares of Common Stock at a conversion price of $16.10 per share and if the Company issues shares of Common Stock at a lower price per share, the conversion price of the Note is lowered to the reduced amount. The Company completed two transactions in 2018, lowering the conversion price to $1.80.

Table of Contents

It was concluded that the conversion option of the draw down in February 2020 of $1,869,000 contained a beneficial conversion feature and the Company recorded a debt discount for the full amount in the quarter ended March 31, 2020. It was also concluded that the conversion option of the draw down in April 2020 of $2,418,000 contained a beneficial conversion feature and the Company recorded a debt discount for the full amount in the quarter ended June 30, 2020. Such discount represented the fair value of the incremental shares up to the proceeds received from the convertible notes. The Company amortized $828,000 and $2,103,000 of debt discount to interest expense for the three and nine months ended September 30, 2020, respectively, and $471,000 and $1,398,000 for the three and nine months ended September 30, 2019, respectively. As of September 30, 2020, the Company had an interest payable balance of $1,519,000 as compared to $1,869,000 at December 31, 2019 related to the Note.

Distributor Agreement

On August 21, 2017, ThermoGenesis Corp. entered into an International Distributor Agreement with Boyalife W.S.N. Under the terms of the agreement, Boyalife W.S.N. was granted the exclusive right, subject to existing distributors and customers (if any), to develop, sell to, and service a customer base for ThermoGenesis Corp’s AXP^® AutoXpress System and BioArchive^® System in the People’s Republic of China (excluding Hong Kong and Taiwan), Singapore, Indonesia, and the Philippines (the “Territories”). Boyalife W.S.N. is related to our Chief Executive Officer and Chairman of our Board of Directors, and an affiliate of Boyalife (Hong Kong) Limited. Boyalife W.S.N,’s rights under the agreement include the exclusive right to distribute AXP^® Disposable Blood Processing Sets and use rights to the AXP^®AutoXpress System, BioArchive^® System and other accessories used for the processing of stem cells from cord blood in the Territories. Boyalife W.S.N. is also appointed as the exclusive service provider to provide repairs and preventative maintenance to ThermoGenesis Corp. products in the Territories.

The term of the agreement is for three years with ThermoGenesis Corp. having the right to renew the agreement for successive two-year periods at its option. However, ThermoGenesis Corp. has the right to terminate the agreement early if Boyalife W.S.N. fails to meet specified minimum purchase requirements.

During the three and nine months ended September 30, 2020, the Company recorded no revenue and for the three and nine months ended September 30, 2019, the Company recorded $214,000 and $794,000, respectively, of revenues from Boyalife related to the aforementioned distributor agreement.

4. CONVERTIBLE PROMISSORY NOTE

On January 29, 2019, the Company agreed to issue and sell an unsecured note payable to an accredited investor (the “Accredited Investor”) for an aggregate of $800,000 face value (the “January 2019 Note”) that, after six months, is convertible into shares of the Company's common stock at a conversion price equal to the lower of (a) $1.80 per share or (b) 90% of the closing sale price of the Company’s common stock on the date of conversion (subject to a floor conversion price of $0.50).

The January 2019 Note bears interest at the rate of twenty-four percent (24%) per annum and is payable quarterly in arrears. Unless sooner converted in the manner described below, all principal under the January 2019 Note, together with all accrued and unpaid interest thereupon, will be due and payable eighteen (18) months from the date of the issuance of the January 2019 Note. The January 2019 Note may be prepaid without penalty at any time after it becomes convertible (at which time the holder will have the right to convert it before prepayment thereof).

Table of Contents

On the date that is six months after the issuance of the January 2019 Note, and for so long thereafter as any principal and accrued but unpaid interest under the January 2019 Note remains outstanding, the holder of the January 2019 Note may convert such holder’s January 2019 Note, in whole or in part, into a number of shares of the Company’s common stock equal to (i) the principal amount being converted, together with any accrued or unpaid interest thereon, divided by (ii) the conversion price in effect at the time of conversion. The January 2019 Note has customary conversion blockers at 4.99% and 9.99% unless otherwise agreed to by the Company and the holder. It was concluded that the conversion option was beneficial. Accordingly, the Company recorded a debt discount in the amount of $800,000, upon stockholder approval of the conversion feature, which occurred on May 30, 2019. The discount represented the fair value of the incremental shares up to the proceeds received from the convertible note.

On July 23, 2019, the Company entered into Amendment No. 1 to the January 2019 Note (“Amended Note”). Under the terms of the amendment, the maturity date of the January 2019 Note was extended from July 29, 2020 to July 31, 2022. All other terms of the January 2019 Note remain the same. The Amended Note was accounted for as an extinguishment of the January 2019 Note as the change in the fair value of the embedded conversion option featured in the January 2019 Note immediately before and after the amendment exceeded 10% of the carrying amount of the January 2019 Note. Accordingly, the Company recorded a loss on the constructive extinguishment of this debt in the amount of $840,000 for the year ended December 31, 2019. The fair value of the Amended Note, which amounted to $1,473,000 was recorded as a liability. The Company also evaluated the conversion option embedded in the Amended Note and determined it was beneficial. Accordingly, the Company recorded a debt discount in the amount of $556,000 on the Amended Note for the year ended December 31, 2019. The Company amortized $77,000 of the debt discount for the January 2019 Note to interest expense for the year ended December 31, 2019. The Company utilized a Monte Carlo simulation model to determine the fair value of the Amended Note.

During the nine months ended September 30, 2020, the holder converted the remainder of the face value of the note into shares of common stock. For the nine months ended September 30, 2020, $369,000 was converted into 204,445 shares of common stock. Additionally, the unamortized premium for the portion of the note that was converted of $46,000 was recorded to interest income during the nine months ended September 30, 2020.

On July 23, 2019, the Company entered into a private placement with the Accredited Investor, pursuant to which the Company issued and sold to such investor an unsecured convertible promissory note in the original principal amount of $1,000,000 (the “July 2019 Note”). Such note is convertible into shares of the Company's common stock at a conversion price equal to the lower of (a) $1.80 per share or (b) 90% of the closing sale price of the Company’s common stock on the date of conversion (subject to a floor conversion price of $0.50). The July 2019 Note bears interest at the rate of twenty-four percent (24%) per annum and is payable quarterly in arrears. Unless sooner converted in the manner described below, all principal under the July 2019 Note, together with all accrued and unpaid interest thereupon, will be due and payable three years from the date of the issuance on July 31, 2022.

The July 2019 Note may be prepaid without penalty at any time after it becomes convertible (at which time the holder will have the right to convert it before prepayment thereof). On the date that is six months after the issuance of the July 2019 Note, the holder may convert the July 2019 Note, in whole or in part, into a number of shares of the Company’s common stock equal to (i) the principal amount being converted, together with any accrued or unpaid interest thereon, divided by (ii) the conversion price in effect at the time of conversion. The Company had accounted for the July 2019 Note as a debt instrument until the conversion feature was approved by the Company’s stockholders. Accordingly, the Company recorded a beneficial conversion feature in the amount of $694,000, upon stockholder approval of the conversion feature, which occurred on June 4, 2020. The discount represented the fair value of the incremental shares up to the proceeds received from the convertible note. The debt discount will be amortized to interest expense over the term of the July 2019 Note. For the three and nine months ended September 30, 2020, $27,000 and $107,000, respectively, were amortized to interest expense.

Table of Contents

5. LEASES

The Company leases the Rancho Cordova, California and Gurgaon, India facilities pursuant to operating leases. The Rancho Cordova lease expires in May 2024. The Gurgaon lease expires in September 2023; however, either party can terminate with three months’ notice. As such, it was accounted for as a short-term lease.

Operating Leases

Operating lease assets and liabilities are recognized at the lease commencement date. Operating lease liabilities represent the present value of lease payments not yet paid. Operating lease assets represent our right to use an underlying asset and are based upon the operating lease liabilities adjusted for prepayments or accrued lease payments, initial direct costs, lease incentives, and impairment of operating lease assets. To determine the present value of lease payments not yet paid, we use the Company’s cost of capital based on existing debt instruments. Our material leases typically contain rent escalations over the lease term. We recognize expense for these leases on a straight-line basis over the lease term.

The following summarizes the Company’s operating leases:

	September 30, 2020
Right-of-use operating lease assets, net	$	765,000
Current lease liability		147,000
Non-current lease liability		648,000

Weighted average remaining lease term		3.7
Discount rate		22	%

Maturities of lease liabilities by year for our operating leases are as follows:

2020 (remaining)	$	76,000
2021		310,000
2022		319,000
2023		328,000
2024		139,000
Thereafter		--
Total lease payments	$	1,172,000
Less: imputed interest		(377,000	)
Present value of operating lease liabilities	$	795,000

Statement of Cash Flows

In January 2019, the Company signed a new amendment to its lease for office space at its corporate headquarters in Rancho Cordova, CA. The amendment was accounted for as a modification and resulted in a right-of-use asset of $966,000 being recognized as a non-cash addition on the date of the amendment. Cash paid for amounts included in the measurement of operating lease liabilities was $225,000 for the nine months ended September 30, 2020 and is included in cash flows from operating activities.

Operating Lease Costs

Operating lease costs were $135,000 and $343,000 for the three and nine months ended September 30, 2020, respectively. These costs are primarily related to long-term operating leases, but also include immaterial amounts for variable lease costs and short-term leases with terms greater than 30 days.

Table of Contents

Finance Leases

Finance leases are included in equipment and other current and non-current liabilities on the condensed consolidated balance sheet. The amortization and interest expense are included in general and administrative expense and interest expense, respectively on the statement of operations. These leases are not and were not material for the three and nine months ended of September 30, 2020.

6. COMMITMENTS AND CONTINGENCIES

Financial Covenants

Effective March 16, 2020, the Company and CBR Systems, Inc. (“CBR”) entered into a Manufacturing and Supply Amending Agreement #1 (the “Amendment”). The Amendment amends the Manufacturing and Supply Agreement entered into on May 15, 2017 by the Company and CBR (the “Original Agreement”). The Amendment, among other things, amends the Original Agreement by reducing from $2.0 million to $1.0 million the required amount of cash and short-term investments, net of debt or borrowed funds due in one year or less, that the Company must have on hand at the end of any month to avoid being in default under the Original Agreement.

On July 13, 2020, the Company, entered into a Manufacturing and Supply Amending Agreement #2 with CBR with an effective date of July 13, 2020 (the “Amendment”). The Amendment, among other things, revised the amount of certain products to be purchased, pricing of those products and removal of the safety stock requirement. In addition, the Amendment updated the financial requirement to exclude convertible debt from the definition of short-term debt under events or conditions that constitute a default. The Amendment states that the Company’s cash balance and short-term investments net of non-convertible debt and borrowed funds that are payable within one year must be greater than $1,000,000 at any month end.

The Company was in compliance with this financial covenant as of September 30, 2020.

Warranty

The Company offers a warranty on all of its non-disposable products of one to two years. The Company warrants disposable products through their expiration date. The Company periodically assesses the adequacy of its recorded warranty liabilities and adjusts the amounts as necessary.

The warranty liability is included in other current liabilities in the unaudited condensed consolidated balance sheets. The change in the warranty liability for the nine months ended September 30, 2020 is summarized in the following table:

Balance at December 31, 2019	$	277,000
Warranties issued during the period		62,000
Settlements made during the period		(171,000	)
Changes in liability for pre-existing warranties during the period		(20,000	)
Balance at September 30, 2020	$	148,000

Contingencies and Restricted Cash

In fiscal 2016, the Company signed an engagement letter with a strategic consulting firm (“Mavericks”). Included in the engagement letter was a success fee due upon the successful conclusion of certain transactions. On May 4, 2017, a lawsuit was filed in California Superior Court against the Company and its Chief Executive Officer by the consulting firm, which argued that it was owed a transaction fee of $1,000,000 under the terms of the engagement letter due to the conversion of the Boyalife debentures in August 2016. In October 2017, to streamline the case by providing for the dismissal of claims against the Company’s Chief Executive Officer based on alter ego theories and without acknowledging any liability, the Company deposited $1,000,000 with the Court, which was recorded as restricted cash. The trial completed in February 2020 with an adverse jury verdict in favor of Mavericks in the total amount of $1,000,000. As a result, the Company recorded in other current liabilities a $1,400,000 loss in general and administrative expenses for the year ended December 31, 2019. The loss includes the $1,000,000 transaction fee and an estimated $400,000 in interest due. The $1,000,000 deposited with the court will be used to settle the transaction fee. At the conclusion of the trial, no judgment had been entered as the parties were disputing whether the defense of equitable estoppel should bar entry of judgment and the proper pre-judgment interest start date. In April 2020, the Company received notice that equitable estoppel defense was denied by the Court. After that ruling, Mavericks and the Company reached agreement for the interest start date and the total amount of Mavericks’ trial-related expenses that must be reimbursed by the Company as result of the verdict. On May 1, 2020 the parties agreed that the Company would pay Mavericks $480,000, representing $369,000 for interest and $111,000 for trial-related expenses. Additionally, the Company agreed not to contest the jury verdict and allowing the Court to release the $1,000,000 cash bond deposited by the Company early in the litigation to Mavericks, effectively ending the case.

Table of Contents

In the normal course of operations, the Company may have disagreements or disputes with customers, employees or vendors. Such potential disputes are seen by management as a normal part of business. As of September 30, 2020, except as disclosed, management believes any liability that may ultimately result from the resolution of these matters will not have a material adverse effect on the Company’s consolidated financial position, operating results or cash flows.

7. STOCKHOLDERS’ EQUITY

Common Stock

On March 25, 2020, the Company entered into a Securities Purchase Agreement (the “Purchase Agreement”) with three institutional and accredited investors (the “Investors”), pursuant to which the Company agreed to issue and sell to the Investors, in a registered direct offering (the “RDO”), an aggregate of 1,000,002 shares of the Company’s common stock at an offering price of $3.50 per share, for gross proceeds of approximately $3.5 million before the deduction of $393,000 in placement agent fees and offering expenses. The shares were issued and sold by the Company pursuant to a registration statement on Form S-3 (File No. 333-235509), which was initially filed with the Securities and Exchange Commission (the “Commission”) on December 13, 2019 and was declared effective by the Commission on January 3, 2020, and the related prospectus supplement filed with the Commission on March 27, 2020. The closing of the RDO occurred on March 27, 2020. The Purchase Agreement also contains representations, warranties, indemnification and other provisions customary for transactions of this nature. Under the Purchase Agreement, (i) the Company and its subsidiaries were prohibited for a period of 30 days after the closing (subject to certain exceptions) from issuing, entering into any agreement to issue, or announcing the issuance or the proposed issuance of any shares of the Company’s common stock or any other securities that are at any time convertible into, or exercisable or exchangeable for, or otherwise entitle the holder thereof to receive, shares of the Company’s common stock and (ii) the Company is prohibited for a period of twelve (12) months after the closing (subject to certain exceptions) from effecting or entering into an agreement to effect any issuance by the Company or any of its subsidiaries of the Company’s common stock or any other securities that are at any time convertible into, or exercisable or exchangeable for, or otherwise entitle the holder thereof to receive, shares of the Company’s common stock involving a Variable Rate Transaction (as defined in the Purchase Agreement).

Table of Contents

On December 13, 2019, the Company entered into an At The Market Offering Agreement, by and between the Company and H.C. Wainwright & Co., LLC, as agent (“H.C. Wainwright”) (the “ATM Agreement”), pursuant to which the Company may offer and sell, from time to time through H.C. Wainwright, shares of Common Stock, having an aggregate offering price of up to $4.4 million and on May 19, 2020 the ATM Agreement was amended to increase the aggregate value of up to $15,280,313 (the “HCW Shares”). The offer and sale of the HCW Shares is made pursuant to a shelf registration statement on Form S-3 and the related prospectus (File No. 333-235509). Pursuant to the ATM Agreement, H.C. Wainwright may sell the HCW Shares by any method permitted by law deemed to be an “at the market offering” as defined in Rule 415 of the Securities Act of 1933, including sales made by means of ordinary brokers’ transactions, including on The NASDAQ Capital Market, at market prices or as otherwise agreed with H.C. Wainwright. H.C. Wainwright will use commercially reasonable efforts consistent with its normal trading and sales practices to sell the HCW Shares from time to time, based upon instructions from the Company, including any price or size limits or other customary parameters or conditions the Company may impose. The Company is not obligated to make any sales of the HCW Shares under the ATM Agreement. The offering of HCW Shares pursuant to the ATM Agreement will terminate upon the earliest of (a) the sale of all of the HCW Shares subject to the ATM Agreement, (b) the termination of the ATM Agreement by H.C. Wainwright or the Company, as permitted therein, or (c) August 9, 2022. The Company will pay H.C. Wainwright a commission rate equal to 3% of the aggregate gross proceeds from each sale of HCW Shares and have agreed to provide H.C. Wainwright with customary indemnification and contribution rights. The Company will also reimburse H.C. Wainwright for certain specified expenses in connection with entering into the ATM Agreement. As of September 30, 2020, the Company sold a total of 517,740 shares of Common Stock for aggregate gross proceeds of $2,785,000 at an average selling price of $5.38 per share, resulting in net proceeds of approximately $2,473,000 after deducting legal expenses, audit fees, commissions and other transaction costs of approximately $312,000.

Subsequent to September 30, 2020, the Company sold a total of 964,130 shares of Common Stock for aggregate gross proceeds of $2,771,000 at an average selling price of $2.87 per share, resulting in net proceeds of approximately $2,683,000 after deducting commissions and other transaction costs of approximately $88,000.

Stock Based Compensation

The Company recorded stock-based compensation of $234,000 and $615,000 for the three and nine months ended September 30, 2020, and $253,000 and $459,000 for the three and nine months ended September 30, 2019, respectively, as comprised of the following:

	Three Months Ended September 30,				Nine Months Ended September 30,
	2020		2019		2020		2019
Cost of revenues	$	3,000	$	1,000	$	5,000	$	2,000
Sales and marketing		65,000		110,000		106,000		166,000
Research and development		36,000		38,000		72,000		75,000
General and administrative		130,000		104,000		432,000		216,000
Total	$	234,000	$	253,000	$	615,000	$	459,000

The following is a summary of option activity for the Company’s stock option plans:

	Number of Shares			Weighted- Average Exercise Price		Weighted- Average Remaining Contractual Life		Aggregate Intrinsic Value
Outstanding at December 31, 2019		291,807		$	13.96

Granted		615,500		$	5.92
Forfeited		(15,158	)	$	5.13
Outstanding at September 30, 2020		892,149		$	8.57		8.997	$	--

Vested and expected to vest at September 30, 2020		565,836		$	9.91		8.736	$	--

Exercisable at September 30, 2020		184,137		$	17.05		7.665	$	--

Table of Contents

The aggregate intrinsic value is calculated as the difference between the exercise price of the underlying awards and the quoted price of the Company’s common stock. There were no options exercised during the nine months ended September 30, 2020.

Warrants

A summary of warrant activity for the nine months ended September 30, 2020 follows:

	Number of Shares			Weighted-Average Exercise Price Per Share
Balance at December 31, 2019		1,716,066		$	25.23
Warrants expired		--			--
Warrants exercised		(599,582	)	$	2.81

Outstanding at September 30, 2020		1,116,484		$	37.27

Exercisable at September 30, 2020		1,046,631		$	34.42

8. MAJOR CUSTOMERS AND ACCOUNTS RECEIVABLE

The Company had certain customers whose revenue individually represented 10% or more of the Company’s total revenue, or whose accounts receivable balances individually represented 10% or more of the Company’s total accounts receivable as follows:

For the three months ended September 30, 2020 and 2019, one customer accounted for 22% and 27% of revenue, a second customer accounted for 20% and 13% of revenue, while a third customer accounted for 10% and 2% of revenue, respectively. For the nine months ended September 30, 2020 and 2019, one customer accounted for 28% and 29% of revenue, a second customer accounted for 12% and 13% of revenue, while a third customer accounted for 12% and 0% of revenue, respectively.

At September 30, 2020, two customers accounted for 59% of accounts receivable. At December 31, 2019, three customers accounted for 53% of accounts receivable.

9. SUBSEQUENT EVENTS

The Company has evaluated events subsequent to the balance sheet date for inclusion in the accompanying consolidated financial statements through the date of issuance and determined that no subsequent events have occurred that would require recognition in the consolidated financial statements or disclosures in the notes thereto except as disclosed above.

Table of Contents

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

Cautionary Note Regarding Forward-Looking Statements

This report contains “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. The forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements contained herein. When used in this report, the words "anticipate," "believe," "estimate," "expect" and similar expressions as they relate to the Company or its management are intended to identify such forward-looking statements. Actual results, performance or achievements could differ materially from the results expressed in, or implied by these forward-looking statements. Readers should be aware of important factors that, in some cases, have affected, and in the future could affect, actual results to differ materially from those expressed in any forward-looking statements made by or on behalf of the Company. These factors include without limitation, the ability to obtain capital and other financing in the amounts and at the times needed to launch new products, market acceptance of new products, the nature and timing of regulatory approvals for both new products and existing products for which the Company proposes new claims, realization of forecasted revenues, expenses and income, initiatives by competitors, price pressures, failure to meet U.S. Food and Drug Administration (“FDA”) regulated requirements governing the Company’s products and operations (including the potential for product recalls associated with such regulations), risks associated with initiating manufacturing for new products, failure to meet Foreign Corrupt Practice Act regulations, legal proceedings, uncertainty associated with the COVID-19 pandemic, and other risk factors listed from time to time in our reports with the Securities and Exchange Commission (“SEC”), including, in particular, those set forth in ThermoGenesis Holdings’ Form 10-K for the year ended December 31, 2019.

Business Overview

ThermoGenesis Holdings, Inc. (“ThermoGenesis Holdings,” the “Company,” “we,” “our,” “us”), develops, commercializes and markets a range of automated technologies for CAR-T and other cell-based therapies. The Company currently markets a full suite of solutions for automated clinical biobanking, point-of-care applications, and automation for immuno-oncology, including its semi-automated, functionally closed CAR-TXpress™ platform, which streamlines the manufacturing process for the emerging CAR-T immunotherapy market. The Company was founded in 1986 and is registered in the State of Delaware and headquartered in Rancho Cordova, CA.

Clinical Bio-Banking Applications:

●

AXP^® Automated Cell Separation System – an automated, fully closed cell separation system for isolating and retrieving stem and progenitor cells from umbilical cord blood.

●

Table of Contents

Point-of-Care Applications:

●

Large Scale Cell Processing and Biomanufacturing:

●

CAR-TXpress™ Platform – a modular designed, functionally closed platform that addresses the critical unmet need for large scale cellular processing and chemistry, manufacturing and controls (“CMC”) needs for manufacturing chimeric antigen receptor (“CAR”) T cell therapies. CAR-TXpress is owned and developed through CARTXpress Bio, Inc. (“CARTXpress Bio”), a subsidiary in which we own 80% of the equity interest.

COVID-19 Testing Kit:

●

On January 1, 2019, the Company entered into a reorganization of the business and equity ownership of its majority-owned ThermoGenesis Corp. subsidiary. Pursuant to the reorganization, the assets acquired by ThermoGenesis Corp. from SynGen Inc. in July 2017 were contributed to a newly formed Delaware subsidiary of ThermoGenesis Corp., CARTXpress Bio and the 20% interest in ThermoGenesis Corp. held by a third party was exchanged for 20% interest in CARTXpress Bio. As a result, the Company holds an 80% equity interest in CARTXpress Bio and the Company has become the owner of 100% of ThermoGenesis Corp. The purpose of the reorganization was to allow CARTXpress Bio to focus on the development and commercialization of the newly launched CARTXpress Bio cellular manufacturing platform.

In the reorganization, the Company reacquired the non-controlling interest shares in ThermoGenesis Corp., which had an accumulated deficit of $1,711,000, in exchange for 20% equity interest in the newly formed subsidiary, CARTXpress Bio, which amounted to approximately $1,100,000. The total amount of $2,843,000 related to the reorganization of the subsidiary and the related increase in non-controlling interest was partially offset by a charge to additional paid in capital in stockholders’ equity.

On November 26, 2019 the Company entered into a joint venture agreement with HealthBanks Biotech Inc. (“HealthBanks”), an affiliate of the Boyalife Group, to form a new company called ImmuneCyte, Inc. (“ImmuneCyte”) to commercialize the Company’s proprietary cell processing platform, CAR-TXpress™, for use in immune cell banking as well as for cell-based contract development and manufacturing services (“CMO/CDMO”). Under the terms of the JV Agreement, ImmuneCyte was initially owned 80% by HealthBanks and 20% by the Company. The Company currently owns 18.79% of the equity of ImmuneCyte.

Table of Contents

ThermoGenesis Holdings is an affiliate of the Boyalife Group, a global diversified life science holding company that focuses on stem cell technology and cell-based therapeutics.

Recent Update on COVID-19 Rapid Test and Antibody Therapeutics

To effectively respond to the COVID-19 pandemic, the Company is seeking to leverage its expertise and global relationships and resources in the medical technology field to bring to market a point-of-care COVID-19 antibody test in the United States. Antibody tests can allow for rapid pre-screening of patients, leading to the identification of individuals who have encountered the virus and have developed antibody immunity. In order to pursue its strategy to sell COVID-19 antibody detection test kits, the Company entered into a supply agreement with BioHit Healthcare (Hefei) Co., Ltd. (“BioHit”) for kits to be marketed under the ThermoGenesis brand. BioHit has obtained an Emergency Use Authorization (“EUA”) from the FDA for its SARS-CoV-2 IgM/IgG Antibody Test Kit.

In addition, the Company began working with ImmuneCyte to develop a convalescent plasma strategy. Convalescent plasma therapy is an exploratory approach that involves giving patients an infusion of plasma from people who have recovered from COVID-19. The Antibody Fast Detection Kits can quickly aid in identifying individuals with an adaptive immune response to SARS-CoV-2. The Company is researching the potential to leverage its technologies along with its proprietary automated cell processing platform, which could potentially allow for simultaneous isolation of convalescent plasma and immune cells for potential anti-COVID-19 antibody development.

In March 2020, the Company signed a supply agreement with ImmuneCyte to purchase antibody testing kits and announced that it filed notification with the FDA of its intent to register a test under the name ThermoGenesis SARS-CoV-2 (COVID-19) IgM/IgG Antibody Fast Detection Kit (Colloidal Gold). In April 2020, the Company received an acknowledgement letter from the U.S. Food and Drug Administration which provided confirmation that the Company’s SARS-CoV-2 (COVID-19) IgM/IgG Antibody Fast Detection Kit had been validated in accordance with Section IV.D. of the “Policy for Diagnostic Tests for Coronavirus Disease – 2019 during the Public Health Emergency,” (“Policy D”) issued by FDA on March 16, 2020. On April 30, 2020, the Company submitted a request to the FDA for review of validation data in order to obtain an EUA for the testing kits. In August 2020, due to concerns over the consistency of performance of these kits, the Company voluntarily withdrew its application for an EUA. Accordingly, the Company determined that it was unlikely that it would be able to sell its on-hand inventory of testing kits. After the Company’s withdrawal of its EUA application, ImmuneCyte agreed to refund their mark-up on the testing kits sold to the Company. That payment of approximately $800,000 was received in the quarter ended September 30, 2020. The Company recorded a loss in cost of goods sold for the remaining carrying value of the testing kits after receipt of the refund of $2,800,000 in the nine-months ended September 30, 2020.

There is significant uncertainty relating to the potential impact of COVID-19 on our business and the general business environment. The extent to which COVID-19 impacts our ability to obtain financing, as well as our results of operations and financial condition, generally, will depend on future developments which are highly uncertain and cannot be predicted, including new information which may emerge concerning the severity of COVID-19 and the actions taken by governments and private businesses to contain COVID-19 or treat its impact, among others. If the disruptions posed by COVID-19 continue for an extended period of time, the markets may not be available to the Company for purposes of raising required capital. Should we not be able to obtain financing when required or on terms which are economically feasible, we may have to significantly delay, scale back, or discontinue the development and/or commercialization of one or more of our product candidates, restrict our operations, or obtain funds by entering into agreements on unfavorable terms.

Table of Contents

Reverse Stock Split

Critical Accounting Policies

Management’s discussion and analysis of its financial condition and results of operations is based upon the condensed consolidated financial statements, which have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”). The preparation of these condensed consolidated financial statements requires management to make estimates and judgments that affect the reported amounts of assets, liabilities, revenues and expenses and related disclosure of contingent assets and liabilities. Estimates are based on historical experience and on various other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions. For a full discussion of our accounting estimates and assumptions that have been identified as critical in the preparation of the Company’s condensed consolidated financial statements, please refer to ThermoGenesis Holdings’ Form 10-K for the year ended December 31, 2019.

Table of Contents

Results of Operations for the Three Months Ended September 30, 2020 as Compared to the Three Months Ended September 30, 2019

Net Revenues

Consolidated net revenues for the three months ended September 30, 2020 were $2,355,000, compared to $4,058,000 for the three months ended September 30, 2019, a decrease of $1,703,000 or 42%. The decrease was driven by AXP^® disposable sales, which declined from approximately 1,000 cases sold in the quarter ended September 30, 2019 to approximately 600 cases sold in the quarter ended September 30, 2020. The decrease resulted in approximately $1,000,000 less in AXP^® disposable revenue for the current quarter. The COVID-19 pandemic appears to be the main driver of the decline in cases sold, as fewer cord blood units are being stored globally during the pandemic. We expect AXP^® disposable sales to increase back to their prior levels after the pandemic is over. Also contributing to the decrease were CAR-TXpress^™ sales which decreased by $489,000. This decrease also appears to be related to the COVID-19 pandemic as the decline was driven by fewer disposable sales.

	September 30, 2020		September 30, 2019
AXP	$	1,169,000	$	2,306,000
BioArchive		619,000		594,000
Manual Disposables		100,000		221,000
CAR-TXpress		425,000		914,000
Other		42,000		23,000
Total	$	2,355,000	$	4,058,000

Gross Profit

The Company’s gross profit was $1,511,000 or 64% of net revenues for the three months ended September 30, 2020, compared to $1,895,000 or 47% of net revenues for three months ended September 30, 2019, a decrease of $384,000. The decrease was driven by a decline in AXP^® disposables sold resulting in approximately $500,000 less gross profit, a decline in AXP^® devices sold resulting in approximately $60,000 less gross profit, a decline in CAR-TXpress^™ sales which generated approximately $250,000 less gross profit, and approximately $250,000 in inventory reserves for X-Series^® disposables. These decreases were partially offset by an increase of approximately $800,000 due to a refund from ImmuneCyte for the mark-up on sales of the COVID-19 testing kits which were previously reserved by the Company in quarter ended June 30, 2020.

Sales and Marketing Expenses

Consolidated sales and marketing expenses were $539,000 for the three months ended September 30, 2020, as compared to $502,000 for the three months ended September 30, 2019, an increase of $37,000 or 7%. The increase was driven by accrued expenses of approximately $45,000 related to the Company’s employee short-term incentive program and approximately $35,000 for consulting expenses. These increases were partially offset by lower stock compensation expense in the quarter ended September 30, 2020.

Research and Development Expenses

Consolidated research and development expenses were $750,000 for the three months ended September 30, 2020 as compared to $584,000 for the three months ended September 30, 2019, an increase of $166,000 or 28%. The increase was driven by development expenses for the Company’s COVID-19 cartridge reader of approximately $150,000.

General and Administrative Expenses

Consolidated general and administrative expenses for the three months ended September 30, 2020 were $1,305,000, compared to $1,139,000 for the three months ended September 30, 2019, an increase of $166,000 or 15%. The primary driver of the increase is approximately $100,000 in accrued expenses related to the Company’s employee short-term incentive program and approximately $70,000 in severance expense.

Interest Expense

Interest expense for the three months ended September 30, 2020 was $1,531,000, compared to $1,188,000 for the three months ended September 30, 2019, an increase of $343,000. The increase was driven by additional interest expense and amortization of the debt discount related to the Revolving Credit Agreement with Boyalife Asset Holding II, Inc.

Table of Contents

Results of Operations for the Nine Months Ended September 30, 2020 as Compared to the Nine Months Ended September 30, 2019

Net Revenues

Consolidated net revenues for the nine months ended September 30, 2020 were $7,797,000, compared to $11,325,000, for the nine months ended September 30, 2019, a decrease of $3,528,000 or 31%. The decrease was driven by AXP^® disposable sales which declined by approximately $2,000,000 with approximately 1,000 fewer cases sold in the nine months ended September 30, 2020 as compared to the nine months ended September 30, 2019. The COVID-19 pandemic has had a significant impact on the cord blood industry, with fewer cord blood units being stored globally after the start of the pandemic. Additionally, AXP^® device sales were approximately $500,000 higher in the year ended September 30, 2019 as compared to September 30, 2020 due to customers converting to new AXP^® II devices. Also contributing to the decrease was BioArchive^® sales which decreased by $816,000, primarily due to two less devices being sold and lower service revenue in the nine months ended September 30, 2020 as compared to the nine months ended September 30, 2019. Partially offsetting these decreases, other revenue increased by $259,000, driven by revenues of approximately $240,000 for COVID-19 testing kits.

	September 30, 2020		September 30, 2019
AXP	$	4,112,000	$	6,710,000
BioArchive		1,575,000		2,391,000
Manual Disposables		499,000		764,000
CAR-TXpress		1,296,000		1,404,000
Other		315,000		56,000
Total	$	7,797,000	$	11,325,000

Gross Profit

The Company’s gross profit was $371,000 or 5% of net revenues for the nine months ended September 30, 2020, compared to $5,105,000 or 45% for the nine months ended September 30, 2019, a decrease of $4,734,000. The gross profit decrease in the current year was driven by an inventory reserve of approximately $2,800,000 in the second quarter, after deducting the $800,000 mark-up refund, for the remaining inventory of COVID-19 testing kits purchased from ImmuneCyte, and approximately $250,000 in inventory reserves for X-Series^® disposables. The nine months ended September 30, 2020 also had reduced gross profit of approximately $1,000,000 less from AXP^® disposable sales and approximately $350,000 less from BioArchive^® sales.

Sales and Marketing Expenses

Consolidated sales and marketing expenses were $1,424,000 for the nine months ended September 30, 2020, as compared to $1,227,000 for the nine months ended September 30, 2019, an increase of $197,000 or 16%. The increase was driven by accrued expenses of approximately $135,000 related to the Company’s employee short-term incentive program and approximately $60,000 for consulting expenses.

Research and Development Expenses

Consolidated research and development expenses were $1,937,000 for the nine months ended September 30, 2020, compared to $1,758,000 for the nine months ended September 30, 2019, an increase of $179,000 or 10%. The increase was driven by development expenses for the Company’s COVID-19 cartridge reader of approximately $150,000.

General and Administrative Expenses

Consolidated general and administrative expenses for the nine months ended September 30, 2020 were $4,489,000, compared to $3,617,000 for the nine months ended September 30, 2019, an increase of $872,000 or 24%. The increase was driven by legal and other expenses related to the Mavericks lawsuit of approximately $220,000, expenses related to the Company’s employee short-term incentive program of approximately $300,000 and approximately $235,000 more for stock compensation expense in the nine months ended September 30, 2020, related to stock options granted to the board of directors and Company executives during the current year.

Table of Contents

Interest Expense

Interest expense increased to $6,377,000 for the nine months ended September 30, 2020 as compared to $3,531,000 for the nine months ended September 30, 2019, an increase of $2,846,000. The increase was driven by the accelerated expense of the unamortized debt discount of $2,486,000 for the beneficial conversion feature associated with the portions of the Revolving Credit Agreement with Boyalife Asset Holding II, Inc. which were converted during the first quarter of 2020. The remainder of the increase was driven by additional interest expense and amortization of the debt discount of approximately $450,000 related to the Revolving Credit Agreement with Boyalife Asset Holding II, Inc.

Liquidity and Capital Resources

At September 30, 2020, the Company had cash and cash equivalents of $4,436,000 and working capital of $7,056,000. This compares to cash and cash equivalents of $3,157,000 and working capital of $3,176,000 at December 31, 2019. We have primarily financed operations through private and public placement of equity securities and our line of credit facility.

The Company has a Revolving Credit Agreement with Boyalife Asset Holding II, Inc. As of September 30, 2020, the outstanding principal balance of the Loan was $10,000,000 of the $10,000,000.

The Company has incurred recurring operating losses and as of September 30, 2020 had an accumulated deficit of $250,434,000. These conditions raise substantial doubt about the Company’s ability to continue as a going concern within one year from the filing of this report. The Company may require additional capital to grow the business, to fund other operating expenses and to make interest payments. The Company’s ability to fund its cash needs is subject to various risks, many of which are beyond its control, including, but not limited to, risks attributable to the COVID-19 pandemic. The Company may seek additional funding through bank borrowings or public or private sales of debt or equity securities or strategic partnerships. The Company cannot guarantee that such funding will be available on a timely basis, in needed quantities or on terms favorable to us, if at all.

Non-GAAP Measures

In addition to the results reported in accordance with U.S. GAAP, we also use a non-GAAP measure, adjusted EBITDA, to evaluate operating performance and to facilitate the comparison of our historical results and trends. The Company calculates adjusted EBITDA as income or (loss) from operations less depreciation, amortization, stock compensation, equity method investments and impairment of intangible assets. This financial measure is not a measure of financial performance under U.S. GAAP and should not be considered in isolation or as a substitute for loss as a measure of performance. The calculation of this non-GAAP measure may not be comparable to similarly titled measures used by other companies. Reconciliations to the most directly comparable GAAP measure are provided below.

Table of Contents

Three months ended September 30, 2020 and 2019, respectively:

	Three Months Ended September 30,
	2020			2019
Net loss	$	(2,609,000	)	$	(2,373,000	)

Deduct:
Interest expense		(1,531,000	)		(1,188,000	)
Loss on extinguishment of debt		--			(840,000	)
Fair value change of derivative instruments and other		5,000			(15,000	)
Loss from operations	$	(1,083,000	)	$	(330,000	)

Add:
Depreciation and amortization		177,000			202,000
Stock-based compensation expense		234,000			253,000
Adjusted EBITDA	$	(672,000	)	$	125,000

Adjusted EBITDA for the three months ended September 30, 2020 was a loss of $672,000, compared to income of $125,000 for the three months ended September 30, 2019, a decrease of $797,000. The adjusted EBITDA decrease was driven by approximately $900,000 less in gross profit as the result of lower sales, approximately $250,000 in inventory reserves for X-Series^® disposables, approximately $175,000 more in expenses related to the Company’s employee short-term incentive program, approximately $150,000 in development expenses for the Company’s COVID-19 cartridge reader and approximately $70,000 in severance expense. These decreases were partially offset by an $800,000 refund the Company received for the mark-up portion of COVID-19 testing kits the Company purchased from ImmuneCyte.

Nine months ended September 30, 2020 and 2019, respectively:

	Nine Months Ended September 30,
	2020			2019
Net Loss	$	(13,862,000	)	$	(5,895,000	)

Deduct:
Interest expense		(6,377,000	)		(3,531,000	)
Fair value change of derivative instruments and other		7,000			(27,000	)
Loss on equity method investments		(13,000	)		--
Loss on extinguishment of debt		--			(840,000	)
Loss from operations	$	(7,479,000	)	$	(1,497,000	)

Add:
Depreciation and amortization		569,000			604,000
Stock-based compensation expense		615,000			459,000
Adjusted EBITDA	$	(6,295,000	)	$	(434,000	)

The adjusted EBITDA loss was $6,295,000 for the nine months ended September 30, 2020 compared to a loss of $434,000 for the nine months ended September 30, 2019, an increase of $5,861,000. The increase was driven by an inventory reserve of approximately $2,800,000, after deducting the $800,000 mark-up refund, for the remaining inventory of COVID-19 testing kits purchased from ImmuneCyte, and approximately $250,000 in inventory reserves for X-Series^® disposables. The nine months ended September 30, 2020 also had reduced gross profit of approximately $1,350,000 due to lower sales, approximately $525,000 more in expenses related to the Company’s employee short-term incentive program, approximately $220,000 in legal and other expenses related to the Mavericks lawsuit, and approximately $150,000 in development expenses for the Company’s COVID-19 cartridge reader.

Off-Balance Sheet Arrangements

As of September 30, 2020, the Company had no off-balance sheet arrangements.

Table of Contents

Item 3. Quantitative and Qualitative Disclosures about Market Risk

ThermoGenesis Holdings, Inc. is a smaller reporting company as defined by Rule 12b-2 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) and is not required to provide information under this item.

Item 4. Controls and Procedures

ThermoGenesis Holdings carried out an evaluation, under the supervision, and with the participation of management, including both the Company’s Chief Executive Officer (principal executive officer) and Chief Financial Officer (principal financial officer), of the effectiveness of the design and operation of ThermoGenesis Holdings’ disclosure controls and procedures (as defined by Exchange Act Rule 13a-15(e) or 15d-15(e)) as of September 30, 2020. Disclosure controls and procedures cover controls and other procedures that are designed to ensure that information required to be disclosed by the Company in reports filed or submitted under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the SEC’s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that such information is accumulated and communicated to management, including the Chief Executive Officer and the Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosure. Based upon that evaluation, ThermoGenesis Holdings’ Chief Executive Officer and Chief Financial Officer have both concluded that the Company’s disclosure controls and procedures were effective as of September 30, 2020.

There were no changes in ThermoGenesis Holdings’ internal controls over financial reporting that occurred during the three months ended September 30, 2020 that have materially affected, or are reasonably likely to materially affect, the Company’s internal controls over financial reporting. Management believes that a control system, no matter how well designed and operated, cannot provide absolute assurance that the objectives of the control system are met, and no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, within any company, have been detected.

Table of Contents

PART II - OTHER INFORMATION

Item 1.

Legal Proceedings.

In the normal course of operations, we may have disagreements or disputes with distributors, vendors or employees. Such potential disputes are seen by management as a normal part of business and while the outcome of such disagreements and disputes cannot be predicted with certainty, except as described below, we do not believe that any pending legal proceedings are material. Regardless of the outcome, litigation can have an adverse impact on us because of defense and settlement costs, diversion of management resources and other factors.

The material set forth in Note 6, “Commitments and Contingencies,” in “Item 1. Financial Statements – Notes to Condensed Consolidated Financial Statements” is incorporated herein by reference.

Item 1A.

Risk Factors.

In addition to the risk factors set forth below and the other information set forth in this report, you should carefully consider the “Risk Factors” discussed in our annual report on Form 10-K for the year ended December 31, 2019.

Marketing of our COVID-19 tests kits under EUAs from FDA is subject to certain limitations, and the continuance of the EUAs is subject to government discretion.

On February 4, 2020, U.S. Department of Health and Human Services (HHS) Secretary Alex Azar issued a declaration that the threat to public health posed by COVID-19 justifies the emergency use of unapproved in vitro diagnostics for the detection or diagnosis of SARS-CoV-2. Under Section 564 of the FDC Act, because HHS has issued this declaration, the FDA Commissioner is authorized to issue Emergency Use Authorizations, or EUAs, to permit certain developers of SARS-CoV-2 diagnostics to begin offering the tests for detection of antibodies to SARS-CoV-2, the virus associated with COVID-19 illness without having completed the normally applicable FDA review and clearance or approval process for marketing authorization (with the related standards that would apply to demonstrate safety and effectiveness). The issuance of an EUA reflects an FDA conclusion that based on the totality of scientific evidence available to the FDA, it is reasonable to believe that the product may be effective in diagnosing COVID-19, and that the known potential benefits of the product outweigh the known and potential risks, and there is no adequate, approved, and available alternative to the emergency use of the product.

On August 13, 2020, we announced that we entered into a supply agreement with BioHit Healthcare (Hefer) Co., Ltd., a manufacturer of a SARS-CoV-2 IgM/IgG Antibody Test Kit which has received an EUA from the U.S. Food and Drug Administration. Under this supply agreement, we will market and sell such Antibody Test Kit in the U.S. under the ThermoGenesis brand. The FDA Commissioner is authorized to issue EUAs to permit certain developers of SARS-CoV-2 diagnostics to begin offering the tests for detection of antibodies to SARS-CoV-2, the virus associated with COVID-19 illness without having completed the normally applicable FDA review and clearance or approval process for marketing authorization (with the related standards that would apply to demonstrate safety and effectiveness). The issuance of an EUA reflects an FDA conclusion that based on the totality of scientific evidence available to the FDA, it is reasonable to believe that the product may be effective in identifying individuals with an adaptive immune response to SARS-CoV-2, indicating recent or prior COVID-19 infection, and that the known potential benefits of the product outweigh the known and potential risks, and there is no adequate, approved, and available alternative to the emergency use of the product. Although there are certain regulatory requirements the FDA has waived for the duration of the EUA, we remain subject to specific conditions of the authorization, including ensuring appropriate labeling as approved by FDA specifically for purposes of the EUA, maintaining records of distribution to authorized laboratories, collecting data on occurrences of any false positives or false negatives, and tracking any adverse events. As with other FDA-regulated products, issues could emerge during the course of the marketing and use of our products under an EUA that could impact our ability to continue the sale and distribution of these products (for example, compliance or product performance issues). The applicable EUAs remain effective only until the applicable declaration of the U.S. Department of Health and Human Services relating to EUAs is terminated or revoked, and FDA may also revoke an EUA if it determines the criteria for issuance are no longer met or other circumstances make such revocation appropriate to protect the public health or safety.

Our COVID-19 test kits may not achieve significant market acceptance.

We only recently entered into a supply agreement with BioHit Healthcare (Hefer) Co., Ltd. to market and sell SARS-CoV-2 IgM/IgG Antibody Test Kits manufactured by BioHit under the ThermoGenesis brand. Therefore, there can be no assurance that our ThermoGenesis-branded test kits will obtain significant market acceptance and fill the market need that is perceived to exist on a timely basis, or at all. In addition, it is possible that our expenses to purchase and market any such test kits will exceed any benefit in revenues, which may be short-lived, or that other products that compete with ours achieve greater commercial success.

Table of Contents

Item 2.

Unregistered Sales of Equity Securities and Use of Proceeds.

None.

Item 3.

Defaults upon Senior Securities.

None.

Item 4.

Mine Safety Disclosure.

Not applicable.

Item 5.

Other Information.

None.

Item 6.

Exhibits.

An index of exhibits is found on page 36 of this report.

Table of Contents

Item 6.

Exhibits.

Exhibit No.	Description
10.1†	Supply Agreement between BioHit Healthcare (Hefei) Co., Ltd. and ThermoGenesis Holdings, Inc. dated August 11, 2020, incorporated by reference to Exhibit 10.6 to Form 10-Q filed August 14, 2020
31.1	Certification by the Principal Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
31.2	Certification by the Principal Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
32	Certification of Principal Executive Officer and Principal Financial Officer pursuant to Section 906 of the Sarbanes Oxley Act of 2002
101.INS	XBRL Instance Document - the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document
101.SCH	XBRL Taxonomy Extension Schema Document
101.CAL	XBRL Taxonomy Extension Calculation Linkbase Document
101.DEF	XBRL Taxonomy Extension Definition Linkbase Document
101.LAB	XBRL Taxonomy Extension Label Linkbase Document
101.PRE	XBRL Taxonomy Extension Presentation Linkbase Document

Footnotes to Exhibit Index

† Portions of this exhibit have been redacted because the Company has determined that such information (i) is not material and (ii) would likely cause competitive harm to the Company if it were to be publicly disclosed.

Table of Contents

ThermoGenesis Holdings, Inc.

Signatures

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

	ThermoGenesis Holdings, Inc. (Registrant)

Dated: November 12, 2020	/s/ Xiaochun (Chris) Xu, Ph.D.
	Xiaochun (Chris) Xu, Ph.D. Chief Executive Officer (Principal Executive Officer)

Dated: November 12, 2020	/s/ Jeff Cauble
	Jeff Cauble Chief Financial Officer (Principal Financial Officer and Principal Accounting Officer)

EX-31.1 2 ex_212674.htm EXHIBIT 31.1 ex_212674.htm

Exhibit 31.1

PRINCIPAL EXECUTIVE OFFICER’S CERTIFICATION
PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

I, Xiaochun (Chris) Xu, certify that:

1. I have reviewed this report on Form 10-Q of ThermoGenesis Holdings, Inc.;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to me by others within those entities, particularly during the period in which this report is being prepared;

(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

(c) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusion about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(d) Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

5. The registrant’s other certifying officer(s) and I have disclosed, based on my most recent evaluation of internal control over financial reporting, to the registrant's auditors and the Audit Committee of the registrant's Board of Directors (or persons performing the equivalent functions):

(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Dated: November 12, 2020

/s/ Xiaochun (Chris) Xu, Ph.D.

Xiaochun (Chris) Xu, Ph.D.

Chief Executive Officer

(Principal Executive Officer)

EX-31.2 3 ex_212675.htm EXHIBIT 31.2 ex_212675.htm

Exhibit 31.2

PRINCIPAL FINANCIAL OFFICER’S CERTIFICATION
PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

I, Jeff Cauble, certify that:

1. I have reviewed this report on Form 10-Q of ThermoGenesis Holdings, Inc.;

4. The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

(c) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

5. The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the Audit Committee of the registrant's Board of Directors (or persons performing the equivalent functions):

(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Dated: November 12, 2020

/s/ Jeff Cauble

Jeff Cauble

Chief Financial Officer

(Principal Financial Officer and Principal Accounting Officer)

EX-32.1 4 ex_212676.htm EXHIBIT 32.1 ex_212676.htm

Exhibit 32

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the quarterly report of ThermoGenesis Holdings, Inc. (the "Company") on Form 10-Q for the period ended September 30, 2020, as filed with the Securities and Exchange Commission (the "Report"), we, Xiaochun (Chris) Xu, Chief Executive Officer and Jeff Cauble, Chief Financial Officer, of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to the best of our knowledge:

(1) the Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2) the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Dated: November 12, 2020	/s/ Xiaochun (Chris) Xu, Ph.D.
	Xiaochun (Chris) Xu, Ph.D. Chief Executive Officer (Principal Executive Officer)


Dated: November 12, 2020	/s/ Jeff Cauble
	Jeff Cauble Chief Financial Officer (Principal Financial Officer and Principal Accounting Officer)

EX-101.INS 5 thmo-20200930.xml XBRL INSTANCE DOCUMENT false --12-31 Q3 2020 2020-09-30 10-Q 0000811212 7796170 Yes false Non-accelerated Filer Yes ThermoGenesis Holdings, Inc. false true Common Stock, $.001 par value thmo 10000 10000 22000 22000 5000 5000 18000 18000 1000 18000 19000 2486000 2486000 1046631 34.42 599582 2.81 25.23 37.27 0.03 0.0499 0.0999 P2Y P3Y P7Y 1473000 -338000 1467000 1519000 1869000 4036000 141000 1.15 1000000 4400000 15280313 0.2 -1526000 -2043000 -6383000 -4398000 0.2 P1Y P2Y 2473000 2683000 5580000 756000 4981000 2313000 800000 2843000 -2843000 2843000 5.38 2.87 2000000 1000000 1000000 100000 224445 50000 150000 216500 7866 267271 47000 47000 1604000 1604000 P2Y P2Y P5Y 33000 7056000

1661000

1447000

1698000

1278000

22000

2000

253537000

237313000

1869000

3112000

1513000

800000

67000

314000

234000

81000

125000

253000

234000

615000

253000

459000

3000

1000

5000

2000

65000

110000

106000

166000

36000

38000

72000

75000

130000

104000

432000

216000

220000

226000

828000

2103000

471000

1398000

77000

27000

107000

2165000

1799000

6988334

6013667

40441

69853

1006190

1300091

892149

296029

8996967

7720081

17289000

15214000

2120000

12776000

9861000

4436000

3157000

4157000

3400000

4436000

3800000

279000

400000

1716066

1116484

0.001

350000000

6832040

2843601

6832040

2843601

7000

3000

-2482000

-2266000

-13482000

-5441000

-146000

-91000

-360000

-445000

-2628000

-2357000

-13842000

-5886000

0.22

0.27

0.2

0.13

0.1

0.02

0.28

0.29

0.12

0.13

0.12

0.59

0.53

2000000

115000

547000

71000

214000

412000

413000

844000

2163000

7426000

6220000

369000

3000000

369000

216000

1666670

204445

3000000

1869000

694000

16.10

1.80

0.50

1.80

0.50

0.9

800000

1000000

0.22

0.24

P1Y180D

800000

556000

4893000

5195000

588000

46000

1690000

620000

700000

286000

1901000

1669000

1404000

569000

604000

-2000

<div style="display: inline; font-family: times new roman; font-size: 10pt"><table style="margin-right: 5%; margin-left: 18pt; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px; min-; min-width: 700px;" cellspacing="0" cellpadding="0" border="0"> <tr style="vertical-align: bottom;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="14" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Three Months Ended September 30, 2020</div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Device Revenue</div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Service Revenue</div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Other Revenue</div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Total Revenue</div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 48%;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-bottom: 0pt; margin-top: 0pt;">AXP</div> </td> <td style="width: 1%; border-bottom: 1px none rgb(0, 0, 0); font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; border-bottom: 1px none rgb(0, 0, 0); font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 10%; border-bottom: 1px none rgb(0, 0, 0); text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">1,137,000</div></td> <td style="width: 1%; border-bottom: 1px none rgb(0, 0, 0); font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; border-bottom: 1px none rgb(0, 0, 0); font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; border-bottom: 1px none rgb(0, 0, 0); font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 10%; border-bottom: 1px none rgb(0, 0, 0); text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">32,000</div></td> <td style="width: 1%; border-bottom: 1px none rgb(0, 0, 0); font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; border-bottom: 1px none rgb(0, 0, 0); font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; border-bottom: 1px none rgb(0, 0, 0); font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 10%; border-bottom: 1px none rgb(0, 0, 0); text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">--</div></td> <td style="width: 1%; border-bottom: 1px none rgb(0, 0, 0); font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; border-bottom: 1px none rgb(0, 0, 0); font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; border-bottom: 1px none rgb(0, 0, 0); font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 10%; border-bottom: 1px none rgb(0, 0, 0); text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">1,169,000</div></td> <td style="width: 1%; border-bottom: 1px none rgb(0, 0, 0); font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-bottom: 0pt; margin-top: 0pt;">BioArchive</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">337,000</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">282,000</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">--</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">619,000</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-bottom: 0pt; margin-top: 0pt;">CAR-TXpress</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">332,000</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">22,000</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">71,000</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">425,000</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-bottom: 0pt; margin-top: 0pt;">Manual Disposables</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">100,000</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">--</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">--</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">100,000</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-bottom: 0pt; margin-top: 0pt;">Other</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">26,000</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">--</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">16,000</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">42,000</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;" nowrap="nowrap"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-bottom: 0pt; margin-top: 0pt; margin-left: 9pt;">Total</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">1,932,000</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">336,000</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">87,000</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">2,355,000</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;" nowrap="nowrap"> </td> </tr> </table></div><div style="display: inline; font-family: times new roman; font-size: 10pt"><table style="margin-right: 5%; margin-left: 18pt; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px; min-; min-width: 700px;" cellspacing="0" cellpadding="0" border="0"> <tr style="vertical-align: bottom;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="14" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Nine Months Ended September 30, 2020</div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Device Revenue</div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Service Revenue</div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Other Revenue</div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Total Revenue</div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 48%;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-bottom: 0pt; margin-top: 0pt;">AXP</div> </td> <td style="width: 1%; border-bottom: 1px none rgb(0, 0, 0); font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; border-bottom: 1px none rgb(0, 0, 0); font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 10%; border-bottom: 1px none rgb(0, 0, 0); text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">4,009,000</div></td> <td style="width: 1%; border-bottom: 1px none rgb(0, 0, 0); font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; border-bottom: 1px none rgb(0, 0, 0); font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; border-bottom: 1px none rgb(0, 0, 0); font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 10%; border-bottom: 1px none rgb(0, 0, 0); text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">103,000</div></td> <td style="width: 1%; border-bottom: 1px none rgb(0, 0, 0); font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; border-bottom: 1px none rgb(0, 0, 0); font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; border-bottom: 1px none rgb(0, 0, 0); font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 10%; border-bottom: 1px none rgb(0, 0, 0); text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">--</div></td> <td style="width: 1%; border-bottom: 1px none rgb(0, 0, 0); font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; border-bottom: 1px none rgb(0, 0, 0); font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; border-bottom: 1px none rgb(0, 0, 0); font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 10%; border-bottom: 1px none rgb(0, 0, 0); text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">4,112,000</div></td> <td style="width: 1%; border-bottom: 1px none rgb(0, 0, 0); font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-bottom: 0pt; margin-top: 0pt;">BioArchive</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">675,000</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">900,000</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">--</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">1,575,000</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-bottom: 0pt; margin-top: 0pt;">CAR-TXpress</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">1,035,000</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">47,000</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">214,000</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">1,296,000</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-bottom: 0pt; margin-top: 0pt;">Manual Disposables</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">499,000</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">--</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">--</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">499,000</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-bottom: 0pt; margin-top: 0pt;">Other</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">276,000</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">--</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">39,000</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">315,000</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;" nowrap="nowrap"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-bottom: 0pt; margin-top: 0pt; margin-left: 9pt;">Total</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">6,494,000</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">1,050,000</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">253,000</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">7,797,000</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;" nowrap="nowrap"> </td> </tr> </table></div><div style="display: inline; font-family: times new roman; font-size: 10pt"><table style="margin-right: 5%; margin-left: 18pt; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px; min-; min-width: 700px;" cellspacing="0" cellpadding="0" border="0"> <tr style="vertical-align: bottom;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="14" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Three Months Ended September 30, 2019</div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Device Revenue</div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Service Revenue</div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Other Revenue</div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Total Revenue</div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 48%;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-bottom: 0pt; margin-top: 0pt;">AXP</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">2,255,000</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">51,000</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">--</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; border-bottom: 1px none rgb(0, 0, 0); font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; border-bottom: 1px none rgb(0, 0, 0); font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 10%; border-bottom: 1px none rgb(0, 0, 0); text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">2,306,000</div></td> <td style="width: 1%; border-bottom: 1px none rgb(0, 0, 0); font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-bottom: 0pt; margin-top: 0pt;">BioArchive</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">243,000</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">351,000</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">--</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">594,000</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-bottom: 0pt; margin-top: 0pt;">Manual Disposables</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">221,000</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">--</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">--</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">221,000</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-bottom: 0pt; margin-top: 0pt;">CAR-TXpress</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">875,000</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">10,000</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">33,000</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">918,000</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-bottom: 0pt; margin-top: 0pt;">Other</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">--</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">--</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">19,000</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">19,000</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;" nowrap="nowrap"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-bottom: 0pt; margin-top: 0pt; margin-left: 9pt;">Total</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">3,594,000</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">412,000</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">52,000</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">4,058,000</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;" nowrap="nowrap"> </td> </tr> </table></div><div style="display: inline; font-family: times new roman; font-size: 10pt"><table style="margin-right: 5%; margin-left: 18pt; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px; min-; min-width: 700px;" cellspacing="0" cellpadding="0" border="0"> <tr style="vertical-align: bottom;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="14" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Nine Months Ended September 30, 2019</div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Device Revenue</div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Service Revenue</div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Other Revenue</div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Total Revenue</div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 48%;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-bottom: 0pt; margin-top: 0pt;">AXP</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">6,550,000</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">160,000</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; border-bottom: 1px none rgb(0, 0, 0); font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; border-bottom: 1px none rgb(0, 0, 0); font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 10%; border-bottom: 1px none rgb(0, 0, 0); text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">--</div></td> <td style="width: 1%; border-bottom: 1px none rgb(0, 0, 0); font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; border-bottom: 1px none rgb(0, 0, 0); font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; border-bottom: 1px none rgb(0, 0, 0); font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 10%; border-bottom: 1px none rgb(0, 0, 0); text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">6,710,000</div></td> <td style="width: 1%; border-bottom: 1px none rgb(0, 0, 0); font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-bottom: 0pt; margin-top: 0pt;">BioArchive</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">1,274,000</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">1,117,000</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">--</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">2,391,000</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-bottom: 0pt; margin-top: 0pt;">Manual Disposables</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">764,000</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">--</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">--</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">764,000</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-bottom: 0pt; margin-top: 0pt;">CAR-TXpress</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">1,365,000</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">6,000</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">33,000</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">1,404,000</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-bottom: 0pt; margin-top: 0pt;">Other</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">5,000</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">11,000</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">40,000</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">56,000</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;" nowrap="nowrap"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-bottom: 0pt; margin-top: 0pt; margin-left: 9pt;">Total</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">9,958,000</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">1,294,000</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">73,000</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">11,325,000</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;" nowrap="nowrap"> </td> </tr> </table></div>

5107000

3518000

-0.37

-0.78

-2.36

-2

-3000

513000

288000

28000

0.8

0.2

0.1879

0.0605

0.7516

32000

15000

-118000

-20000

-1400000

840000

-840000

1305000

1139000

4489000

3617000

781000

1511000

1895000

371000

5105000

13000

-13000

223000

-542000

414000

2908000

80000

354000

-350000

-116000

225000

-298000

6086000

-980000

-1326000

-145000

-6000

227000

1382000

1467000

1531000

1188000

6377000

3531000

46000

2094000

1613000

580000

1519000

1869000

5876000

3824000

755000

350000

2800000

<div style="display: inline; font-family: times new roman; font-size: 10pt"><table style="margin-right: 5%; margin-left: 5%; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px; min-; min-width: 700px;" cellspacing="0" cellpadding="0" border="0"> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 83%;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">2020 (remaining)</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">76,000</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">2021</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">310,000</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">2022</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">319,000</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">2023</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">328,000</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">2024</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">139,000</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Thereafter</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">--</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;" nowrap="nowrap"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Total lease payments</div> </td> <td style="width: 1%; border-bottom: 1px none rgb(0, 0, 0); font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; border-bottom: 1px none rgb(0, 0, 0); font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 14%; border-bottom: 1px none rgb(0, 0, 0); text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">1,172,000</div></td> <td style="width: 1%; border-bottom: 1px none rgb(0, 0, 0); font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Less: imputed interest</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">(377,000</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;" nowrap="nowrap">)</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Present value of operating lease liabilities</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">795,000</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;" nowrap="nowrap"> </td> </tr> </table></div>

1172000

310000

139000

328000

319000

76000

377000

13987000

14298000

17289000

15214000

296000

5720000

6685000

10000000

1000000

10000000

480000

1000000

111000

400000

369000

1473000

411000

1000000

-1711000

1100000

170000

530000

0.2

0.8

12164000

4096000

-23000

-178000

-11859000

-3518000

-146000

-91000

-360000

-445000

-2463000

-2282000

-13502000

-5450000

-4602000

-141000

-4743000

-6437000

-73000

-6510000

-2463000

-146000

-2609000

-1871000

-176000

-2047000

-1297000

-178000

-1475000

-2282000

-91000

-2373000

235000

2594000

2225000

7850000

6602000

-1083000

-330000

-7479000

-1497000

135000

343000

795000

147000

648000

761000

225000

966000

765000

859000

0.22

P3Y255D

<div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic; font: inherit;">2.</div>     </div><div style="display: inline; text-decoration: underline;"><div style="display: inline; font-weight: bold;">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</div></div></div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><div style="display: inline; font-style: italic;"><div style="display: inline; font-weight: bold;"> </div></div></div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><div style="display: inline; font-style: italic;"><div style="display: inline; font-weight: bold;"></div></div></div> <div style="display: inline; font-style: italic; font: inherit;"><div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><div style="display: inline; font-style: italic;"><div style="display: inline; font-weight: bold;">Recently Issued Accounting Standards</div></div></div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">In <div style="display: inline; font-style: italic; font: inherit;"> August 2020, </div>the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) <div style="display: inline; font-style: italic; font: inherit;">2020</div>-<div style="display: inline; font-style: italic; font: inherit;">06</div> <div style="display: inline; font-style: italic;">“Debt-Debt with Conversion and Other Options (</div><div style="display: inline; font-style: italic;">“</div><div style="display: inline; font-style: italic;">Subtopic <div style="display: inline; font-style: italic; font: inherit;">470</div>-<div style="display: inline; font-style: italic; font: inherit;">20</div></div><div style="display: inline; font-style: italic;">”</div><div style="display: inline; font-style: italic;">) and Derivatives and Hedging—Contracts in Entity's Own Equity (</div><div style="display: inline; font-style: italic;">“</div><div style="display: inline; font-style: italic;">Subtopic <div style="display: inline; font-style: italic; font: inherit;">815</div>-<div style="display: inline; font-style: italic; font: inherit;">40</div></div><div style="display: inline; font-style: italic;">”</div><div style="display: inline; font-style: italic;">): Accounting for Convertible Instruments and Contracts in an Entity's Own Equity,”</div> which, among other things, provides guidance on how to account for contracts on an entity's own equity. This ASU simplifies the accounting for certain financial instruments with characteristics of liabilities and equity. Specifically, the ASU eliminated the need for the Company to assess whether a contract on the entity's own equity (<div style="display: inline; font-style: italic; font: inherit;">1</div>) permits settlement in unregistered shares, (<div style="display: inline; font-style: italic; font: inherit;">2</div>) whether counterparty rights rank higher than shareholder's rights, and (<div style="display: inline; font-style: italic; font: inherit;">3</div>) whether collateral is required. In addition, the ASU requires incremental disclosure related to contracts on the entity's own equity and clarifies the treatment of certain financial instruments accounted for under this ASU on earnings per share. This ASU <div style="display: inline; font-style: italic; font: inherit;"> may </div>be applied on a full retrospective of modified retrospective basis. This ASU is effective <div style="display: inline; font-style: italic; font: inherit;"> January 1, 2022 </div>and interim periods presented. Early adoption of the ASU is permitted by the Company effective <div style="display: inline; font-style: italic; font: inherit;"> January 1, 2021. </div>The Company is in the process of assessing the impact of the adoption of the ASU on the Company's financial statements.</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"> </div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">In <div style="display: inline; font-style: italic; font: inherit;"> December 2019, </div>FASB issued ASU <div style="display: inline; font-style: italic; font: inherit;">2019</div>-<div style="display: inline; font-style: italic; font: inherit;">12</div> “<div style="display: inline; font-style: italic;">Income Taxes (</div><div style="display: inline; font-style: italic;">“</div><div style="display: inline; font-style: italic;">Topic <div style="display: inline; font-style: italic; font: inherit;">740</div></div><div style="display: inline; font-style: italic;">”</div><div style="display: inline; font-style: italic;">): Simplifying the Accounting of Income Taxes</div><div style="display: inline; font-style: italic;">,</div>” which is intended to simplify various aspects related to accounting for income taxes. ASU <div style="display: inline; font-style: italic; font: inherit;">2019</div>-<div style="display: inline; font-style: italic; font: inherit;">12</div> removes certain exceptions to the general principles in Topic <div style="display: inline; font-style: italic; font: inherit;">740</div> and also clarifies and amends existing guidance to improve consistent application. This guidance is effective for fiscal years and interim periods within those fiscal years, beginning after <div style="display: inline; font-style: italic; font: inherit;"> December 15, 2020, </div>with early adoption permitted. The Company doesn't expect the adoption of the standard to have a material impact.</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"> </div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">In <div style="display: inline; font-style: italic; font: inherit;"> June 2016, </div>the FASB issued<div style="display: inline; font-style: italic;"> ASU <div style="display: inline; font-style: italic; font: inherit;">2016</div>-<div style="display: inline; font-style: italic; font: inherit;">13,</div> </div><div style="display: inline; font-style: italic;">“</div><div style="display: inline; font-style: italic;">Financial Instruments - Credit Losses (</div><div style="display: inline; font-style: italic;">“</div><div style="display: inline; font-style: italic;">Topic <div style="display: inline; font-style: italic; font: inherit;">326</div></div><div style="display: inline; font-style: italic;">”</div><div style="display: inline; font-style: italic;">).</div><div style="display: inline; font-style: italic;">”</div><div style="display: inline; font-style: italic;"> </div>The ASU introduces a new accounting model, the Current Expected Credit Losses model (“CECL”), which requires<div style="display: inline; font-style: italic;"> </div>earlier recognition of credit losses and additional disclosures related to credit risk. The CECL model utilizes a lifetime expected credit loss measurement objective for the recognition of credit losses at the time the financial asset is originated or acquired. ASU <div style="display: inline; font-style: italic; font: inherit;">2016</div>-<div style="display: inline; font-style: italic; font: inherit;">13</div> is effective for annual periods beginning after <div style="display: inline; font-style: italic; font: inherit;"> December 15, 2022, </div>including interim reporting periods within those annual reporting periods. We expect that the impact of adoption will <div style="display: inline; font-style: italic; font: inherit;">not</div> have a material impact.</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><div style="display: inline; font-style: italic;"><div style="display: inline; font-weight: bold;"> </div></div></div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><div style="display: inline; font-style: italic;"><div style="display: inline; font-weight: bold;">Recently Adopted Accounting Standards</div></div></div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">In <div style="display: inline; font-style: italic; font: inherit;"> August 2018, </div>the FASB issued ASU <div style="display: inline; font-style: italic; font: inherit;">2018</div>-<div style="display: inline; font-style: italic; font: inherit;">13,</div> “<div style="display: inline; font-style: italic;">Fair Value Measurement (“Topic <div style="display: inline; font-style: italic; font: inherit;">820”</div>): Disclosure Framework-Changes to the Disclosure Requirements for Fair Value Measurement</div>.” This ASU eliminates, adds and modifies certain disclosure requirements for fair value measurements as part of its disclosure framework project. The standard was adopted and did <div style="display: inline; font-style: italic; font: inherit;">not</div> have a material impact on the Company's financial statements.</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"> </div></div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"></div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"><div style="display: inline; font-style: italic;"><div style="display: inline; font-weight: bold;"></div></div></div> <div style="display: inline; font-style: italic; font: inherit;"><div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"><div style="display: inline; font-style: italic;"><div style="display: inline; font-weight: bold;">Revenue Recognition </div></div></div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">Revenue is recognized based on the <div style="display: inline; font-style: italic; font: inherit;">five</div>-step process outlined in Accounting Standards Codification (“ASC”) <div style="display: inline; font-style: italic; font: inherit;">606.</div></div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><div style="display: inline; font-style: italic;"> </div></div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">The following tables summarize the revenues by product line:</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><div style="display: inline; font-weight: bold;"> </div></div> <div> <table style="margin-right: 5%; margin-left: 18pt; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px; min-width: 700px;" cellspacing="0" cellpadding="0" border="0"> <tr style="vertical-align: bottom;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="14" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Three Months Ended September 30, 2020</div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Device Revenue</div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Service Revenue</div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Other Revenue</div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Total Revenue</div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 48%;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-bottom: 0pt; margin-top: 0pt;">AXP</div> </td> <td style="width: 1%; border-bottom: 1px none rgb(0, 0, 0); font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; border-bottom: 1px none rgb(0, 0, 0); font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 10%; border-bottom: 1px none rgb(0, 0, 0); text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">1,137,000</div></td> <td style="width: 1%; border-bottom: 1px none rgb(0, 0, 0); font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; border-bottom: 1px none rgb(0, 0, 0); font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; border-bottom: 1px none rgb(0, 0, 0); font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 10%; border-bottom: 1px none rgb(0, 0, 0); text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">32,000</div></td> <td style="width: 1%; border-bottom: 1px none rgb(0, 0, 0); font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; border-bottom: 1px none rgb(0, 0, 0); font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; border-bottom: 1px none rgb(0, 0, 0); font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 10%; border-bottom: 1px none rgb(0, 0, 0); text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">--</div></td> <td style="width: 1%; border-bottom: 1px none rgb(0, 0, 0); font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; border-bottom: 1px none rgb(0, 0, 0); font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; border-bottom: 1px none rgb(0, 0, 0); font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 10%; border-bottom: 1px none rgb(0, 0, 0); text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">1,169,000</div></td> <td style="width: 1%; border-bottom: 1px none rgb(0, 0, 0); font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-bottom: 0pt; margin-top: 0pt;">BioArchive</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">337,000</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">282,000</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">--</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">619,000</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-bottom: 0pt; margin-top: 0pt;">CAR-TXpress</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">332,000</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">22,000</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">71,000</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">425,000</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-bottom: 0pt; margin-top: 0pt;">Manual Disposables</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">100,000</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">--</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">--</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">100,000</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-bottom: 0pt; margin-top: 0pt;">Other</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">26,000</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">--</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">16,000</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">42,000</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;" nowrap="nowrap"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-bottom: 0pt; margin-top: 0pt; margin-left: 9pt;">Total</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">1,932,000</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">336,000</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">87,000</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">2,355,000</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;" nowrap="nowrap"> </td> </tr> </table> </div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </div> <div> <table style="margin-right: 5%; margin-left: 18pt; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px; min-width: 700px;" cellspacing="0" cellpadding="0" border="0"> <tr style="vertical-align: bottom;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="14" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Nine Months Ended September 30, 2020</div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Device Revenue</div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Service Revenue</div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Other Revenue</div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Total Revenue</div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 48%;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-bottom: 0pt; margin-top: 0pt;">AXP</div> </td> <td style="width: 1%; border-bottom: 1px none rgb(0, 0, 0); font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; border-bottom: 1px none rgb(0, 0, 0); font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 10%; border-bottom: 1px none rgb(0, 0, 0); text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">4,009,000</div></td> <td style="width: 1%; border-bottom: 1px none rgb(0, 0, 0); font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; border-bottom: 1px none rgb(0, 0, 0); font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; border-bottom: 1px none rgb(0, 0, 0); font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 10%; border-bottom: 1px none rgb(0, 0, 0); text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">103,000</div></td> <td style="width: 1%; border-bottom: 1px none rgb(0, 0, 0); font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; border-bottom: 1px none rgb(0, 0, 0); font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; border-bottom: 1px none rgb(0, 0, 0); font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 10%; border-bottom: 1px none rgb(0, 0, 0); text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">--</div></td> <td style="width: 1%; border-bottom: 1px none rgb(0, 0, 0); font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; border-bottom: 1px none rgb(0, 0, 0); font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; border-bottom: 1px none rgb(0, 0, 0); font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 10%; border-bottom: 1px none rgb(0, 0, 0); text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">4,112,000</div></td> <td style="width: 1%; border-bottom: 1px none rgb(0, 0, 0); font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-bottom: 0pt; margin-top: 0pt;">BioArchive</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">675,000</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">900,000</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">--</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">1,575,000</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-bottom: 0pt; margin-top: 0pt;">CAR-TXpress</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">1,035,000</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">47,000</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">214,000</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">1,296,000</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-bottom: 0pt; margin-top: 0pt;">Manual Disposables</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">499,000</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">--</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">--</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">499,000</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-bottom: 0pt; margin-top: 0pt;">Other</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">276,000</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">--</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">39,000</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">315,000</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;" nowrap="nowrap"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-bottom: 0pt; margin-top: 0pt; margin-left: 9pt;">Total</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">6,494,000</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">1,050,000</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">253,000</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">7,797,000</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;" nowrap="nowrap"> </td> </tr> </table> </div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </div> <div> <table style="margin-right: 5%; margin-left: 18pt; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px; min-width: 700px;" cellspacing="0" cellpadding="0" border="0"> <tr style="vertical-align: bottom;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="14" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Three Months Ended September 30, 2019</div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Device Revenue</div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Service Revenue</div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Other Revenue</div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Total Revenue</div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 48%;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-bottom: 0pt; margin-top: 0pt;">AXP</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">2,255,000</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">51,000</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">--</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; border-bottom: 1px none rgb(0, 0, 0); font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; border-bottom: 1px none rgb(0, 0, 0); font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 10%; border-bottom: 1px none rgb(0, 0, 0); text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">2,306,000</div></td> <td style="width: 1%; border-bottom: 1px none rgb(0, 0, 0); font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-bottom: 0pt; margin-top: 0pt;">BioArchive</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">243,000</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">351,000</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">--</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">594,000</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-bottom: 0pt; margin-top: 0pt;">Manual Disposables</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">221,000</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">--</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">--</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">221,000</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-bottom: 0pt; margin-top: 0pt;">CAR-TXpress</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">875,000</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">10,000</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">33,000</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">918,000</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-bottom: 0pt; margin-top: 0pt;">Other</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">--</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">--</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">19,000</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">19,000</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;" nowrap="nowrap"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-bottom: 0pt; margin-top: 0pt; margin-left: 9pt;">Total</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">3,594,000</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">412,000</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">52,000</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">4,058,000</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;" nowrap="nowrap"> </td> </tr> </table> </div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </div> <div> <table style="margin-right: 5%; margin-left: 18pt; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px; min-width: 700px;" cellspacing="0" cellpadding="0" border="0"> <tr style="vertical-align: bottom;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="14" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Nine Months Ended September 30, 2019</div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Device Revenue</div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Service Revenue</div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Other Revenue</div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Total Revenue</div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 48%;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-bottom: 0pt; margin-top: 0pt;">AXP</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">6,550,000</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">160,000</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; border-bottom: 1px none rgb(0, 0, 0); font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; border-bottom: 1px none rgb(0, 0, 0); font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 10%; border-bottom: 1px none rgb(0, 0, 0); text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">--</div></td> <td style="width: 1%; border-bottom: 1px none rgb(0, 0, 0); font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; border-bottom: 1px none rgb(0, 0, 0); font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; border-bottom: 1px none rgb(0, 0, 0); font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 10%; border-bottom: 1px none rgb(0, 0, 0); text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">6,710,000</div></td> <td style="width: 1%; border-bottom: 1px none rgb(0, 0, 0); font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-bottom: 0pt; margin-top: 0pt;">BioArchive</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">1,274,000</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">1,117,000</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">--</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">2,391,000</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-bottom: 0pt; margin-top: 0pt;">Manual Disposables</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">764,000</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">--</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">--</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">764,000</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-bottom: 0pt; margin-top: 0pt;">CAR-TXpress</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">1,365,000</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">6,000</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">33,000</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">1,404,000</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-bottom: 0pt; margin-top: 0pt;">Other</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">5,000</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">11,000</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">40,000</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">56,000</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;" nowrap="nowrap"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-bottom: 0pt; margin-top: 0pt; margin-left: 9pt;">Total</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">9,958,000</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">1,294,000</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">73,000</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">11,325,000</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;" nowrap="nowrap"> </td> </tr> </table> </div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"> </div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"><div style="display: inline; font-style: italic;"><div style="display: inline; font-weight: bold;">Contract Balances</div></div></div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">Generally, all sales are contract sales (with either an underlying contract or purchase order). The Company does <div style="display: inline; font-style: italic; font: inherit;">not</div> have any material contract assets. When invoicing occurs prior to revenue recognition, a contract liability is recorded (as deferred revenue on the consolidated balance sheet). Revenues recognized during the <div style="display: inline; font-style: italic; font: inherit;">three</div> and <div style="display: inline; font-style: italic; font: inherit;">nine</div> months ended <div style="display: inline; font-style: italic; font: inherit;"> September 30, 2020 </div>that were included in the beginning balance of deferred revenue were <div style="display: inline; font-style: italic; font: inherit;">$115,000</div> and <div style="display: inline; font-style: italic; font: inherit;">$547,000,</div> respectively. Short-term deferred revenues increased from <div style="display: inline; font-style: italic; font: inherit;">$620,000</div> to <div style="display: inline; font-style: italic; font: inherit;">$700,000</div> and long-term deferred revenues decreased from <div style="display: inline; font-style: italic; font: inherit;">$1,901,000</div> to <div style="display: inline; font-style: italic; font: inherit;">$1,669,000</div> during the <div style="display: inline; font-style: italic; font: inherit;">nine</div> months ended <div style="display: inline; font-style: italic; font: inherit;"> September 30, 2020, </div>respectively.</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"><div style="display: inline; font-style: italic;"><div style="display: inline; font-weight: bold;"> </div></div></div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"><div style="display: inline; font-style: italic;"><div style="display: inline; font-weight: bold;">Exclusivity Fee</div></div></div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">On <div style="display: inline; font-style: italic; font: inherit;"> August 30, 2019, </div>the Company entered into a Supply Agreement with Corning Incorporated (the “Supply Agreement”). The Supply Agreement has an initial term of <div style="display: inline; font-style: italic; font: inherit;">five</div> years with automatic <div style="display: inline; font-style: italic; font: inherit;">two</div>-year renewal terms, unless terminated by either party in accordance with the terms of the Supply Agreement (collectively, the “Term”). Pursuant to the Supply Agreement, the Company has granted to Corning exclusive worldwide distribution rights for substantially all <div style="display: inline; font-style: italic; font: inherit;">X</div>-Series<div style="display: inline; bottom:.33em; font-size: 82%; position: relative; vertical-align: baseline; vertical-align:top;line-height:120%;font-size:pt">®</div> products under the CAR-TXpress™ platform (the “Products”) manufactured by its subsidiary, ThermoGenesis Corp., for the duration of the Term, subject to certain geographical and other exceptions. As consideration for the exclusive worldwide distribution rights for the Products, Corning paid a <div style="display: inline; font-style: italic; font: inherit;">$2,000,000</div> exclusivity fee, in addition to any amounts payable throughout the Term for the Products.</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"> </div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">The Company performed an evaluation of the revenue recognition of the <div style="display: inline; font-style: italic; font: inherit;">$2,000,000</div> fee under ASC <div style="display: inline; font-style: italic; font: inherit;">606.</div> It determined that the <div style="display: inline; font-style: italic; font: inherit;">$2,000,000</div> will be recognized over time, based on the term of the contract. It was determined that the most likely outcome is the agreement is extended for <div style="display: inline; font-style: italic; font: inherit;">one</div> additional <div style="display: inline; font-style: italic; font: inherit;">two</div>-year term after the initial <div style="display: inline; font-style: italic; font: inherit;">five</div>-year contract is complete. Consequently, the term to recognize the exclusivity fee is over <div style="display: inline; font-style: italic; font: inherit;">seven</div> years. The Company will allocate the upfront fee evenly to each daily performance obligation of providing exclusivity and recognize the revenue ratably over the <div style="display: inline; font-style: italic; font: inherit;">seven</div>-year period. As each day passes, the Company will recognize the portion of the exclusivity fee allocated to that day. For the <div style="display: inline; font-style: italic; font: inherit;">three</div> and <div style="display: inline; font-style: italic; font: inherit;">nine</div> months ended <div style="display: inline; font-style: italic; font: inherit;"> September 30, 2020, </div>the Company recorded revenue of <div style="display: inline; font-style: italic; font: inherit;">$71,000</div> and <div style="display: inline; font-style: italic; font: inherit;">$214,000,</div> respectively, related to the exclusivity fee. The remaining balance of the <div style="display: inline; font-style: italic; font: inherit;">$2,000,000</div> payment of <div style="display: inline; font-style: italic; font: inherit;">$1,690,000</div> was recorded to deferred revenue, with <div style="display: inline; font-style: italic; font: inherit;">$286,000</div> in short-term deferred revenue and <div style="display: inline; font-style: italic; font: inherit;">$1,404,000</div> recorded in long-term deferred revenue.</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"> </div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"><div style="display: inline; font-style: italic;"><div style="display: inline; font-weight: bold;">Backlog of Remaining Customer Performance Obligations</div></div></div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">The following table includes revenue expected to be recognized and recorded as sales in the future from the backlog of performance obligations that are unsatisfied (or partially unsatisfied) at the end of the reporting period.</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"> </div> <div> <table style="; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px; min-width: 700px;" cellspacing="0" cellpadding="0" border="0"> <tr style="vertical-align: bottom;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Remainder of 2020</div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">2021</div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">2022</div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">2023</div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">2024 and beyond</div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Total</div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 28%;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Service revenue</div> </td> <td style="width: 1%; border-bottom: 1px none rgb(0, 0, 0); font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; border-bottom: 1px none rgb(0, 0, 0); font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">$</div></td> <td style="width: 9%; border-bottom: 1px none rgb(0, 0, 0); text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">310,000</div></td> <td style="width: 1%; border-bottom: 1px none rgb(0, 0, 0); font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; border-bottom: 1px none rgb(0, 0, 0); font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; border-bottom: 1px none rgb(0, 0, 0); font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">$</div></td> <td style="width: 9%; border-bottom: 1px none rgb(0, 0, 0); text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">958,000</div></td> <td style="width: 1%; border-bottom: 1px none rgb(0, 0, 0); font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; border-bottom: 1px none rgb(0, 0, 0); font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; border-bottom: 1px none rgb(0, 0, 0); font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">$</div></td> <td style="width: 9%; border-bottom: 1px none rgb(0, 0, 0); text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">561,000</div></td> <td style="width: 1%; border-bottom: 1px none rgb(0, 0, 0); font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; border-bottom: 1px none rgb(0, 0, 0); font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; border-bottom: 1px none rgb(0, 0, 0); font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">$</div></td> <td style="width: 9%; border-bottom: 1px none rgb(0, 0, 0); text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">298,000</div></td> <td style="width: 1%; border-bottom: 1px none rgb(0, 0, 0); font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; border-bottom: 1px none rgb(0, 0, 0); font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; border-bottom: 1px none rgb(0, 0, 0); font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">$</div></td> <td style="width: 9%; border-bottom: 1px none rgb(0, 0, 0); text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">38,000</div></td> <td style="width: 1%; border-bottom: 1px none rgb(0, 0, 0); font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; border-bottom: 1px none rgb(0, 0, 0); font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; border-bottom: 1px none rgb(0, 0, 0); font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">$</div></td> <td style="width: 9%; border-bottom: 1px none rgb(0, 0, 0); text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">2,165,000</div></td> <td style="width: 1%; border-bottom: 1px none rgb(0, 0, 0); font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Clinical revenue</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><div style="display: inline; font-style: italic; font: inherit;"> </div></td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">3,000</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><div style="display: inline; font-style: italic; font: inherit;"> </div></td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">13,000</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><div style="display: inline; font-style: italic; font: inherit;"> </div></td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">13,000</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><div style="display: inline; font-style: italic; font: inherit;"> </div></td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">13,000</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><div style="display: inline; font-style: italic; font: inherit;"> </div></td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">175,000</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><div style="display: inline; font-style: italic; font: inherit;"> </div></td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">217,000</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Exclusivity fee</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;"> </div></td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">71,000</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;"> </div></td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">286,000</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;"> </div></td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">286,000</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;"> </div></td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">286,000</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;"> </div></td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">761,000</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;"> </div></td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">1,690,000</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;" nowrap="nowrap"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Total</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">$</div></td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">384,000</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">$</div></td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">1,257,000</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">$</div></td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">860,000</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">$</div></td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">597,000</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">$</div></td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">974,000</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">$</div></td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">4,072,000</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;" nowrap="nowrap"> </td> </tr> </table> </div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"> </div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Revenues are net of normal discounts. Shipping and handling fees billed to customers are included in net revenues, while the related costs are included in cost of revenues.</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </div></div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"></div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><div style="display: inline; font-style: italic;"><div style="display: inline; font-weight: bold;"></div></div></div> <div style="display: inline; font-style: italic; font: inherit;"><div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><div style="display: inline; font-style: italic;"><div style="display: inline; font-weight: bold;">Fair Value Measurements</div></div></div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">In accordance with ASC <div style="display: inline; font-style: italic; font: inherit;">820,</div> “<div style="display: inline; font-style: italic;">Fair Value Measurements and Disclosures</div>,” fair value is defined as the exit price, or the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants as of the measurement date.</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"> </div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">The guidance also establishes a hierarchy for inputs used in measuring fair value that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that the most observable inputs be used when available. Observable inputs are inputs that market participants would use in valuing the asset or liability and are developed based on market data obtained from sources independent of the Company. Unobservable inputs are inputs that reflect the Company's assumptions about the factors that market participants would use in valuing the asset or liability. The guidance establishes <div style="display: inline; font-style: italic; font: inherit;">three</div> levels of inputs that <div style="display: inline; font-style: italic; font: inherit;"> may </div>be used to measure fair value:</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"> </div> <table style="; text-indent: 0px; min-width: 700px;" cellspacing="0" cellpadding="0" border="0"> <tr style="vertical-align: top;"> <td style="width: 36pt;"> </td> <td style="width: 45pt;"> <div style=" margin: 0pt; text-align: justify; font-family: "Times New Roman", Times, serif; font-size: 10pt;">Level <div style="display: inline; font-style: italic; font: inherit;">1:</div></div> </td> <td> <div style=" margin: 0pt; text-align: justify; font-family: "Times New Roman", Times, serif; font-size: 10pt;">Quoted market prices in active markets for identical assets or liabilities.</div> </td> </tr> </table> <table style="; text-indent: 0px; min-width: 700px;" cellspacing="0" cellpadding="0" border="0"> <tr style="vertical-align: top;"> <td style="width: 36pt;"> </td> <td style="width: 45pt;"> <div style=" margin: 0pt; text-align: justify; font-family: "Times New Roman", Times, serif; font-size: 10pt;">Level <div style="display: inline; font-style: italic; font: inherit;">2:</div></div> </td> <td> <div style=" margin: 0pt; text-align: justify; font-family: "Times New Roman", Times, serif; font-size: 10pt;">Observable market-based inputs or unobservable inputs that are corroborated by market data.</div> </td> </tr> </table> <table style="; text-indent: 0px; min-width: 700px;" cellspacing="0" cellpadding="0" border="0"> <tr style="vertical-align: top;"> <td style="width: 36pt;"> </td> <td style="width: 45pt;"> <div style=" margin: 0pt; text-align: justify; font-family: "Times New Roman", Times, serif; font-size: 10pt;">Level <div style="display: inline; font-style: italic; font: inherit;">3:</div></div> </td> <td> <div style=" margin: 0pt; text-align: justify; font-family: "Times New Roman", Times, serif; font-size: 10pt;">Unobservable inputs which are supported by little or <div style="display: inline; font-style: italic; font: inherit;">no</div> market activity.</div> </td> </tr> </table> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;"> </div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">The carrying values of cash and cash equivalents, accounts receivable and accounts payable approximate fair value due to their short duration. The fair value of the Company's derivative obligation liability is classified as Level <div style="display: inline; font-style: italic; font: inherit;">3</div> within the fair value hierarchy since the valuation model of the derivative obligation is based on unobservable inputs. The derivative obligation is <div style="display: inline; font-style: italic; font: inherit;">not</div> material to the financial statements of the Company. The impairment of goodwill and intangible assets is a non-recurring Level <div style="display: inline; font-style: italic; font: inherit;">3</div> fair value measurement.</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"> </div></div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"></div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"><div style="display: inline; font-style: italic;"><div style="display: inline; font-weight: bold;"></div></div></div> <div style="display: inline; font-style: italic; font: inherit;"><div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"><div style="display: inline; font-style: italic;"><div style="display: inline; font-weight: bold;">Net Loss per Share</div></div></div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">Net loss per share is computed by dividing the net loss by the weighted average number of common shares outstanding plus pre-funded warrants. For the purpose of calculating basic net loss per share, the additional shares of common stock that are issuable upon exercise of the pre-funded warrants have been included since the shares are issuable for a negligible consideration and have <div style="display: inline; font-style: italic; font: inherit;">no</div> vesting or other contingencies associated with them. As of <div style="display: inline; font-style: italic; font: inherit;"> September 30, 2020, </div>all pre-funded warrants previously issued have been exercised and <div style="display: inline; font-style: italic; font: inherit;">none</div> are currently outstanding. The calculation of the basic and diluted earnings per share is the same for all periods presented, as the effect of the potential common stock equivalents noted below is anti-dilutive due to the Company's net loss position for all periods presented. Anti-dilutive securities consisted of the following at <div style="display: inline; font-style: italic; font: inherit;"> September 30:</div></div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"> </div> <div> <table style="margin-right: 5%; margin-left: 18pt; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px; min-width: 700px;" cellspacing="0" cellpadding="0" border="0"> <tr style="vertical-align: bottom;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">2020</div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">2019</div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 68%;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Common stock equivalents of convertible promissory note and accrued interest</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">6,988,334</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">6,013,667</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Vested Series A warrants</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">40,441</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">40,441</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Unvested Series A warrants<div style="display: inline; bottom:.33em; font-size: 82%; position: relative; vertical-align: baseline; vertical-align:top;line-height:120%;font-size:pt">(1)</div></div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">69,853</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">69,853</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Warrants – other</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">1,006,190</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">1,300,091</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Stock options</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">892,149</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">296,029</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;" nowrap="nowrap"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Total</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">8,996,967</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">7,720,081</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;" nowrap="nowrap"> </td> </tr> </table> </div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">___________</div> <table style=";font-family:'Times New Roman', Times, serif;font-size:10pt; min-width: 700px;" cellspacing="0" cellpadding="0" border="0"> <tr> <td style="width:18pt;"> </td> <td style="width:18pt;vertical-align:top;"> <div style=" font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;">(<div style="display: inline; font-style: italic; font: inherit;">1</div>)</div> </td> <td style="vertical-align:top;"> <div style=" font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;">The unvested Series A warrants were subject to vesting based upon the amount of funds actually received by the Company in the <div style="display: inline; font-style: italic; font: inherit;">second</div> close of the <div style="display: inline; font-style: italic; font: inherit;"> August 2015 </div>financing which never occurred. The warrants will remain outstanding but unvested until they expire in <div style="display: inline; font-style: italic; font: inherit;"> February 2021.</div></div> </td> </tr> </table> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:22.5pt;margin-right:0pt;margin-top:0pt;text-align:justify;"> </div></div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:22.5pt;margin-right:0pt;margin-top:0pt;text-align:justify;"></div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"><div style="display: inline; font-style: italic;"><div style="display: inline; font-weight: bold;"></div></div></div> <div style="display: inline; font-style: italic; font: inherit;"><div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"><div style="display: inline; font-style: italic;"><div style="display: inline; font-weight: bold;">Reclassifications</div></div></div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">Certain prior period amounts have been reclassified to conform to the current period presentation. The reclassifications did <div style="display: inline; font-style: italic; font: inherit;">not</div> have an impact on net loss as previously reported.</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:22.5pt;margin-right:0pt;margin-top:0pt;text-align:justify;"> </div></div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:22.5pt;margin-right:0pt;margin-top:0pt;text-align:justify;"></div></div>

48000

218000

38000

1000

-19000

-4000

-3000

16000

20000

9000

1092000

2461000

20000

5000

-15000

7000

-27000

393000

312000

88000

23000

178000

0.001

2000000

766000

602000

1800000

2000000

3700000

3500000

2785000

2771000

646000

1869000

2418000

646000

4287000

1513000

1683000

42000

277000

148000

171000

-20000

62000

1313000

1422000

-13862000

-5895000

-2609000

-2373000

1537000

2028000

-6000

-53000

3600000

750000

584000

1937000

1758000

1000000

-250434000

-236932000

2355000

4058000

7797000

11325000

<div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"><div style="display: inline; font-style: italic;"><div style="display: inline; font-weight: bold;">Revenue Recognition </div></div></div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">Revenue is recognized based on the <div style="display: inline; font-style: italic; font: inherit;">five</div>-step process outlined in Accounting Standards Codification (“ASC”) <div style="display: inline; font-style: italic; font: inherit;">606.</div></div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><div style="display: inline; font-style: italic;"> </div></div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">The following tables summarize the revenues by product line:</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><div style="display: inline; font-weight: bold;"> </div></div> <div> <table style="margin-right: 5%; margin-left: 18pt; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px; min-width: 700px;" cellspacing="0" cellpadding="0" border="0"> <tr style="vertical-align: bottom;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="14" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Three Months Ended September 30, 2020</div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Device Revenue</div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Service Revenue</div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Other Revenue</div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Total Revenue</div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 48%;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-bottom: 0pt; margin-top: 0pt;">AXP</div> </td> <td style="width: 1%; border-bottom: 1px none rgb(0, 0, 0); font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; border-bottom: 1px none rgb(0, 0, 0); font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 10%; border-bottom: 1px none rgb(0, 0, 0); text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">1,137,000</div></td> <td style="width: 1%; border-bottom: 1px none rgb(0, 0, 0); font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; border-bottom: 1px none rgb(0, 0, 0); font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; border-bottom: 1px none rgb(0, 0, 0); font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 10%; border-bottom: 1px none rgb(0, 0, 0); text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">32,000</div></td> <td style="width: 1%; border-bottom: 1px none rgb(0, 0, 0); font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; border-bottom: 1px none rgb(0, 0, 0); font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; border-bottom: 1px none rgb(0, 0, 0); font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 10%; border-bottom: 1px none rgb(0, 0, 0); text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">--</div></td> <td style="width: 1%; border-bottom: 1px none rgb(0, 0, 0); font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; border-bottom: 1px none rgb(0, 0, 0); font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; border-bottom: 1px none rgb(0, 0, 0); font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 10%; border-bottom: 1px none rgb(0, 0, 0); text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">1,169,000</div></td> <td style="width: 1%; border-bottom: 1px none rgb(0, 0, 0); font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-bottom: 0pt; margin-top: 0pt;">BioArchive</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">337,000</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">282,000</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">--</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">619,000</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-bottom: 0pt; margin-top: 0pt;">CAR-TXpress</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">332,000</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">22,000</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">71,000</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">425,000</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-bottom: 0pt; margin-top: 0pt;">Manual Disposables</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">100,000</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">--</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">--</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">100,000</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-bottom: 0pt; margin-top: 0pt;">Other</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">26,000</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">--</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">16,000</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">42,000</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;" nowrap="nowrap"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-bottom: 0pt; margin-top: 0pt; margin-left: 9pt;">Total</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">1,932,000</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">336,000</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">87,000</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">2,355,000</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;" nowrap="nowrap"> </td> </tr> </table> </div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </div> <div> <table style="margin-right: 5%; margin-left: 18pt; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px; min-width: 700px;" cellspacing="0" cellpadding="0" border="0"> <tr style="vertical-align: bottom;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="14" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Nine Months Ended September 30, 2020</div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Device Revenue</div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Service Revenue</div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Other Revenue</div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Total Revenue</div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 48%;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-bottom: 0pt; margin-top: 0pt;">AXP</div> </td> <td style="width: 1%; border-bottom: 1px none rgb(0, 0, 0); font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; border-bottom: 1px none rgb(0, 0, 0); font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 10%; border-bottom: 1px none rgb(0, 0, 0); text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">4,009,000</div></td> <td style="width: 1%; border-bottom: 1px none rgb(0, 0, 0); font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; border-bottom: 1px none rgb(0, 0, 0); font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; border-bottom: 1px none rgb(0, 0, 0); font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 10%; border-bottom: 1px none rgb(0, 0, 0); text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">103,000</div></td> <td style="width: 1%; border-bottom: 1px none rgb(0, 0, 0); font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; border-bottom: 1px none rgb(0, 0, 0); font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; border-bottom: 1px none rgb(0, 0, 0); font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 10%; border-bottom: 1px none rgb(0, 0, 0); text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">--</div></td> <td style="width: 1%; border-bottom: 1px none rgb(0, 0, 0); font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; border-bottom: 1px none rgb(0, 0, 0); font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; border-bottom: 1px none rgb(0, 0, 0); font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 10%; border-bottom: 1px none rgb(0, 0, 0); text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">4,112,000</div></td> <td style="width: 1%; border-bottom: 1px none rgb(0, 0, 0); font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-bottom: 0pt; margin-top: 0pt;">BioArchive</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">675,000</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">900,000</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">--</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">1,575,000</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-bottom: 0pt; margin-top: 0pt;">CAR-TXpress</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">1,035,000</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">47,000</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">214,000</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">1,296,000</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-bottom: 0pt; margin-top: 0pt;">Manual Disposables</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">499,000</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">--</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">--</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">499,000</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-bottom: 0pt; margin-top: 0pt;">Other</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">276,000</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">--</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">39,000</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">315,000</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;" nowrap="nowrap"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-bottom: 0pt; margin-top: 0pt; margin-left: 9pt;">Total</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">6,494,000</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">1,050,000</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">253,000</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">7,797,000</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;" nowrap="nowrap"> </td> </tr> </table> </div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </div> <div> <table style="margin-right: 5%; margin-left: 18pt; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px; min-width: 700px;" cellspacing="0" cellpadding="0" border="0"> <tr style="vertical-align: bottom;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="14" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Three Months Ended September 30, 2019</div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Device Revenue</div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Service Revenue</div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Other Revenue</div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Total Revenue</div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 48%;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-bottom: 0pt; margin-top: 0pt;">AXP</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">2,255,000</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">51,000</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">--</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; border-bottom: 1px none rgb(0, 0, 0); font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; border-bottom: 1px none rgb(0, 0, 0); font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 10%; border-bottom: 1px none rgb(0, 0, 0); text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">2,306,000</div></td> <td style="width: 1%; border-bottom: 1px none rgb(0, 0, 0); font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-bottom: 0pt; margin-top: 0pt;">BioArchive</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">243,000</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">351,000</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">--</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">594,000</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-bottom: 0pt; margin-top: 0pt;">Manual Disposables</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">221,000</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">--</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">--</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">221,000</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-bottom: 0pt; margin-top: 0pt;">CAR-TXpress</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">875,000</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">10,000</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">33,000</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">918,000</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-bottom: 0pt; margin-top: 0pt;">Other</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">--</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">--</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">19,000</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">19,000</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;" nowrap="nowrap"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-bottom: 0pt; margin-top: 0pt; margin-left: 9pt;">Total</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">3,594,000</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">412,000</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">52,000</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">4,058,000</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;" nowrap="nowrap"> </td> </tr> </table> </div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </div> <div> <table style="margin-right: 5%; margin-left: 18pt; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px; min-width: 700px;" cellspacing="0" cellpadding="0" border="0"> <tr style="vertical-align: bottom;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="14" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Nine Months Ended September 30, 2019</div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Device Revenue</div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Service Revenue</div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Other Revenue</div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Total Revenue</div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 48%;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-bottom: 0pt; margin-top: 0pt;">AXP</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">6,550,000</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">160,000</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; border-bottom: 1px none rgb(0, 0, 0); font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; border-bottom: 1px none rgb(0, 0, 0); font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 10%; border-bottom: 1px none rgb(0, 0, 0); text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">--</div></td> <td style="width: 1%; border-bottom: 1px none rgb(0, 0, 0); font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; border-bottom: 1px none rgb(0, 0, 0); font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; border-bottom: 1px none rgb(0, 0, 0); font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 10%; border-bottom: 1px none rgb(0, 0, 0); text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">6,710,000</div></td> <td style="width: 1%; border-bottom: 1px none rgb(0, 0, 0); font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-bottom: 0pt; margin-top: 0pt;">BioArchive</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">1,274,000</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">1,117,000</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">--</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">2,391,000</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-bottom: 0pt; margin-top: 0pt;">Manual Disposables</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">764,000</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">--</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">--</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">764,000</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-bottom: 0pt; margin-top: 0pt;">CAR-TXpress</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">1,365,000</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">6,000</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">33,000</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">1,404,000</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-bottom: 0pt; margin-top: 0pt;">Other</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">5,000</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">11,000</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">40,000</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">56,000</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;" nowrap="nowrap"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-bottom: 0pt; margin-top: 0pt; margin-left: 9pt;">Total</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">9,958,000</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">1,294,000</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">73,000</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">11,325,000</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;" nowrap="nowrap"> </td> </tr> </table> </div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"> </div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"><div style="display: inline; font-style: italic;"><div style="display: inline; font-weight: bold;">Contract Balances</div></div></div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">Generally, all sales are contract sales (with either an underlying contract or purchase order). The Company does <div style="display: inline; font-style: italic; font: inherit;">not</div> have any material contract assets. When invoicing occurs prior to revenue recognition, a contract liability is recorded (as deferred revenue on the consolidated balance sheet). Revenues recognized during the <div style="display: inline; font-style: italic; font: inherit;">three</div> and <div style="display: inline; font-style: italic; font: inherit;">nine</div> months ended <div style="display: inline; font-style: italic; font: inherit;"> September 30, 2020 </div>that were included in the beginning balance of deferred revenue were <div style="display: inline; font-style: italic; font: inherit;">$115,000</div> and <div style="display: inline; font-style: italic; font: inherit;">$547,000,</div> respectively. Short-term deferred revenues increased from <div style="display: inline; font-style: italic; font: inherit;">$620,000</div> to <div style="display: inline; font-style: italic; font: inherit;">$700,000</div> and long-term deferred revenues decreased from <div style="display: inline; font-style: italic; font: inherit;">$1,901,000</div> to <div style="display: inline; font-style: italic; font: inherit;">$1,669,000</div> during the <div style="display: inline; font-style: italic; font: inherit;">nine</div> months ended <div style="display: inline; font-style: italic; font: inherit;"> September 30, 2020, </div>respectively.</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"><div style="display: inline; font-style: italic;"><div style="display: inline; font-weight: bold;"> </div></div></div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"><div style="display: inline; font-style: italic;"><div style="display: inline; font-weight: bold;">Exclusivity Fee</div></div></div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">On <div style="display: inline; font-style: italic; font: inherit;"> August 30, 2019, </div>the Company entered into a Supply Agreement with Corning Incorporated (the “Supply Agreement”). The Supply Agreement has an initial term of <div style="display: inline; font-style: italic; font: inherit;">five</div> years with automatic <div style="display: inline; font-style: italic; font: inherit;">two</div>-year renewal terms, unless terminated by either party in accordance with the terms of the Supply Agreement (collectively, the “Term”). Pursuant to the Supply Agreement, the Company has granted to Corning exclusive worldwide distribution rights for substantially all <div style="display: inline; font-style: italic; font: inherit;">X</div>-Series<div style="display: inline; bottom:.33em; font-size: 82%; position: relative; vertical-align: baseline; vertical-align:top;line-height:120%;font-size:pt">®</div> products under the CAR-TXpress™ platform (the “Products”) manufactured by its subsidiary, ThermoGenesis Corp., for the duration of the Term, subject to certain geographical and other exceptions. As consideration for the exclusive worldwide distribution rights for the Products, Corning paid a <div style="display: inline; font-style: italic; font: inherit;">$2,000,000</div> exclusivity fee, in addition to any amounts payable throughout the Term for the Products.</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"> </div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">The Company performed an evaluation of the revenue recognition of the <div style="display: inline; font-style: italic; font: inherit;">$2,000,000</div> fee under ASC <div style="display: inline; font-style: italic; font: inherit;">606.</div> It determined that the <div style="display: inline; font-style: italic; font: inherit;">$2,000,000</div> will be recognized over time, based on the term of the contract. It was determined that the most likely outcome is the agreement is extended for <div style="display: inline; font-style: italic; font: inherit;">one</div> additional <div style="display: inline; font-style: italic; font: inherit;">two</div>-year term after the initial <div style="display: inline; font-style: italic; font: inherit;">five</div>-year contract is complete. Consequently, the term to recognize the exclusivity fee is over <div style="display: inline; font-style: italic; font: inherit;">seven</div> years. The Company will allocate the upfront fee evenly to each daily performance obligation of providing exclusivity and recognize the revenue ratably over the <div style="display: inline; font-style: italic; font: inherit;">seven</div>-year period. As each day passes, the Company will recognize the portion of the exclusivity fee allocated to that day. For the <div style="display: inline; font-style: italic; font: inherit;">three</div> and <div style="display: inline; font-style: italic; font: inherit;">nine</div> months ended <div style="display: inline; font-style: italic; font: inherit;"> September 30, 2020, </div>the Company recorded revenue of <div style="display: inline; font-style: italic; font: inherit;">$71,000</div> and <div style="display: inline; font-style: italic; font: inherit;">$214,000,</div> respectively, related to the exclusivity fee. The remaining balance of the <div style="display: inline; font-style: italic; font: inherit;">$2,000,000</div> payment of <div style="display: inline; font-style: italic; font: inherit;">$1,690,000</div> was recorded to deferred revenue, with <div style="display: inline; font-style: italic; font: inherit;">$286,000</div> in short-term deferred revenue and <div style="display: inline; font-style: italic; font: inherit;">$1,404,000</div> recorded in long-term deferred revenue.</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"> </div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"><div style="display: inline; font-style: italic;"><div style="display: inline; font-weight: bold;">Backlog of Remaining Customer Performance Obligations</div></div></div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">The following table includes revenue expected to be recognized and recorded as sales in the future from the backlog of performance obligations that are unsatisfied (or partially unsatisfied) at the end of the reporting period.</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"> </div> <div> <table style="; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px; min-width: 700px;" cellspacing="0" cellpadding="0" border="0"> <tr style="vertical-align: bottom;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Remainder of 2020</div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">2021</div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">2022</div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">2023</div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">2024 and beyond</div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Total</div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 28%;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Service revenue</div> </td> <td style="width: 1%; border-bottom: 1px none rgb(0, 0, 0); font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; border-bottom: 1px none rgb(0, 0, 0); font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; border-bottom: 1px none rgb(0, 0, 0); text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">310,000</div></td> <td style="width: 1%; border-bottom: 1px none rgb(0, 0, 0); font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; border-bottom: 1px none rgb(0, 0, 0); font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; border-bottom: 1px none rgb(0, 0, 0); font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; border-bottom: 1px none rgb(0, 0, 0); text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">958,000</div></td> <td style="width: 1%; border-bottom: 1px none rgb(0, 0, 0); font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; border-bottom: 1px none rgb(0, 0, 0); font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; border-bottom: 1px none rgb(0, 0, 0); font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; border-bottom: 1px none rgb(0, 0, 0); text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">561,000</div></td> <td style="width: 1%; border-bottom: 1px none rgb(0, 0, 0); font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; border-bottom: 1px none rgb(0, 0, 0); font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; border-bottom: 1px none rgb(0, 0, 0); font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; border-bottom: 1px none rgb(0, 0, 0); text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">298,000</div></td> <td style="width: 1%; border-bottom: 1px none rgb(0, 0, 0); font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; border-bottom: 1px none rgb(0, 0, 0); font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; border-bottom: 1px none rgb(0, 0, 0); font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; border-bottom: 1px none rgb(0, 0, 0); text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">38,000</div></td> <td style="width: 1%; border-bottom: 1px none rgb(0, 0, 0); font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; border-bottom: 1px none rgb(0, 0, 0); font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; border-bottom: 1px none rgb(0, 0, 0); font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; border-bottom: 1px none rgb(0, 0, 0); text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">2,165,000</div></td> <td style="width: 1%; border-bottom: 1px none rgb(0, 0, 0); font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Clinical revenue</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">3,000</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">13,000</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">13,000</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">13,000</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">175,000</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">217,000</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Exclusivity fee</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">71,000</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">286,000</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">286,000</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">286,000</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">761,000</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">1,690,000</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;" nowrap="nowrap"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Total</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">384,000</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">1,257,000</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">860,000</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">597,000</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">974,000</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">4,072,000</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;" nowrap="nowrap"> </td> </tr> </table> </div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"> </div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Revenues are net of normal discounts. Shipping and handling fees billed to customers are included in net revenues, while the related costs are included in cost of revenues.</div></div></div>

214000

794000

310000

958000

561000

298000

38000

3000

13000

175000

71000

286000

761000

384000

1257000

860000

597000

974000

2165000

217000

1690000

4072000

P91D

P1Y

P91D

P1Y

P91D

P1Y

P91D

P1Y

<div style="display: inline; font-family: times new roman; font-size: 10pt"><table style="; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px; min-; min-width: 700px;" cellspacing="0" cellpadding="0" border="0"> <tr style="vertical-align: bottom;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Remainder of 2020</div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">2021</div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">2022</div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">2023</div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">2024 and beyond</div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Total</div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 28%;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Service revenue</div> </td> <td style="width: 1%; border-bottom: 1px none rgb(0, 0, 0); font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; border-bottom: 1px none rgb(0, 0, 0); font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">$</div></td> <td style="width: 9%; border-bottom: 1px none rgb(0, 0, 0); text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">310,000</div></td> <td style="width: 1%; border-bottom: 1px none rgb(0, 0, 0); font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; border-bottom: 1px none rgb(0, 0, 0); font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; border-bottom: 1px none rgb(0, 0, 0); font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">$</div></td> <td style="width: 9%; border-bottom: 1px none rgb(0, 0, 0); text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">958,000</div></td> <td style="width: 1%; border-bottom: 1px none rgb(0, 0, 0); font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; border-bottom: 1px none rgb(0, 0, 0); font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; border-bottom: 1px none rgb(0, 0, 0); font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">$</div></td> <td style="width: 9%; border-bottom: 1px none rgb(0, 0, 0); text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">561,000</div></td> <td style="width: 1%; border-bottom: 1px none rgb(0, 0, 0); font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; border-bottom: 1px none rgb(0, 0, 0); font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; border-bottom: 1px none rgb(0, 0, 0); font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">$</div></td> <td style="width: 9%; border-bottom: 1px none rgb(0, 0, 0); text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">298,000</div></td> <td style="width: 1%; border-bottom: 1px none rgb(0, 0, 0); font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; border-bottom: 1px none rgb(0, 0, 0); font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; border-bottom: 1px none rgb(0, 0, 0); font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">$</div></td> <td style="width: 9%; border-bottom: 1px none rgb(0, 0, 0); text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">38,000</div></td> <td style="width: 1%; border-bottom: 1px none rgb(0, 0, 0); font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; border-bottom: 1px none rgb(0, 0, 0); font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; border-bottom: 1px none rgb(0, 0, 0); font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">$</div></td> <td style="width: 9%; border-bottom: 1px none rgb(0, 0, 0); text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">2,165,000</div></td> <td style="width: 1%; border-bottom: 1px none rgb(0, 0, 0); font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Clinical revenue</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><div style="display: inline; font-style: italic; font: inherit;"> </div></td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">3,000</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><div style="display: inline; font-style: italic; font: inherit;"> </div></td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">13,000</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><div style="display: inline; font-style: italic; font: inherit;"> </div></td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">13,000</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><div style="display: inline; font-style: italic; font: inherit;"> </div></td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">13,000</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><div style="display: inline; font-style: italic; font: inherit;"> </div></td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">175,000</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><div style="display: inline; font-style: italic; font: inherit;"> </div></td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">217,000</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Exclusivity fee</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;"> </div></td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">71,000</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;"> </div></td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">286,000</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;"> </div></td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">286,000</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;"> </div></td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">286,000</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;"> </div></td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">761,000</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;"> </div></td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">1,690,000</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;" nowrap="nowrap"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Total</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">$</div></td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">384,000</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">$</div></td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">1,257,000</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">$</div></td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">860,000</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">$</div></td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">597,000</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">$</div></td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">974,000</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">$</div></td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">4,072,000</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;" nowrap="nowrap"> </td> </tr> </table></div>

1137000

32000

1169000

337000

282000

619000

332000

22000

71000

425000

100000

26000

16000

42000

1932000

336000

87000

2355000

4009000

103000

4112000

675000

900000

1575000

1035000

47000

214000

1296000

499000

276000

39000

315000

6494000

1050000

253000

7797000

2255000

51000

2306000

243000

351000

594000

221000

875000

10000

33000

918000

19000

3594000

412000

52000

4058000

6550000

160000

6710000

1274000

1117000

2391000

764000

1365000

6000

33000

1404000

5000

11000

40000

56000

9958000

1294000

73000

11325000

966000

<div style="display: inline; font-family: times new roman; font-size: 10pt"><table style="margin-right: 2.5%; margin-left: 2.5%; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px; min-; min-width: 700px;" cellspacing="0" cellpadding="0" border="0"> <tr style="vertical-align: bottom;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="6" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Three Months Ended</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">September 30,</div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="6" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Nine Months Ended</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">September 30,</div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">2020</div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">2019</div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">2020</div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">2019</div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 48%;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Cost of revenues</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">3,000</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">1,000</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">5,000</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">2,000</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Sales and marketing</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">65,000</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">110,000</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">106,000</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">166,000</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Research and development</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">36,000</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">38,000</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">72,000</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">75,000</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">General and administrative</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">130,000</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">104,000</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">432,000</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">216,000</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;" nowrap="nowrap"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-left: 9pt;">Total</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">234,000</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">253,000</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">615,000</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">459,000</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;" nowrap="nowrap"> </td> </tr> </table></div>

<div style="display: inline; font-family: times new roman; font-size: 10pt"><table border="0" cellpadding="0" cellspacing="0" style="; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px; min-; min-width: 700px;"> <tr style="vertical-align: bottom;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Number of Shares</div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Weighted- Average Exercise Price</div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Weighted- Average Remaining Contractual Life</div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Aggregate Intrinsic</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Value</div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 52%;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt; text-indent: -9pt;">Outstanding at December 31, 2019</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">291,807</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">13.96</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><div style="display: inline; font-style: italic; font: inherit;"> </div></td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><div style="display: inline; font-style: italic; font: inherit;"> </div></td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Granted</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">615,500</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">5.92</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><div style="display: inline; font-style: italic; font: inherit;"> </div></td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><div style="display: inline; font-style: italic; font: inherit;"> </div></td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Forfeited</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">(15,158</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">5.13</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><div style="display: inline; font-style: italic; font: inherit;"> </div></td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><div style="display: inline; font-style: italic; font: inherit;"> </div></td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt; text-indent: -9pt;">Outstanding at September 30, 2020</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">892,149</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">8.57</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">8.997</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">--</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt; text-indent: -9pt;">Vested and expected to vest at September 30, 2020</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">565,836</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">9.91</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">8.736</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">--</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt; text-indent: -9pt;">Exercisable at September 30, 2020</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">184,137</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">17.05</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">7.665</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">--</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> </tr> </table></div>

<div style="display: inline; font-family: times new roman; font-size: 10pt"><table border="0" cellpadding="0" cellspacing="0" style="margin-right: 5%; margin-left: 5%; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px; min-; min-width: 700px;"> <tr style="vertical-align: bottom;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Number</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">of Shares</div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Weighted-Average</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Exercise Price Per Share</div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 66%;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Balance at December 31, 2019</div> </td> <td style="width: 1%; border-bottom: 1px none rgb(0, 0, 0); font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; border-bottom: 1px none rgb(0, 0, 0); font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 14%; border-bottom: 1px none rgb(0, 0, 0); text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">1,716,066</div></td> <td nowrap="nowrap" style="width: 1%; border-bottom: 1px none rgb(0, 0, 0); font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; border-bottom: 1px none rgb(0, 0, 0); font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; border-bottom: 1px none rgb(0, 0, 0); font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 14%; border-bottom: 1px none rgb(0, 0, 0); text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">25.23</div></td> <td nowrap="nowrap" style="width: 1%; border-bottom: 1px none rgb(0, 0, 0); font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Warrants expired</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">--</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">--</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Warrants exercised</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">(599,582</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">2.81</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Outstanding at September 30, 2020</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">1,116,484</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">37.27</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Exercisable at September 30, 2020</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">1,046,631</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">34.42</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> </table></div>

539000

502000

1424000

1227000

615000

459000

184137

17.05

15158

615500

291807

892149

13.96

8.57

565836

9.91

5.13

5.92

P7Y242D

P8Y363D

P8Y268D

3.50

2843601

5768885

6709465

6832040

2168337

2218337

2368337

2704837

1666670

100000

104445

120000

643750

1000002

517740

964130

1050748

344419

122575

2000

2998000

3000000

180000

1000

188000

189000

216000

1000

3220000

3221000

1993000

366000

756000

3132000

386000

3000

237313000

-236932000

2000

530000

916000

6000

245704000

-241534000

40000

389000

4605000

7000

252937000

-247971000

41000

316000

5330000

7000

253537000

-250434000

22000

170000

3302000

2000

235888000

-227435000

-13000

-1711000

6731000

2000

234644000

-229306000

-17000

956000

6279000

2000

236343000

-230603000

-20000

778000

6500000

3000

236830000

-232885000

-4000

687000

4631000

6711664

2913198

5728105

2720502

Accumulated other comprehensive loss. The unvested Series A warrants were subject to vesting based upon the amount of funds actually received by the Company in the second close of the August 2015 financing which never occurred. The warrants will remain outstanding but unvested until they expire in February 2021. xbrli:shares xbrli:pure iso4217:USD iso4217:USD xbrli:shares 0000811212 thmo:LitigationRelatedToStrategicAdvisoryServicesMember 2017-05-04 2017-05-04 0000811212 thmo:BoyalifeWSNMember 2017-08-21 2017-08-21 0000811212 thmo:LitigationRelatedToStrategicAdvisoryServicesMember 2017-10-01 2017-10-31 0000811212 us-gaap:NoncontrollingInterestMember 2019-01-01 2019-01-01 0000811212 2019-01-01 2019-03-31 0000811212 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-01-01 2019-03-31 0000811212 us-gaap:AdditionalPaidInCapitalMember 2019-01-01 2019-03-31 0000811212 us-gaap:CommonStockMember 2019-01-01 2019-03-31 0000811212 us-gaap:NoncontrollingInterestMember 2019-01-01 2019-03-31 0000811212 us-gaap:RetainedEarningsMember 2019-01-01 2019-03-31 0000811212 2019-01-01 2019-09-30 0000811212 us-gaap:ConvertibleDebtSecuritiesMember 2019-01-01 2019-09-30 0000811212 us-gaap:EmployeeStockOptionMember 2019-01-01 2019-09-30 0000811212 thmo:UnvestedSeriesAWarrantsMember 2019-01-01 2019-09-30 0000811212 thmo:VestedSeriesAWarrantsMember 2019-01-01 2019-09-30 0000811212 thmo:WarrantOtherMember 2019-01-01 2019-09-30 0000811212 us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember thmo:Customer1Member 2019-01-01 2019-09-30 0000811212 us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember thmo:Customer2Member 2019-01-01 2019-09-30 0000811212 us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember thmo:Customer3Member 2019-01-01 2019-09-30 0000811212 us-gaap:RevolvingCreditFacilityMember thmo:BoyalifeInvestmentFundIiIncMember 2019-01-01 2019-09-30 0000811212 thmo:ConversionOfJanuary2019AmendedNotesToCommonStockMember 2019-01-01 2019-09-30 0000811212 thmo:ConversionOfRelatedPartyConvertiblePromissoryNoteIntoCommonStockMember 2019-01-01 2019-09-30 0000811212 us-gaap:CostOfSalesMember 2019-01-01 2019-09-30 0000811212 us-gaap:GeneralAndAdministrativeExpenseMember 2019-01-01 2019-09-30 0000811212 us-gaap:ResearchAndDevelopmentExpenseMember 2019-01-01 2019-09-30 0000811212 us-gaap:SellingAndMarketingExpenseMember 2019-01-01 2019-09-30 0000811212 thmo:DeviceRevenueMember 2019-01-01 2019-09-30 0000811212 thmo:DeviceRevenueMember thmo:DeviceMember thmo:AxpMember 2019-01-01 2019-09-30 0000811212 thmo:DeviceRevenueMember thmo:DeviceMember thmo:BioarchiveMember 2019-01-01 2019-09-30 0000811212 thmo:DeviceRevenueMember thmo:DeviceMember thmo:CARTXpressMember 2019-01-01 2019-09-30 0000811212 thmo:DeviceRevenueMember thmo:DeviceMember thmo:ManualDisposablesMember 2019-01-01 2019-09-30 0000811212 thmo:DeviceRevenueMember thmo:DeviceMember thmo:OtherSubsegmentsMember 2019-01-01 2019-09-30 0000811212 thmo:OtherMember 2019-01-01 2019-09-30 0000811212 thmo:OtherMember thmo:DeviceMember thmo:AxpMember 2019-01-01 2019-09-30 0000811212 thmo:OtherMember thmo:DeviceMember thmo:BioarchiveMember 2019-01-01 2019-09-30 0000811212 thmo:OtherMember thmo:DeviceMember thmo:CARTXpressMember 2019-01-01 2019-09-30 0000811212 thmo:OtherMember thmo:DeviceMember thmo:ManualDisposablesMember 2019-01-01 2019-09-30 0000811212 thmo:OtherMember thmo:DeviceMember thmo:OtherSubsegmentsMember 2019-01-01 2019-09-30 0000811212 us-gaap:ServiceMember 2019-01-01 2019-09-30 0000811212 us-gaap:ServiceMember thmo:DeviceMember thmo:AxpMember 2019-01-01 2019-09-30 0000811212 us-gaap:ServiceMember thmo:DeviceMember thmo:BioarchiveMember 2019-01-01 2019-09-30 0000811212 us-gaap:ServiceMember thmo:DeviceMember thmo:CARTXpressMember 2019-01-01 2019-09-30 0000811212 us-gaap:ServiceMember thmo:DeviceMember thmo:ManualDisposablesMember 2019-01-01 2019-09-30 0000811212 us-gaap:ServiceMember thmo:DeviceMember thmo:OtherSubsegmentsMember 2019-01-01 2019-09-30 0000811212 thmo:BoyalifeWSNMember 2019-01-01 2019-09-30 0000811212 thmo:DeviceMember thmo:AxpMember 2019-01-01 2019-09-30 0000811212 thmo:DeviceMember thmo:BioarchiveMember 2019-01-01 2019-09-30 0000811212 thmo:DeviceMember thmo:CARTXpressMember 2019-01-01 2019-09-30 0000811212 thmo:DeviceMember thmo:ManualDisposablesMember 2019-01-01 2019-09-30 0000811212 thmo:DeviceMember thmo:OtherSubsegmentsMember 2019-01-01 2019-09-30 0000811212 us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember thmo:TwoCustomersMember 2019-01-01 2019-12-31 0000811212 thmo:January2019NotesAmendmentNo1Member us-gaap:ConvertibleDebtMember 2019-01-01 2019-12-31 0000811212 thmo:NotesMember us-gaap:ConvertibleDebtMember 2019-01-29 2019-01-29 0000811212 2019-04-01 2019-06-30 0000811212 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-04-01 2019-06-30 0000811212 us-gaap:AdditionalPaidInCapitalMember 2019-04-01 2019-06-30 0000811212 us-gaap:CommonStockMember 2019-04-01 2019-06-30 0000811212 us-gaap:NoncontrollingInterestMember 2019-04-01 2019-06-30 0000811212 us-gaap:RetainedEarningsMember 2019-04-01 2019-06-30 0000811212 thmo:ReverseStockSplitMember 2019-06-04 2019-06-04 0000811212 2019-07-01 2019-09-30 0000811212 us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember thmo:Customer1Member 2019-07-01 2019-09-30 0000811212 us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember thmo:Customer2Member 2019-07-01 2019-09-30 0000811212 us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember thmo:Customer3Member 2019-07-01 2019-09-30 0000811212 us-gaap:RevolvingCreditFacilityMember thmo:BoyalifeInvestmentFundIiIncMember 2019-07-01 2019-09-30 0000811212 us-gaap:CostOfSalesMember 2019-07-01 2019-09-30 0000811212 us-gaap:GeneralAndAdministrativeExpenseMember 2019-07-01 2019-09-30 0000811212 us-gaap:ResearchAndDevelopmentExpenseMember 2019-07-01 2019-09-30 0000811212 us-gaap:SellingAndMarketingExpenseMember 2019-07-01 2019-09-30 0000811212 thmo:DeviceRevenueMember 2019-07-01 2019-09-30 0000811212 thmo:DeviceRevenueMember thmo:DeviceMember thmo:AxpMember 2019-07-01 2019-09-30 0000811212 thmo:DeviceRevenueMember thmo:DeviceMember thmo:BioarchiveMember 2019-07-01 2019-09-30 0000811212 thmo:DeviceRevenueMember thmo:DeviceMember thmo:CARTXpressMember 2019-07-01 2019-09-30 0000811212 thmo:DeviceRevenueMember thmo:DeviceMember thmo:ManualDisposablesMember 2019-07-01 2019-09-30 0000811212 thmo:DeviceRevenueMember thmo:DeviceMember thmo:OtherSubsegmentsMember 2019-07-01 2019-09-30 0000811212 thmo:OtherMember 2019-07-01 2019-09-30 0000811212 thmo:OtherMember thmo:DeviceMember thmo:AxpMember 2019-07-01 2019-09-30 0000811212 thmo:OtherMember thmo:DeviceMember thmo:BioarchiveMember 2019-07-01 2019-09-30 0000811212 thmo:OtherMember thmo:DeviceMember thmo:CARTXpressMember 2019-07-01 2019-09-30 0000811212 thmo:OtherMember thmo:DeviceMember thmo:ManualDisposablesMember 2019-07-01 2019-09-30 0000811212 thmo:OtherMember thmo:DeviceMember thmo:OtherSubsegmentsMember 2019-07-01 2019-09-30 0000811212 us-gaap:ServiceMember 2019-07-01 2019-09-30 0000811212 us-gaap:ServiceMember thmo:DeviceMember thmo:AxpMember 2019-07-01 2019-09-30 0000811212 us-gaap:ServiceMember thmo:DeviceMember thmo:BioarchiveMember 2019-07-01 2019-09-30 0000811212 us-gaap:ServiceMember thmo:DeviceMember thmo:CARTXpressMember 2019-07-01 2019-09-30 0000811212 us-gaap:ServiceMember thmo:DeviceMember thmo:ManualDisposablesMember 2019-07-01 2019-09-30 0000811212 us-gaap:ServiceMember thmo:DeviceMember thmo:OtherSubsegmentsMember 2019-07-01 2019-09-30 0000811212 thmo:BoyalifeWSNMember 2019-07-01 2019-09-30 0000811212 thmo:DeviceMember thmo:AxpMember 2019-07-01 2019-09-30 0000811212 thmo:DeviceMember thmo:BioarchiveMember 2019-07-01 2019-09-30 0000811212 thmo:DeviceMember thmo:CARTXpressMember 2019-07-01 2019-09-30 0000811212 thmo:DeviceMember thmo:ManualDisposablesMember 2019-07-01 2019-09-30 0000811212 thmo:DeviceMember thmo:OtherSubsegmentsMember 2019-07-01 2019-09-30 0000811212 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-07-01 2019-09-30 0000811212 us-gaap:AdditionalPaidInCapitalMember 2019-07-01 2019-09-30 0000811212 us-gaap:CommonStockMember 2019-07-01 2019-09-30 0000811212 us-gaap:NoncontrollingInterestMember 2019-07-01 2019-09-30 0000811212 us-gaap:RetainedEarningsMember 2019-07-01 2019-09-30 0000811212 thmo:TheJuly2019NoteMember us-gaap:ConvertibleDebtMember 2019-07-23 2019-07-23 0000811212 thmo:SupplyAgreementMember 2019-08-30 2019-08-30 0000811212 thmo:ImmunecyteMember 2019-11-26 2020-09-30 0000811212 thmo:ImmunecyteMember us-gaap:CommonClassAMember 2019-11-26 2020-09-30 0000811212 thmo:AtTheMarketOfferingAgreementMember 2019-12-13 2019-12-13 0000811212 2020-01-01 2020-03-31 0000811212 thmo:BoyalifeInvestmentFundIiIncMember 2020-01-01 2020-03-31 0000811212 thmo:BoyalifeInvestmentFundIiIncMember us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-01-01 2020-03-31 0000811212 thmo:BoyalifeInvestmentFundIiIncMember us-gaap:AdditionalPaidInCapitalMember 2020-01-01 2020-03-31 0000811212 thmo:BoyalifeInvestmentFundIiIncMember us-gaap:CommonStockMember 2020-01-01 2020-03-31 0000811212 thmo:BoyalifeInvestmentFundIiIncMember us-gaap:NoncontrollingInterestMember 2020-01-01 2020-03-31 0000811212 thmo:BoyalifeInvestmentFundIiIncMember us-gaap:RetainedEarningsMember 2020-01-01 2020-03-31 0000811212 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-01-01 2020-03-31 0000811212 us-gaap:AdditionalPaidInCapitalMember 2020-01-01 2020-03-31 0000811212 us-gaap:CommonStockMember 2020-01-01 2020-03-31 0000811212 us-gaap:NoncontrollingInterestMember 2020-01-01 2020-03-31 0000811212 us-gaap:RetainedEarningsMember 2020-01-01 2020-03-31 0000811212 2020-01-01 2020-09-30 0000811212 us-gaap:ConvertibleDebtSecuritiesMember 2020-01-01 2020-09-30 0000811212 us-gaap:EmployeeStockOptionMember 2020-01-01 2020-09-30 0000811212 thmo:UnvestedSeriesAWarrantsMember 2020-01-01 2020-09-30 0000811212 thmo:VestedSeriesAWarrantsMember 2020-01-01 2020-09-30 0000811212 thmo:WarrantOtherMember 2020-01-01 2020-09-30 0000811212 us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember thmo:TwoCustomersMember 2020-01-01 2020-09-30 0000811212 us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember thmo:Customer1Member 2020-01-01 2020-09-30 0000811212 us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember thmo:Customer2Member 2020-01-01 2020-09-30 0000811212 us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember thmo:Customer3Member 2020-01-01 2020-09-30 0000811212 us-gaap:RevolvingCreditFacilityMember thmo:BoyalifeInvestmentFundIiIncMember 2020-01-01 2020-09-30 0000811212 thmo:ConversionOfConvertiblePromissoryNoteToCommonStockMember 2020-01-01 2020-09-30 0000811212 thmo:ConversionOfJanuary2019AmendedNotesToCommonStockMember 2020-01-01 2020-09-30 0000811212 thmo:ConversionOfRelatedPartyConvertiblePromissoryNoteIntoCommonStockMember 2020-01-01 2020-09-30 0000811212 thmo:TheJuly2019NoteMember us-gaap:ConvertibleDebtMember 2020-01-01 2020-09-30 0000811212 us-gaap:CostOfSalesMember 2020-01-01 2020-09-30 0000811212 us-gaap:GeneralAndAdministrativeExpenseMember 2020-01-01 2020-09-30 0000811212 us-gaap:ResearchAndDevelopmentExpenseMember 2020-01-01 2020-09-30 0000811212 us-gaap:SellingAndMarketingExpenseMember 2020-01-01 2020-09-30 0000811212 thmo:DeviceRevenueMember 2020-01-01 2020-09-30 0000811212 thmo:DeviceRevenueMember thmo:DeviceMember thmo:AxpMember 2020-01-01 2020-09-30 0000811212 thmo:DeviceRevenueMember thmo:DeviceMember thmo:BioarchiveMember 2020-01-01 2020-09-30 0000811212 thmo:DeviceRevenueMember thmo:DeviceMember thmo:CARTXpressMember 2020-01-01 2020-09-30 0000811212 thmo:DeviceRevenueMember thmo:DeviceMember thmo:ManualDisposablesMember 2020-01-01 2020-09-30 0000811212 thmo:DeviceRevenueMember thmo:DeviceMember thmo:OtherSubsegmentsMember 2020-01-01 2020-09-30 0000811212 thmo:ExclusivityFeeMember 2020-01-01 2020-09-30 0000811212 thmo:OtherMember 2020-01-01 2020-09-30 0000811212 thmo:OtherMember thmo:DeviceMember thmo:AxpMember 2020-01-01 2020-09-30 0000811212 thmo:OtherMember thmo:DeviceMember thmo:BioarchiveMember 2020-01-01 2020-09-30 0000811212 thmo:OtherMember thmo:DeviceMember thmo:CARTXpressMember 2020-01-01 2020-09-30 0000811212 thmo:OtherMember thmo:DeviceMember thmo:ManualDisposablesMember 2020-01-01 2020-09-30 0000811212 thmo:OtherMember thmo:DeviceMember thmo:OtherSubsegmentsMember 2020-01-01 2020-09-30 0000811212 us-gaap:ServiceMember 2020-01-01 2020-09-30 0000811212 us-gaap:ServiceMember thmo:DeviceMember thmo:AxpMember 2020-01-01 2020-09-30 0000811212 us-gaap:ServiceMember thmo:DeviceMember thmo:BioarchiveMember 2020-01-01 2020-09-30 0000811212 us-gaap:ServiceMember thmo:DeviceMember thmo:CARTXpressMember 2020-01-01 2020-09-30 0000811212 us-gaap:ServiceMember thmo:DeviceMember thmo:ManualDisposablesMember 2020-01-01 2020-09-30 0000811212 us-gaap:ServiceMember thmo:DeviceMember thmo:OtherSubsegmentsMember 2020-01-01 2020-09-30 0000811212 thmo:COVID19TestingKitsMember 2020-01-01 2020-09-30 0000811212 thmo:COVID19TestingKitsMember thmo:ImmunecyteMember 2020-01-01 2020-09-30 0000811212 srt:MaximumMember 2020-01-01 2020-09-30 0000811212 srt:MinimumMember 2020-01-01 2020-09-30 0000811212 thmo:BoyalifeWSNMember 2020-01-01 2020-09-30 0000811212 thmo:ImmunecyteMember 2020-01-01 2020-09-30 0000811212 thmo:DeviceMember thmo:AxpMember 2020-01-01 2020-09-30 0000811212 thmo:DeviceMember thmo:BioarchiveMember 2020-01-01 2020-09-30 0000811212 thmo:DeviceMember thmo:CARTXpressMember 2020-01-01 2020-09-30 0000811212 thmo:DeviceMember thmo:ManualDisposablesMember 2020-01-01 2020-09-30 0000811212 thmo:DeviceMember thmo:OtherSubsegmentsMember 2020-01-01 2020-09-30 0000811212 thmo:AtTheMarketOfferingAgreementMember 2020-01-01 2020-09-30 0000811212 thmo:SupplyAgreementMember 2020-01-01 2020-09-30 0000811212 us-gaap:RevolvingCreditFacilityMember thmo:BoyalifeInvestmentFundIiIncMember 2020-02-01 2020-02-29 0000811212 thmo:ConversionOfRelatedPartyConvertiblePromissoryNoteIntoCommonStockMember 2020-02-01 2020-02-29 0000811212 thmo:LitigationRelatedToStrategicAdvisoryServicesMember 2020-02-01 2020-02-29 0000811212 us-gaap:RevolvingCreditFacilityMember thmo:BoyalifeInvestmentFundIiIncMember 2020-02-29 2020-02-29 0000811212 thmo:RegisteredDirectOfferingMember 2020-03-25 2020-03-27 0000811212 2020-04-01 2020-06-30 0000811212 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-04-01 2020-06-30 0000811212 us-gaap:AdditionalPaidInCapitalMember 2020-04-01 2020-06-30 0000811212 us-gaap:CommonStockMember 2020-04-01 2020-06-30 0000811212 us-gaap:NoncontrollingInterestMember 2020-04-01 2020-06-30 0000811212 us-gaap:RetainedEarningsMember 2020-04-01 2020-06-30 0000811212 thmo:PaycheckProtectionProgramCaresActMember 2020-04-21 2020-04-21 0000811212 us-gaap:RevolvingCreditFacilityMember thmo:BoyalifeInvestmentFundIiIncMember 2020-04-28 2020-04-28 0000811212 thmo:AgreementWithPlaintiffForReimbursementOfTrialRelatedExpensesMember 2020-05-01 2020-05-01 0000811212 thmo:TheJuly2019NoteMember us-gaap:ConvertibleDebtMember 2020-06-04 2020-06-04 0000811212 2020-07-01 2020-09-30 0000811212 us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember thmo:Customer1Member 2020-07-01 2020-09-30 0000811212 us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember thmo:Customer2Member 2020-07-01 2020-09-30 0000811212 us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember thmo:Customer3Member 2020-07-01 2020-09-30 0000811212 us-gaap:RevolvingCreditFacilityMember thmo:BoyalifeInvestmentFundIiIncMember 2020-07-01 2020-09-30 0000811212 thmo:TheJuly2019NoteMember us-gaap:ConvertibleDebtMember 2020-07-01 2020-09-30 0000811212 us-gaap:CostOfSalesMember 2020-07-01 2020-09-30 0000811212 us-gaap:GeneralAndAdministrativeExpenseMember 2020-07-01 2020-09-30 0000811212 us-gaap:ResearchAndDevelopmentExpenseMember 2020-07-01 2020-09-30 0000811212 us-gaap:SellingAndMarketingExpenseMember 2020-07-01 2020-09-30 0000811212 thmo:DeviceRevenueMember 2020-07-01 2020-09-30 0000811212 thmo:DeviceRevenueMember thmo:DeviceMember thmo:AxpMember 2020-07-01 2020-09-30 0000811212 thmo:DeviceRevenueMember thmo:DeviceMember thmo:BioarchiveMember 2020-07-01 2020-09-30 0000811212 thmo:DeviceRevenueMember thmo:DeviceMember thmo:CARTXpressMember 2020-07-01 2020-09-30 0000811212 thmo:DeviceRevenueMember thmo:DeviceMember thmo:ManualDisposablesMember 2020-07-01 2020-09-30 0000811212 thmo:DeviceRevenueMember thmo:DeviceMember thmo:OtherSubsegmentsMember 2020-07-01 2020-09-30 0000811212 thmo:ExclusivityFeeMember 2020-07-01 2020-09-30 0000811212 thmo:OtherMember 2020-07-01 2020-09-30 0000811212 thmo:OtherMember thmo:DeviceMember thmo:AxpMember 2020-07-01 2020-09-30 0000811212 thmo:OtherMember thmo:DeviceMember thmo:BioarchiveMember 2020-07-01 2020-09-30 0000811212 thmo:OtherMember thmo:DeviceMember thmo:CARTXpressMember 2020-07-01 2020-09-30 0000811212 thmo:OtherMember thmo:DeviceMember thmo:ManualDisposablesMember 2020-07-01 2020-09-30 0000811212 thmo:OtherMember thmo:DeviceMember thmo:OtherSubsegmentsMember 2020-07-01 2020-09-30 0000811212 us-gaap:ServiceMember 2020-07-01 2020-09-30 0000811212 us-gaap:ServiceMember thmo:DeviceMember thmo:AxpMember 2020-07-01 2020-09-30 0000811212 us-gaap:ServiceMember thmo:DeviceMember thmo:BioarchiveMember 2020-07-01 2020-09-30 0000811212 us-gaap:ServiceMember thmo:DeviceMember thmo:CARTXpressMember 2020-07-01 2020-09-30 0000811212 us-gaap:ServiceMember thmo:DeviceMember thmo:ManualDisposablesMember 2020-07-01 2020-09-30 0000811212 us-gaap:ServiceMember thmo:DeviceMember thmo:OtherSubsegmentsMember 2020-07-01 2020-09-30 0000811212 thmo:COVID19TestingKitsMember thmo:ImmunecyteMember 2020-07-01 2020-09-30 0000811212 thmo:BoyalifeWSNMember 2020-07-01 2020-09-30 0000811212 thmo:ImmunecyteMember 2020-07-01 2020-09-30 0000811212 thmo:DeviceMember thmo:AxpMember 2020-07-01 2020-09-30 0000811212 thmo:DeviceMember thmo:BioarchiveMember 2020-07-01 2020-09-30 0000811212 thmo:DeviceMember thmo:CARTXpressMember 2020-07-01 2020-09-30 0000811212 thmo:DeviceMember thmo:ManualDisposablesMember 2020-07-01 2020-09-30 0000811212 thmo:DeviceMember thmo:OtherSubsegmentsMember 2020-07-01 2020-09-30 0000811212 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-07-01 2020-09-30 0000811212 us-gaap:AdditionalPaidInCapitalMember 2020-07-01 2020-09-30 0000811212 us-gaap:CommonStockMember 2020-07-01 2020-09-30 0000811212 us-gaap:NoncontrollingInterestMember 2020-07-01 2020-09-30 0000811212 us-gaap:RetainedEarningsMember 2020-07-01 2020-09-30 0000811212 us-gaap:SubsequentEventMember thmo:AtTheMarketOfferingAgreementMember 2020-10-01 2020-11-12 0000811212 us-gaap:RevolvingCreditFacilityMember thmo:BoyalifeInvestmentFundIiIncMember 2017-03-31 0000811212 us-gaap:ConvertibleDebtMember thmo:BoyalifeInvestmentFundIiIncMember 2018-04-16 0000811212 2018-12-31 0000811212 us-gaap:ConvertibleDebtMember thmo:BoyalifeInvestmentFundIiIncMember 2018-12-31 0000811212 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-12-31 0000811212 us-gaap:AdditionalPaidInCapitalMember 2018-12-31 0000811212 us-gaap:CommonStockMember 2018-12-31 0000811212 us-gaap:NoncontrollingInterestMember 2018-12-31 0000811212 us-gaap:RetainedEarningsMember 2018-12-31 0000811212 us-gaap:AccountingStandardsUpdate201602Member 2019-01-01 0000811212 thmo:CARTXpressMember 2019-01-01 0000811212 thmo:ThermoGenesisMember 2019-01-01 0000811212 thmo:NotesMember us-gaap:ConvertibleDebtMember 2019-01-29 0000811212 thmo:NotesMember us-gaap:ConvertibleDebtMember srt:MaximumMember 2019-01-29 0000811212 thmo:NotesMember us-gaap:ConvertibleDebtMember srt:MinimumMember 2019-01-29 0000811212 2019-03-31 0000811212 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-03-31 0000811212 us-gaap:AdditionalPaidInCapitalMember 2019-03-31 0000811212 us-gaap:CommonStockMember 2019-03-31 0000811212 us-gaap:NoncontrollingInterestMember 2019-03-31 0000811212 us-gaap:RetainedEarningsMember 2019-03-31 0000811212 thmo:NotesMember us-gaap:ConvertibleDebtMember 2019-05-30 0000811212 2019-06-04 0000811212 2019-06-30 0000811212 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-06-30 0000811212 us-gaap:AdditionalPaidInCapitalMember 2019-06-30 0000811212 us-gaap:CommonStockMember 2019-06-30 0000811212 us-gaap:NoncontrollingInterestMember 2019-06-30 0000811212 us-gaap:RetainedEarningsMember 2019-06-30 0000811212 thmo:January2019NotesAmendmentNo1Member us-gaap:ConvertibleDebtMember 2019-07-23 0000811212 thmo:TheJuly2019NoteMember us-gaap:ConvertibleDebtMember 2019-07-23 0000811212 thmo:TheJuly2019NoteMember us-gaap:ConvertibleDebtMember srt:MaximumMember 2019-07-23 0000811212 thmo:TheJuly2019NoteMember us-gaap:ConvertibleDebtMember srt:MinimumMember 2019-07-23 0000811212 thmo:SupplyAgreementMember 2019-08-30 0000811212 2019-09-30 0000811212 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-09-30 0000811212 us-gaap:AdditionalPaidInCapitalMember 2019-09-30 0000811212 us-gaap:CommonStockMember 2019-09-30 0000811212 us-gaap:NoncontrollingInterestMember 2019-09-30 0000811212 us-gaap:RetainedEarningsMember 2019-09-30 0000811212 thmo:HealthbanksBiotechMember thmo:ImmunecyteMember 2019-11-26 0000811212 thmo:ImmunecyteMember 2019-11-26 0000811212 thmo:AtTheMarketOfferingAgreementMember 2019-12-13 0000811212 2019-12-31 0000811212 us-gaap:RevolvingCreditFacilityMember thmo:BoyalifeInvestmentFundIiIncMember 2019-12-31 0000811212 thmo:January2019NotesAmendmentNo1Member us-gaap:ConvertibleDebtMember 2019-12-31 0000811212 thmo:ConvertiblePromissoryNoteMember 2019-12-31 0000811212 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-12-31 0000811212 us-gaap:AdditionalPaidInCapitalMember 2019-12-31 0000811212 us-gaap:CommonStockMember 2019-12-31 0000811212 us-gaap:NoncontrollingInterestMember 2019-12-31 0000811212 us-gaap:RetainedEarningsMember 2019-12-31 0000811212 2020-03-17 0000811212 thmo:RegisteredDirectOfferingMember 2020-03-27 0000811212 2020-03-31 0000811212 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-03-31 0000811212 us-gaap:AdditionalPaidInCapitalMember 2020-03-31 0000811212 us-gaap:CommonStockMember 2020-03-31 0000811212 us-gaap:NoncontrollingInterestMember 2020-03-31 0000811212 us-gaap:RetainedEarningsMember 2020-03-31 0000811212 us-gaap:RevolvingCreditFacilityMember thmo:BoyalifeInvestmentFundIiIncMember 2020-04-28 0000811212 thmo:AtTheMarketOfferingAgreementMember 2020-05-19 0000811212 2020-06-30 0000811212 thmo:CARTXpressMember 2020-06-30 0000811212 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-06-30 0000811212 us-gaap:AdditionalPaidInCapitalMember 2020-06-30 0000811212 us-gaap:CommonStockMember 2020-06-30 0000811212 us-gaap:NoncontrollingInterestMember 2020-06-30 0000811212 us-gaap:RetainedEarningsMember 2020-06-30 0000811212 2020-07-13 0000811212 2020-09-30 0000811212 thmo:CurrentLiabilitiesMember 2020-09-30 0000811212 us-gaap:RevolvingCreditFacilityMember thmo:BoyalifeInvestmentFundIiIncMember 2020-09-30 0000811212 thmo:ExclusivityFeeMember 2020-09-30 0000811212 thmo:PaycheckProtectionProgramCaresActMember 2020-09-30 0000811212 thmo:HealthbanksBiotechMember thmo:ImmunecyteMember 2020-09-30 0000811212 thmo:ImmunecyteMember srt:MaximumMember us-gaap:CommonClassAMember 2020-09-30 0000811212 thmo:ImmunecyteMember srt:MinimumMember us-gaap:CommonClassAMember 2020-09-30 0000811212 thmo:PrivateInstitutionMember thmo:ImmunecyteMember 2020-09-30 0000811212 thmo:CARTXpressMember 2020-09-30 0000811212 thmo:ClinicalRevenueMember 2020-09-30 0000811212 thmo:ClinicalRevenueMember

2020-10-01

2020-09-30 0000811212 thmo:ClinicalRevenueMember

2021-01-01

2020-09-30 0000811212 thmo:ClinicalRevenueMember

2022-01-01

2020-09-30 0000811212 thmo:ClinicalRevenueMember

2023-01-01

2020-09-30 0000811212 thmo:ClinicalRevenueMember

2024-01-01

2020-09-30 0000811212 thmo:ExclusivityFeeMember 2020-09-30 0000811212 thmo:ExclusivityFeeMember

2020-10-01

2020-09-30 0000811212 thmo:ExclusivityFeeMember

2021-01-01

2020-09-30 0000811212 thmo:ExclusivityFeeMember

2022-01-01

2020-09-30 0000811212 thmo:ExclusivityFeeMember

2023-01-01

2020-09-30 0000811212 thmo:ExclusivityFeeMember

2024-01-01

2020-09-30 0000811212 us-gaap:ServiceMember 2020-09-30 0000811212 us-gaap:ServiceMember

2020-10-01

2020-09-30 0000811212 us-gaap:ServiceMember

2021-01-01

2020-09-30 0000811212 us-gaap:ServiceMember

2022-01-01

2020-09-30 0000811212 us-gaap:ServiceMember

2023-01-01

2020-09-30 0000811212 us-gaap:ServiceMember

2024-01-01

2020-09-30 0000811212 thmo:ConvertiblePromissoryNoteMember 2020-09-30 0000811212

2020-01-01

2020-09-30 0000811212

2021-01-01

2020-09-30 0000811212

2022-01-01

2020-09-30 0000811212

2023-01-01

2020-09-30 0000811212

2024-01-01

2020-09-30 0000811212 thmo:ImmunecyteMember 2020-09-30 0000811212 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-09-30 0000811212 us-gaap:AdditionalPaidInCapitalMember 2020-09-30 0000811212 us-gaap:CommonStockMember 2020-09-30 0000811212 us-gaap:NoncontrollingInterestMember 2020-09-30 0000811212 us-gaap:RetainedEarningsMember 2020-09-30 0000811212 2020-11-10

EX-101.SCH 6 thmo-20200930.xsd XBRL TAXONOMY EXTENSION SCHEMA 000 - Document - Document And Entity Information link:calculationLink link:definitionLink link:presentationLink 001 - Statement - Condensed Consolidated Balance Sheets (Current Period Unaudited) link:calculationLink link:definitionLink link:presentationLink 002 - Statement - Condensed Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals) link:calculationLink link:definitionLink link:presentationLink 003 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) link:calculationLink link:definitionLink link:presentationLink 004 - Statement - Condensed Consolidated Statements of Equity (Unaudited) link:calculationLink link:definitionLink link:presentationLink 005 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited) link:calculationLink link:definitionLink link:presentationLink 006 - Disclosure - Note 1 - Description of Business, Basis of Presentation and Going Concern link:calculationLink link:definitionLink link:presentationLink 007 - Disclosure - Note 2 - Summary of Significant Accounting Policies link:calculationLink link:definitionLink link:presentationLink 009 - Disclosure - Note 4 - Convertible Promissory Note link:calculationLink link:definitionLink link:presentationLink 010 - Disclosure - Note 5 - Leases link:calculationLink link:definitionLink link:presentationLink 011 - Disclosure - Note 6 - Commitments and Contingencies link:calculationLink link:definitionLink link:presentationLink 012 - Disclosure - Note 7 - Stockholders' Equity link:calculationLink link:definitionLink link:presentationLink 013 - Disclosure - Note 8 - Major Customers and Accounts Receivable link:calculationLink link:definitionLink link:presentationLink 014 - Disclosure - Note 9 - Subsequent Events link:calculationLink link:definitionLink link:presentationLink 015 - Disclosure - Significant Accounting Policies (Policies) link:calculationLink link:definitionLink link:presentationLink 016 - Disclosure - Note 2 - Summary of Significant Accounting Policies (Tables) link:calculationLink link:definitionLink link:presentationLink 017 - Disclosure - Note 5 - Leases (Tables) link:calculationLink link:definitionLink link:presentationLink 018 - Disclosure - Note 6 - Commitments and Contingencies (Tables) link:calculationLink link:definitionLink link:presentationLink 019 - Disclosure - Note 7 - Stockholders' Equity (Tables) link:calculationLink link:definitionLink link:presentationLink 020 - Disclosure - Note 1 - Description of Business, Basis of Presentation and Going Concern (Details Textual) link:calculationLink link:definitionLink link:presentationLink 021 - Disclosure - Note 2 - Summary of Significant Accounting Policies (Details Textual) link:calculationLink link:definitionLink link:presentationLink 022 - Disclosure - Note 2 - Summary of Significant Accounting Policies - Revenues (Details) link:calculationLink link:definitionLink link:presentationLink 023 - Disclosure - Note 2 - Summary of Significant Accounting Policies - Remaining Performance Obligations (Details) link:calculationLink link:definitionLink link:presentationLink 024 - Disclosure - Note 2 - Summary of Significant Accounting Policies - Remaining Performance Obligations 2 (Details) link:calculationLink link:definitionLink link:presentationLink 025 - Disclosure - Note 2 - Summary of Significant Accounting Policies - Anti-dilutive Securities (Details) link:calculationLink link:definitionLink link:presentationLink 027 - Disclosure - Note 4 - Convertible Promissory Note (Details Textual) link:calculationLink link:definitionLink link:presentationLink 028 - Disclosure - Note 5 - Leases (Details Textual) link:calculationLink link:definitionLink link:presentationLink 029 - Disclosure - Note 5 - Leases - Lease Information (Details) link:calculationLink link:definitionLink link:presentationLink 030 - Disclosure - Note 5 - Leases - Maturities of Lease Liabilities (Details) link:calculationLink link:definitionLink link:presentationLink 031 - Disclosure - Note 6 - Commitments and Contingencies (Details Textual) link:calculationLink link:definitionLink link:presentationLink 032 - Disclosure - Note 6 - Commitments and Contingencies - Changes in Product Liability Included in Accrued Liabilities (Details) link:calculationLink link:definitionLink link:presentationLink 033 - Disclosure - Note 7 - Stockholders' Equity (Details Textual) link:calculationLink link:definitionLink link:presentationLink 034 - Disclosure - Note 7 - Stockholders' Equity - Stock-based Compensation (Details) link:calculationLink link:definitionLink link:presentationLink 035 - Disclosure - Note 7 - Stockholders' Equity - Option Activity for Stock Option Plans (Details) link:calculationLink link:definitionLink link:presentationLink 036 - Disclosure - Note 7 - Stockholders' Equity - Warrant Activity (Details) link:calculationLink link:definitionLink link:presentationLink 037 - Disclosure - Note 8 - Major Customers and Accounts Receivable (Details Textual) link:calculationLink link:definitionLink link:presentationLink EX-101.CAL 7 thmo-20200930_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE EX-101.DEF 8 thmo-20200930_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 9 thmo-20200930_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Document And Entity Information thmo_PeriodOfWarrantyOnProducts Period Of Warranty On Products (Year) This line item represents the minimum period of warranty that an entity offers on all of its products. Other income (expenses): thmo_ShortTermInvestmentMinimum Short Term Investment Minimum Description of minimum financial levels (for example, tangible net worth and working capital) and achievement of certain financial ratios, and adherence to certain clauses which must be met in order to avoid default. May also include a discussion of the adverse consequences that would result if the entity violates or fails to satisfy the covenants. Note To Financial Statement Details Textual us-gaap_DerivativeGainLossOnDerivativeNet Change in fair value derivative Significant Accounting Policies Note 2 - Summary of Significant Accounting Policies Note 5 - Leases Note 6 - Commitments and Contingencies Note 7 - Stockholders' Equity Note 2 - Summary of Significant Accounting Policies - Revenues (Details) Note 2 - Summary of Significant Accounting Policies - Remaining Performance Obligations (Details) Note 2 - Summary of Significant Accounting Policies - Remaining Performance Obligations 2 (Details) Note 2 - Summary of Significant Accounting Policies - Anti-dilutive Securities (Details) Note 5 - Leases - Lease Information (Details) Note 5 - Leases - Maturities of Lease Liabilities (Details) Note 6 - Commitments and Contingencies - Changes in Product Liability Included in Accrued Liabilities (Details) Note 7 - Stockholders' Equity - Stock-based Compensation (Details) us-gaap_LiabilitiesCurrent Liabilities, Current, Total Total current liabilities Note 7 - Stockholders' Equity - Option Activity for Stock Option Plans (Details) Note 7 - Stockholders' Equity - Warrant Activity (Details) Notes To Financial Statements Notes To Financial Statements [Abstract] Other current liabilities thmo_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRights Outstanding, weighted average exercise price (in dollars per share) Outstanding, weighted average exercise price (in dollars per share) The weighted average exercise price of each class of warrants or rights outstanding. us-gaap_LitigationSettlementAmountAwardedToOtherParty Loss Contingency, Damages Awarded, Value Share-based Payment Arrangement, Option, Activity [Table Text Block] us-gaap_LitigationSettlementInterest Litigation Settlement Interest us-gaap_LitigationSettlementExpense Litigation Settlement, Expense Agreement with Plaintiff For Reimbursement of Trial Related Expenses [Member] Represents the agreement with the plaintiff for reimbursement of trial related expenses. Foreign currency translation gain (loss) Foreign currency translation adjustments gain (loss) Reserve for excess and slow-moving inventories The amount of change in the reserve for inventory. us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1 Vested and expected to vest, weighted average remaining contractual life, options (Year) Proceeds from issuance of common stock, net of expenses Proceeds from Issuance of Common Stock, Net The net cash inflow from the additional capital contribution to the entity after payment for issuance costs. us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber Vested and expected to vest, options (in shares) us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice Vested and expected to vest, weighted average exercise price, options (in dollars per share) Vested and expected to vest, aggregate intrinsic value, options us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice Exercisable, weighted average exercise price, options (in dollars per share) us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 Exercisable, weighted average remaining contractual life, options (Year) Note payable – short-term Notes Payable, Current, Total Exercisable, aggregate intrinsic value, options thmo_ClassOfWarrantOrRightExercisedDuringPeriod Warrants exercised (in shares) The number of warrants or rights exercised during period. thmo_ClassOfWarrantOrRightExpiredOrCancelledDuringPeriod Warrants expired (in shares) The number of warrants or rights expired or cancelled during period. us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest Total equity Balance Balance us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber Exercisable, options (in shares) Warrants expired, weighted average exercise price (in dollars per share) Weighted Average exercise price per share of warrants or rights expired or cancelled during period. us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 Outstanding, weighted average remaining contractual life, options (Year) Exercisable, weighted average exercise price (in dollars per share) Weighted Average exercise price per share or per unit of warrants or rights exercisable. Outstanding, aggregate intrinsic value, options Warrants exercised, weighted average exercise price (in dollars per share) Weighted Average exercise price per share of warrants or rights exercised during period. us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice Outstanding, weighted average exercise price, options (in dollars per share) Outstanding, weighted average exercise price, options (in dollars per share) Forfeited, weighted average exercise price, options (in dollars per share) Granted, weighted average exercise price, options (in dollars per share) Accrued payroll and related expenses Long-term deferred revenue and other noncurrent liabilities The amount of increase (decrease) in long-term deferred revenue and other noncurrent liabilities. Lessee, Operating Leases [Text Block] Accounts payable thmo_SupplyAgreementRenewalTerm Supply Agreement, Renewal Term (Year) The renewal term of a supply agreement. Revolving Credit Facility [Member] us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber Outstanding, options (in shares) Outstanding, options (in shares) thmo_SupplyAgreementTerm Supply Agreement, Term (Year) The term of a supply agreement. Supply Agreement [Member] Related to the supply agreement. Credit Facility [Axis] Credit Facility [Domain] us-gaap_PolicyTextBlockAbstract Accounting Policies January 2019 Notes, Amendment No. 1 [Member] Related to the January 2019 notes, amendment no. 1. BioArchive [Member] The type or description of the product or service. AXP [Member] The type or description of the product or service. ImmuneCyte [Member] Related to ImmuneCyte. thmo_JointVenturePurchasePercentOfCompanysCost Joint Venture Purchase, Percent of Company's Cost The percent of a company's cost that is paid for the purchase of a joint venture. Manual Disposables [Member] The type or description of the product or service. CAR-TXpress [Member] Related to the CAR-TXpress subsegment. Other [Member] The type or description of the product or service. us-gaap_PaymentsToAcquirePropertyPlantAndEquipment Capital expenditures Current liabilities: Supplemental disclosures of cash flow information: us-gaap_Assets Total assets us-gaap_LongTermDebtFairValue Long-term Debt, Fair Value us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic Net loss attributable to common stockholders Exclusivity Fee [Member] Information pertaining to the exclusivity fee. us-gaap_LossContingencyDamagesSoughtValue Loss Contingency, Damages Sought, Value us-gaap_LossContingencyDamagesAwardedValue Loss Contingency, Damages Awarded, Value Share-based Payment Arrangement [Text Block] Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block] Business Description and Basis of Presentation [Text Block] ThermoGenesis [Member] Information pertaining to ThermoGensis. At The Market Offering Agreement [Member] Information pertaining to At The Market Offering Agreement. thmo_CommissionAsPercentageOfGrossProceeds Commission as Percentage of Gross Proceeds Represents the commission as percentage of gross proceeds. Private Institution [Member] Information pertaining to private institution. Intangible assets, net HealthBanks Biotech [Member] Information pertaining to HealthBanks Biotech. thmo_MaximumOfferingPriceForIssuanceOfCommonStock Maximum Offering Price for Issuance of Common Stock Represents the maximum offering price for issuance of common stock. thmo_SharesIssuedAveragePricePerShare Shares Issued, Average Price Per Share (in dollars per share) Average per share or per unit amount of equity securities issued. Loss attributable to noncontrolling interests Convertible Debt Securities [Member] Share-based Payment Arrangement, Option [Member] Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block] Antidilutive Securities [Axis] Antidilutive Securities, Name [Domain] Comprehensive loss attributable to noncontrolling interests Commitments and Contingencies Disclosure [Text Block] Equipment and leasehold improvements, net Goodwill Paycheck Protection Program CARES Act [Member] Represents loan designed to provide funds for small businesses to keep their employees on the payroll. Device [Member] Information pertaining to the Device business segment. Long-term Debt, Type [Axis] Long-term Debt, Type [Domain] Conversion of Convertible Promissory Note to Common Stock [Member] Represents the conversion of convertible promissory note to common stock. us-gaap_EquityMethodInvestmentOwnershipPercentage Equity Method Investment, Ownership Percentage Net loss Net Income (Loss), Including Portion Attributable to Noncontrolling Interest, Total Net loss thmo_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour Thereafter Amount of lessee's undiscounted obligation for lease payment for operating lease due after fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest Comprehensive loss us-gaap_NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest Net loss Cash flows from investing activities: us-gaap_RevenueFromRelatedParties Revenue from Related Parties Convertible Debt [Member] Loss on equity method investments Income (Loss) from Equity Method Investments, Total us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty Related Party Transaction, Purchases from Related Party us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities Accrued payroll and related expenses Recording of beneficial conversion feature on debt Represents the amount recorded as beneficial conversion feature on debt. Related Party Transactions Disclosure [Text Block] thmo_WorkingCapital Working Capital A measure of both a company's efficiency and its short-term financial health. The working capital is calculated as: Working Capital= Current Asset - Current Liabilities. us-gaap_OperatingExpenses Total operating expenses us-gaap_IncreaseDecreaseInDueToRelatedPartiesCurrent Interest payable - related party us-gaap_DebtInstrumentTerm Debt Instrument, Term (Month) thmo_DistributorAgreementTerm Distributor Agreement Term (Year) Represents the term of the distributor agreement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. us-gaap_IncreaseDecreaseInAccountsPayableTrade Accounts payable thmo_DistributorAgreementRenewalTerm Distributor Agreement, Renewal Term (Year) Represents the renewal term of the distributor agreement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Restricted cash General and administrative Convertible Promissory Note [Member] Information pertaining to the Convertible Promissory Note. Boyalife W.S.N. [Member] Information pertaining to Boyalife W.S.N. Cash and cash equivalents Cash and Cash Equivalents, at Carrying Value, Ending Balance us-gaap_IncreaseDecreaseInOtherCurrentLiabilities Other current liabilities us-gaap_DebtInstrumentConvertibleConversionPrice1 Debt Instrument, Convertible, Conversion Price (in dollars per share) Stock-based compensation us-gaap_AllocatedShareBasedCompensationExpense Share-based Payment Arrangement, Expense us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger Debt Instrument, Convertible, Threshold Percentage of Stock Price Trigger us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature Debt Instrument, Convertible, Beneficial Conversion Feature Amendment Flag Other comprehensive loss: us-gaap_ComprehensiveIncomeNetOfTax Comprehensive loss attributable to common stockholders New Accounting Pronouncements, Policy [Policy Text Block] thmo_RefundFromRelatedPartyPurchases Refund from Related Party Purchases The amount of refund received from a related party for previous purchases. Reclassification, Comparability Adjustment [Policy Text Block] us-gaap_SharesOutstanding Balance (in shares) Balance (in shares) Common stock, shares outstanding (in shares) Preferred stock, shares outstanding (in shares) Current Fiscal Year End Date us-gaap_DebtInstrumentInterestRateStatedPercentage Debt Instrument, Interest Rate, Stated Percentage us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets Prepaid expenses and other assets Discount rate Document Fiscal Period Focus us-gaap_OperatingLeaseCost Operating Lease, Cost Document Fiscal Year Focus Lease, Cost [Table Text Block] Document Period End Date Right-to-use asset acquired under operating lease Weighted average remaining lease term (Year) Entity Emerging Growth Company us-gaap_DebtInstrumentFaceAmount Debt Instrument, Face Amount Document Type Loss on extinguishment of debt Gain (Loss) on Extinguishment of Debt, Total Loss on extinguishment of debt Entity Small Business us-gaap_GainLossRelatedToLitigationSettlement Gain (Loss) Related to Litigation Settlement, Total Entity Shell Company Document Information [Line Items] Document Information [Table] Service [Member] Entity Filer Category Debt Instrument [Axis] Entity Current Reporting Status Debt Instrument, Name [Domain] us-gaap_ConcentrationRiskPercentage1 Concentration Risk, Percentage Stock-based compensation expense us-gaap_IncreaseDecreaseInAccountsReceivable Accounts receivable Discount due to beneficial conversion features Entity Central Index Key Entity Registrant Name Entity [Domain] Legal Entity [Axis] Customer Concentration Risk [Member] Concentration Risk Type [Axis] Concentration Risk Type [Domain] Reverse Stock Split [Member] The conversion of a reverse stock split where there is a reduction in the shares outstanding. Entity Common Stock, Shares Outstanding (in shares) Unvested Series A Warrants [Member] Information about the unvested series A warrants. Vested Series A Warrants [Member] Information about the vested series A warrants. Revenue Benchmark [Member] Accounts Receivable [Member] us-gaap_IncreaseDecreaseInInventories Inventories EX-101.PRE 10 thmo-20200930_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 11 R1.htm IDEA: XBRL DOCUMENT

Document And Entity Information - shares	9 Months Ended
Document And Entity Information - shares	Sep. 30, 2020	Nov. 10, 2020
Document Information [Line Items]
Entity Registrant Name	ThermoGenesis Holdings, Inc.
Entity Central Index Key	0000811212
Trading Symbol	thmo
Current Fiscal Year End Date	--12-31
Entity Filer Category	Non-accelerated Filer
Entity Current Reporting Status	Yes
Entity Emerging Growth Company	false
Entity Small Business	true
Entity Interactive Data Current	Yes
Entity Common Stock, Shares Outstanding (in shares)		7,796,170
Entity Shell Company	false
Document Type	10-Q
Document Period End Date	Sep. 30, 2020
Document Fiscal Year Focus	2020
Document Fiscal Period Focus	Q3
Amendment Flag	false
Title of 12(b) Security	Common Stock, $.001 par value

XML 12 R2.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Balance Sheets (Current Period Unaudited) - USD ($)	Sep. 30, 2020	Dec. 31, 2019
Current assets:
Cash and cash equivalents	$ 4,436,000	$ 3,157,000
Restricted cash		1,000,000
Accounts receivable, net of allowance for doubtful accounts of $220,000 ($226,000 at December 31, 2019)	1,698,000	1,278,000
Inventories, net of reserves of $755,000 ($350,000 at December 31, 2019)	5,876,000	3,824,000
Prepaid expenses and other current assets	766,000	602,000
Total current assets	12,776,000	9,861,000
Equipment and leasehold improvements, net	1,537,000	2,028,000
Right-of-use operating lease assets, net	765,000	859,000
Goodwill	781,000	781,000
Intangible assets, net	1,382,000	1,467,000
Other assets	48,000	218,000
Total assets	17,289,000	15,214,000
Current liabilities:
Accounts payable	1,661,000	1,447,000
Accrued payroll and related expenses	513,000	288,000
Deferred revenue – short-term	700,000	620,000
Interest payable – related party	1,519,000	1,869,000
Note payable – short-term	235,000
Other current liabilities	1,092,000	2,461,000
Total current liabilities	5,720,000	6,685,000
Convertible promissory note – related party, less debt discount of $4,893,000 ($5,195,000 at December 31, 2019)	5,107,000	3,518,000
Convertible promissory notes, less debt discount of $588,000 (plus debt premium of $46,000 at December 31, 2019)	412,000	413,000
Note payable	411,000	1,000,000
Operating lease obligations – long-term	648,000	761,000
Deferred revenue – long-term	1,669,000	1,901,000
Other noncurrent liabilities	20,000	20,000
Total liabilities	13,987,000	14,298,000
Commitments and contingencies
Stockholders’ equity:
Preferred stock, $0.001 par value; 2,000,000 shares authorized, none outstanding
Common stock, $0.001 par value; 350,000,000 shares authorized; 6,832,040 issued and outstanding (2,843,601 at December 31, 2019)	7,000	3,000
Additional paid in capital	253,537,000	237,313,000
Accumulated deficit	(250,434,000)	(236,932,000)
Accumulated other comprehensive loss	22,000	2,000
Total ThermoGenesis Holdings, Inc. stockholders’ equity	3,132,000	386,000
Noncontrolling interests	170,000	530,000
Total equity	3,302,000	916,000
Total liabilities and equity	$ 17,289,000	$ 15,214,000

XML 13 R3.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals) - USD ($)	Sep. 30, 2020	Dec. 31, 2019
Accounts receivable, allowance for doubtful accounts	$ 220,000	$ 226,000
Inventories, reserves	755,000	350,000
Debt discount	$ 588,000	$ 46,000
Preferred stock, par value (in dollars per share)	$ 0.001	$ 0.001
Preferred stock, shares authorized (in shares)	2,000,000	2,000,000
Preferred stock, shares issued (in shares)	0	0
Preferred stock, shares outstanding (in shares)	0	0
Common stock, par value (in dollars per share)	$ 0.001	$ 0.001
Common stock, shares authorized (in shares)	350,000,000	350,000,000
Common stock, shares issued (in shares)	6,832,040	2,843,601
Common stock, shares outstanding (in shares)	6,832,040	2,843,601
Convertible Promissory Note [Member]
Debt discount	$ 4,893,000	$ 5,195,000

XML 14 R4.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019
Net revenues	$ 2,355,000	$ 4,058,000	$ 7,797,000	$ 11,325,000
Cost of revenues	844,000	2,163,000	7,426,000	6,220,000
Gross profit	1,511,000	1,895,000	371,000	5,105,000
Expenses:
Sales and marketing	539,000	502,000	1,424,000	1,227,000
Research and development	750,000	584,000	1,937,000	1,758,000
General and administrative	1,305,000	1,139,000	4,489,000	3,617,000
Total operating expenses	2,594,000	2,225,000	7,850,000	6,602,000
Loss from operations	(1,083,000)	(330,000)	(7,479,000)	(1,497,000)
Other income (expenses):
Interest expense	(1,531,000)	(1,188,000)	(6,377,000)	(3,531,000)
Loss on equity method investments			(13,000)
Loss on extinguishment of debt		(840,000)		(840,000)
Other income (expense)	5,000	(15,000)	7,000	(27,000)
Total other expense	(1,526,000)	(2,043,000)	(6,383,000)	(4,398,000)
Net loss	(2,609,000)	(2,373,000)	(13,862,000)	(5,895,000)
Loss attributable to noncontrolling interests	(146,000)	(91,000)	(360,000)	(445,000)
Net loss attributable to common stockholders	(2,463,000)	(2,282,000)	(13,502,000)	(5,450,000)
Net loss	(2,609,000)	(2,373,000)	(13,862,000)	(5,895,000)
Other comprehensive loss:
Foreign currency translation adjustments gain (loss)	(19,000)	16,000	20,000	9,000
Comprehensive loss	(2,628,000)	(2,357,000)	(13,842,000)	(5,886,000)
Comprehensive loss attributable to noncontrolling interests	(146,000)	(91,000)	(360,000)	(445,000)
Comprehensive loss attributable to common stockholders	$ (2,482,000)	$ (2,266,000)	$ (13,482,000)	$ (5,441,000)
Per share data:
Basic and diluted net loss per common share (in dollars per share)	$ (0.37)	$ (0.78)	$ (2.36)	$ (2)
Weighted average common shares outstanding basic and diluted (in shares)	6,711,664	2,913,198	5,728,105	2,720,502

XML 15 R5.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Statements of Equity (Unaudited) - USD ($)

Boyalife Investment Fund II, Inc. [Member]

Common Stock [Member]

Boyalife Investment Fund II, Inc. [Member]

Additional Paid-in Capital [Member]

Boyalife Investment Fund II, Inc. [Member]

Retained Earnings [Member]

Boyalife Investment Fund II, Inc. [Member]

AOCI Attributable to Parent [Member]

^[1]

Boyalife Investment Fund II, Inc. [Member]

Noncontrolling Interest [Member]

Boyalife Investment Fund II, Inc. [Member]

Common Stock [Member]

Additional Paid-in Capital [Member]

Retained Earnings [Member]

AOCI Attributable to Parent [Member]

^[1]

Noncontrolling Interest [Member]

Total

Balance (in shares) at Dec. 31, 2018

2,168,337

Balance at Dec. 31, 2018

$ 2,000

$ 235,888,000

$ (227,435,000)

$ (13,000)

$ (1,711,000)

$ 6,731,000

Stock-based compensation expense

81,000

Exercise of pre-funded warrants (in shares)

50,000

Exercise of pre-funded warrants

5,000

Discount due to beneficial conversion features

1,513,000

Foreign currency translation gain (loss)

(4,000)

Net loss

(1,871,000)

(176,000)

(2,047,000)

Reorganization of subsidiary and related change in non-controlling interest

(2,843,000)

2,843,000

Balance (in shares) at Mar. 31, 2019

2,218,337

Balance at Mar. 31, 2019

$ 2,000

234,644,000

(229,306,000)

(17,000)

956,000

6,279,000

Balance (in shares) at Dec. 31, 2018

2,168,337

Balance at Dec. 31, 2018

$ 2,000

235,888,000

(227,435,000)

(13,000)

(1,711,000)

6,731,000

Foreign currency translation gain (loss)

9,000

Balance (in shares) at Sep. 30, 2019

2,704,837

Balance at Sep. 30, 2019

$ 3,000

236,830,000

(232,885,000)

(4,000)

687,000

4,631,000

Balance (in shares) at Mar. 31, 2019

2,218,337

Balance at Mar. 31, 2019

$ 2,000

234,644,000

(229,306,000)

(17,000)

956,000

6,279,000

Stock-based compensation expense

125,000

Exercise of pre-funded warrants (in shares)

150,000

Exercise of pre-funded warrants

18,000

Discount due to beneficial conversion features

800,000

Issuance of common stock, net

756,000

Foreign currency translation gain (loss)

(3,000)

Net loss

(1,297,000)

(178,000)

(1,475,000)

Balance (in shares) at Jun. 30, 2019

2,368,337

Balance at Jun. 30, 2019

$ 2,000

236,343,000

(230,603,000)

(20,000)

778,000

6,500,000

Stock-based compensation expense

253,000

Exercise of pre-funded warrants (in shares)

216,500

Exercise of pre-funded warrants

$ 1,000

18,000

19,000

Conversion of note payable to common stock (in shares)

120,000

Conversion of note payable to common stock

216,000

Foreign currency translation gain (loss)

16,000

Net loss

(2,282,000)

(91,000)

(2,373,000)

Balance (in shares) at Sep. 30, 2019

2,704,837

Balance at Sep. 30, 2019

$ 3,000

236,830,000

(232,885,000)

(4,000)

687,000

4,631,000

Balance (in shares) at Dec. 31, 2019

2,843,601

Balance at Dec. 31, 2019

$ 3,000

237,313,000

(236,932,000)

2,000

530,000

916,000

Stock-based compensation expense

67,000

Exercise of pre-funded warrants (in shares)

100,000

Exercise of pre-funded warrants

10,000

Exercise of warrants (in shares)

7,866

Exercise of warrants

47,000

Discount due to beneficial conversion features

1,869,000

Conversion of note payable to common stock (in shares)

1,666,670

100,000

Conversion of note payable to common stock

$ 2,000

$ 2,998,000

$ 3,000,000

180,000

Issuance of common stock, net (in shares)

1,050,748

Issuance of common stock, net

$ 1,000

3,220,000

3,221,000

Foreign currency translation gain (loss)

38,000

Net loss

(4,602,000)

(141,000)

(4,743,000)

Balance (in shares) at Mar. 31, 2020

5,768,885

Balance at Mar. 31, 2020

$ 6,000

245,704,000

(241,534,000)

40,000

389,000

4,605,000

Balance (in shares) at Dec. 31, 2019

2,843,601

Balance at Dec. 31, 2019

$ 3,000

237,313,000

(236,932,000)

2,000

530,000

916,000

Foreign currency translation gain (loss)

20,000

Balance (in shares) at Sep. 30, 2020

6,832,040

Balance at Sep. 30, 2020

$ 7,000

253,537,000

(250,434,000)

22,000

170,000

3,302,000

Balance (in shares) at Mar. 31, 2020

5,768,885

Balance at Mar. 31, 2020

$ 6,000

245,704,000

(241,534,000)

40,000

389,000

4,605,000

Stock-based compensation expense

314,000

Exercise of pre-funded warrants (in shares)

224,445

Exercise of pre-funded warrants

22,000

Exercise of warrants (in shares)

267,271

Exercise of warrants

1,604,000

Discount due to beneficial conversion features

3,112,000

Conversion of note payable to common stock (in shares)

104,445

Conversion of note payable to common stock

$ 1,000

188,000

189,000

Issuance of common stock, net (in shares)

344,419

Issuance of common stock, net

1,993,000

Foreign currency translation gain (loss)

1,000

Net loss

(6,437,000)

(73,000)

(6,510,000)

Balance (in shares) at Jun. 30, 2020

6,709,465

Balance at Jun. 30, 2020

$ 7,000

252,937,000

(247,971,000)

41,000

316,000

5,330,000

Stock-based compensation expense

234,000

Issuance of common stock, net (in shares)

122,575

Issuance of common stock, net

366,000

Foreign currency translation gain (loss)

(19,000)

Net loss

(2,463,000)

(146,000)

(2,609,000)

Balance (in shares) at Sep. 30, 2020

6,832,040

Balance at Sep. 30, 2020

$ 7,000

$ 253,537,000

$ (250,434,000)

$ 22,000

$ 170,000

$ 3,302,000

[1]	Accumulated other comprehensive loss.

XML 16 R6.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)	3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019	Dec. 31, 2019
Cash flows from operating activities:
Net loss	$ (2,609,000)	$ (2,373,000)	$ (13,862,000)	$ (5,895,000)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization			569,000	604,000
Stock based compensation expense			615,000	459,000
Amortization of debt discount/premium, net			2,165,000	1,799,000
Amortization of accelerated debt discount due to conversion			2,486,000
Reserve for excess and slow-moving inventories			4,036,000	141,000
Reserve for bad debt expense			(6,000)	(53,000)
Change in fair value derivative				2,000
Loss on disposal of equipment			118,000	20,000
Loss on extinguishment of debt		840,000		840,000
Net change in operating assets and liabilities:
Accounts receivable			(414,000)	(2,908,000)
Inventories			(6,086,000)	980,000
Prepaid expenses and other assets			6,000	(227,000)
Accounts payable			223,000	(542,000)
Interest payable - related party			(350,000)	(116,000)
Accrued payroll and related expenses			225,000	(298,000)
Deferred revenue – short-term			80,000	354,000
Other current liabilities			(1,326,000)	(145,000)
Long-term deferred revenue and other noncurrent liabilities			(338,000)	1,467,000
Net cash used in operating activities			(11,859,000)	(3,518,000)
Cash flows from investing activities:
Capital expenditures			(23,000)	(178,000)
Net cash used in investing activities			(23,000)	(178,000)
Cash flows from financing activities:
Proceeds from convertible promissory note-related party			4,287,000	1,513,000
Payments on financing lease obligations			(32,000)	(15,000)
Proceeds from issuance of common stock, net of expenses			5,580,000	756,000
Proceeds from exercise of options, warrants and pre-funded warrants			1,683,000	42,000
Proceeds from long-term debt				1,800,000
Proceeds from note payable			646,000
Net cash provided by financing activities			12,164,000	4,096,000
Effects of foreign currency rate changes on cash and cash equivalents			(3,000)
Net increase (decrease) in cash, cash equivalents and restricted cash			279,000	400,000
Cash, cash equivalents and restricted cash at beginning of period			4,157,000	3,400,000	$ 3,400,000
Cash, cash equivalents and restricted cash at end of period	$ 4,436,000	$ 3,800,000	4,436,000	3,800,000	$ 4,157,000
Supplemental disclosures of cash flow information:
Cash paid for interest			2,094,000	1,613,000
Supplemental non-cash financing and investing information:
Recording of beneficial conversion feature on debt			4,981,000	2,313,000
Right-to-use asset acquired under operating lease				966,000
Fair value of amended convertible note issued in connection with the extinguishment of original convertible note				1,473,000
Transfer of equipment to inventories				33,000
Conversion of Related Party Convertible Promissory Note Into Common Stock [Member]
Supplemental non-cash financing and investing information:
Promissory note converted to common stock			3,000,000
Conversion of January 2019 Amended Notes to Common Stock [Member]
Supplemental non-cash financing and investing information:
Promissory note converted to common stock			$ 369,000	$ 216,000

XML 17 R7.htm IDEA: XBRL DOCUMENT

Note 1 - Description of Business, Basis of Presentation and Going Concern

9 Months Ended

Sep. 30, 2020

Notes to Financial Statements

Business Description and Basis of Presentation [Text Block]

ESCRIPTION

USINESS

ASIS

RESENTATION

AND GOING CONCERN

Organization and Basis of Presentation

1986

and is registered in the State of Delaware and headquartered in Rancho Cordova, CA.

The Company previously had

two

reportable segments, a Device Segment and a Clinical Development Segment. Due to the winding down of the Clinical Development Segment in

2019,

the Company

longer has any material revenues or expenses in that segment. As a result, the Company's chief operating decision maker

longer reviews unconsolidated operating results and the Company

longer reports in

two

segments. The Company provides the AutoXpress

and BioArchive

platforms for automated clinical bio-banking, PXP

platform for point-of-care cell-based therapies and CAR-TXpress™ platform under development for bio-manufacturing for immuno-oncology applications. The Company and its subsidiaries currently manufacture and market the following products:

Clinical Bio-Banking Applications:

●

AXP

Automated Cell Separation System – an automated, fully closed cell separation system for isolating and retrieving stem and progenitor cells from umbilical cord blood.

●

BioArchive

Automated Cryopreservation System – an automated, robotic, liquid nitrogen controlled-rate-freezing and cryogenic storage system for cord blood samples and cell therapeutic products used in clinical applications.

Point-of-Care Applications:

●

PXP

Point-of-Care System – an automated, fully closed, sterile system allows for the rapid, automated processing of autologous peripheral blood or bone marrow aspirate derived stem cells at the point-of-care, such as surgical centers or clinics.

Large Scale Cell Processing and Biomanufacturing:

●

-Series

Products:

-Lab

for cell isolation,

-Wash

System for cell washing and reformulation,

-Mini

for high efficiency small scale cell purification, and

-BACS™ System under development for large scale cell purification using our proprietary buoyance-activated cell sorting (“BACS”) technology.

●

80%

of the equity interest.

COVID-

Testing Kit:

●

Antibody Test – The ThermoGenesis SARS-CoV-

IgM/IgG Antibody Test Kit is a single-use rapid immunochromatographic test for the qualitative detection and differentiation of Immunoglobulin M (IgM) and Immunoglobulin G (IgG) antibodies to SARS-CoV-

in human serum, plasma (heparin, dipotassium EDTA, and sodium citrate), and venous whole blood (heparin, dipotassium EDTA, and sodium citrate).

January 1, 2019,

the Company entered into a reorganization of the business and equity ownership of its majority-owned ThermoGenesis Corp. subsidiary. Pursuant to the reorganization, the assets acquired by ThermoGenesis Corp. from SynGen Inc. in

July 2017

were contributed to a newly formed Delaware subsidiary of ThermoGenesis Corp., CARTXpress Bio, and the

20%

interest in ThermoGenesis Corp. held by a

third

party was exchanged for

20%

interest in CARTXpress Bio. As a result, the Company holds an

80%

equity interest in CARTXpress Bio and the Company has become the owner of

100%

of ThermoGenesis Corp. The purpose of the reorganization was to allow CARTXpress Bio to focus on the development and commercialization of the newly launched CARTXpress Bio cellular manufacturing platform.

In the reorganization, the Company reacquired the non-controlling interest shares in ThermoGenesis Corp., which had an accumulated deficit of

$1,711,000,

in exchange for

20%

equity interest in the newly formed subsidiary, CARTXpress Bio, which amounted to approximately

$1,100,000.

The total amount of

$2,843,000

related to the reorganization of subsidiary and the related increase in non-controlling interest was partially offset by a charge to additional paid in capital in stockholders' equity.

November 26, 2019

the Company entered into a joint venture agreement with HealthBanks Biotech Inc. (“HealthBanks”), an affiliate of the Boyalife Group, to form a new company called ImmuneCyte, Inc. (“ImmuneCyte”) to commercialize the Company's proprietary cell processing platform, CAR-TXpress™, for use in immune cell banking as well as for cell-based contract development and manufacturing services (CMO/CDMO). Under the terms of the JV Agreement, ImmuneCyte was initially owned

80%

by HealthBanks and

20%

by the Company. The Company currently owns

18.79%

of the equity of ImmuneCyte.

ThermoGenesis Holdings is an affiliate of the Boyalife Group, a global diversified life science holding company that focuses on stem cell technology and cell-based therapeutics.

Reverse Stock Split

June 4, 2019,

the Company effected a

one

(

) for

ten

(

) reverse split of its issued and outstanding common stock. The total number of shares of common stock authorized for issuance by the Company of

350,000,000

shares did

not

change in connection with the reverse stock split. All historical share amounts disclosed herein have been retroactively restated to reflect the reverse split and subsequent resulting share exchange.

Going Concern

The Company has a Revolving Credit Agreement (“Credit Agreement”) with Boyalife Asset Holding II, Inc. (Refer to Note

), allowing the Company to borrow up to

$10,000,000

in principal amount outstanding at any time. As of

September 30, 2020,

the Company had drawn down the full amount available under the Credit Agreement and had an outstanding balance of

$10,000,000.

Boyalife Asset Holding II, Inc. is a wholly owned subsidiary of Boyalife Group Inc., which is owned and controlled by the Company's Chief Executive Officer and Chairman of our Board of Directors.

April 21, 2020,

the Company entered into a promissory note and received a loan (collectively, the “PPP Loan”) from Comerica Bank (“Comerica”) under the Paycheck Protection Program (“PPP”), which was established under the Coronavirus Aid, Relief, and Economic Security Act (“CARES Act”) administered by the U.S. Small Business Administration. The Company received net proceeds of

$646,000

from the PPP Loan. The current portion of the PPP loan is

$235,000

and the noncurrent portion is

$411,000.

The term of the PPP Loan is

two

years with an interest rate of

1.00%

per annum, which shall be deferred for the

first

six

months of the term of the loan or after an application is filed for loan forgiveness, whichever is later. Each monthly payment shall be in the amount which would fully amortize the principal balance outstanding under the PPP Loan. Pursuant to the terms of the CARES Act, the proceeds of the PPP Loan

may

be used for payroll costs, mortgage interest, rent or utility costs. The promissory note of the PPP Loan contains customary events of default relating to, among other things, payment defaults, breach of representations and warranties, or provisions of the promissory note. The occurrence of an event of default

may

result in a claim for the immediate repayment of the amount outstanding under the PPP Loan.

September 30, 2020,

the Company had cash and cash equivalents of

$4,436,000

and working capital of

$7,056,000.

The Company has incurred recurring operating losses and as of

September 30, 2020

had an accumulated deficit of

$250,434,000.

These recurring losses raise substantial doubt about the Company's ability to continue as a going concern within

one

year from the filing of this report. The Company

may

need to raise additional capital to grow its business, fund operating expenses and make interest payments. The Company's ability to fund its cash needs is subject to various risks, many of which are beyond its control. The Company

may

seek additional funding through debt borrowings, sales of debt or equity securities or strategic partnerships. The Company cannot guarantee that such funding will be available on a timely basis, in needed quantities or on terms favorable to the Company, if at all.

not

include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classifications of liabilities that

may

result should the Company be unable to continue as a going concern.

Principles of Consolidation

The consolidated financial statements include the accounts of ThermoGenesis Holdings and its wholly-owned subsidiaries, ThermoGenesis Corp. and TotipotentRX Cell Therapy, Pvt. Ltd and ThermoGenesis Corp's majority-owned subsidiary, CARTXpress Bio. All significant intercompany accounts and transactions have been eliminated upon consolidation.

Non-controlling Interests

The

20%

ownership interest of CARTXpress Bio that is

not

owned by ThermoGenesis Holdings is accounted for as a non-controlling interest as the Company has an

80%

ownership interest in CARTXpress Bio. Earnings or losses attributable to other stockholders of a consolidated affiliated company are classified separately as "non-controlling interest" in the Company's consolidated statements of operations. Net loss attributable to non-controlling interests reflects only its share of the after-tax earnings or losses of an affiliated company. The Company's condensed consolidated balance sheets reflect non-controlling interests within the equity section.

Interim Reporting

-Q and Article

of Regulation S-

Accordingly, certain information and footnote disclosures normally included in annual financial statements prepared in accordance with U.S. GAAP have been condensed or omitted pursuant to such Securities and Exchange Commission (“SEC”) rules and regulations and accounting principles applicable for interim periods. In the opinion of management, all adjustments (consisting of normal recurring accruals) considered necessary for a fair presentation have been included. Events subsequent to the balance sheet date have been evaluated for inclusion in the accompanying condensed consolidated financial statements through the date of issuance. Operating results for the

three

and

nine

month periods ended

September 30, 2020

are

not

necessarily indicative of the results that

may

be expected for the year ending

December 31, 2020.

These unaudited condensed consolidated financial statements should be read in conjunction with the consolidated financial statements and the notes thereto included in ThermoGenesis Holdings' Annual Report on Form

-K for the year ended

December 31, 2019.

XML 18 R8.htm IDEA: XBRL DOCUMENT

Note 2 - Summary of Significant Accounting Policies

9 Months Ended

Sep. 30, 2020

Notes to Financial Statements

Organization, Consolidation and Presentation of Financial Statements Disclosure and Significant Accounting Policies [Text Block]

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Recently Issued Accounting Standards

August 2020,

the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”)

2020

“Debt-Debt with Conversion and Other Options (

“

Subtopic

470

”

) and Derivatives and Hedging—Contracts in Entity's Own Equity (

“

Subtopic

815

”

): Accounting for Convertible Instruments and Contracts in an Entity's Own Equity,”

which, among other things, provides guidance on how to account for contracts on an entity's own equity. This ASU simplifies the accounting for certain financial instruments with characteristics of liabilities and equity. Specifically, the ASU eliminated the need for the Company to assess whether a contract on the entity's own equity (

) permits settlement in unregistered shares, (

) whether counterparty rights rank higher than shareholder's rights, and (

) whether collateral is required. In addition, the ASU requires incremental disclosure related to contracts on the entity's own equity and clarifies the treatment of certain financial instruments accounted for under this ASU on earnings per share. This ASU

may

be applied on a full retrospective of modified retrospective basis. This ASU is effective

January 1, 2022

and interim periods presented. Early adoption of the ASU is permitted by the Company effective

January 1, 2021.

The Company is in the process of assessing the impact of the adoption of the ASU on the Company's financial statements.

December 2019,

FASB issued ASU

2019

“

Income Taxes (

“

Topic

740

”

): Simplifying the Accounting of Income Taxes

” which is intended to simplify various aspects related to accounting for income taxes. ASU

2019

removes certain exceptions to the general principles in Topic

740

and also clarifies and amends existing guidance to improve consistent application. This guidance is effective for fiscal years and interim periods within those fiscal years, beginning after

December 15, 2020,

with early adoption permitted. The Company doesn't expect the adoption of the standard to have a material impact.

June 2016,

the FASB issued

ASU

2016

13,

“

Financial Instruments - Credit Losses (

“

Topic

326

”

The ASU introduces a new accounting model, the Current Expected Credit Losses model (“CECL”), which requires

earlier recognition of credit losses and additional disclosures related to credit risk. The CECL model utilizes a lifetime expected credit loss measurement objective for the recognition of credit losses at the time the financial asset is originated or acquired. ASU

2016

is effective for annual periods beginning after

December 15, 2022,

including interim reporting periods within those annual reporting periods. We expect that the impact of adoption will

not

have a material impact.

Recently Adopted Accounting Standards

August 2018,

the FASB issued ASU

2018

13,

“

Fair Value Measurement (“Topic

820”

): Disclosure Framework-Changes to the Disclosure Requirements for Fair Value Measurement

.” This ASU eliminates, adds and modifies certain disclosure requirements for fair value measurements as part of its disclosure framework project. The standard was adopted and did

not

have a material impact on the Company's financial statements.

Revenue Recognition

Revenue is recognized based on the

five

-step process outlined in Accounting Standards Codification (“ASC”)

606.

The following tables summarize the revenues by product line:

	Three Months Ended September 30, 2020
	Device Revenue		Service Revenue		Other Revenue		Total Revenue
AXP	$	1,137,000	$	32,000	$	--	$	1,169,000
BioArchive		337,000		282,000		--		619,000
CAR-TXpress		332,000		22,000		71,000		425,000
Manual Disposables		100,000		--		--		100,000
Other		26,000		--		16,000		42,000
Total	$	1,932,000	$	336,000	$	87,000	$	2,355,000

	Nine Months Ended September 30, 2020
	Device Revenue		Service Revenue		Other Revenue		Total Revenue
AXP	$	4,009,000	$	103,000	$	--	$	4,112,000
BioArchive		675,000		900,000		--		1,575,000
CAR-TXpress		1,035,000		47,000		214,000		1,296,000
Manual Disposables		499,000		--		--		499,000
Other		276,000		--		39,000		315,000
Total	$	6,494,000	$	1,050,000	$	253,000	$	7,797,000

	Three Months Ended September 30, 2019
	Device Revenue		Service Revenue		Other Revenue		Total Revenue
AXP	$	2,255,000	$	51,000	$	--	$	2,306,000
BioArchive		243,000		351,000		--		594,000
Manual Disposables		221,000		--		--		221,000
CAR-TXpress		875,000		10,000		33,000		918,000
Other		--		--		19,000		19,000
Total	$	3,594,000	$	412,000	$	52,000	$	4,058,000

	Nine Months Ended September 30, 2019
	Device Revenue		Service Revenue		Other Revenue		Total Revenue
AXP	$	6,550,000	$	160,000	$	--	$	6,710,000
BioArchive		1,274,000		1,117,000		--		2,391,000
Manual Disposables		764,000		--		--		764,000
CAR-TXpress		1,365,000		6,000		33,000		1,404,000
Other		5,000		11,000		40,000		56,000
Total	$	9,958,000	$	1,294,000	$	73,000	$	11,325,000

Contract Balances

Generally, all sales are contract sales (with either an underlying contract or purchase order). The Company does

not

have any material contract assets. When invoicing occurs prior to revenue recognition, a contract liability is recorded (as deferred revenue on the consolidated balance sheet). Revenues recognized during the

three

and

nine

months ended

September 30, 2020

that were included in the beginning balance of deferred revenue were

$115,000

and

$547,000,

respectively. Short-term deferred revenues increased from

$620,000

$700,000

and long-term deferred revenues decreased from

$1,901,000

$1,669,000

during the

nine

months ended

September 30, 2020,

respectively.

Exclusivity Fee

August 30, 2019,

the Company entered into a Supply Agreement with Corning Incorporated (the “Supply Agreement”). The Supply Agreement has an initial term of

five

years with automatic

two

-year renewal terms, unless terminated by either party in accordance with the terms of the Supply Agreement (collectively, the “Term”). Pursuant to the Supply Agreement, the Company has granted to Corning exclusive worldwide distribution rights for substantially all

-Series

products under the CAR-TXpress™ platform (the “Products”) manufactured by its subsidiary, ThermoGenesis Corp., for the duration of the Term, subject to certain geographical and other exceptions. As consideration for the exclusive worldwide distribution rights for the Products, Corning paid a

$2,000,000

exclusivity fee, in addition to any amounts payable throughout the Term for the Products.

The Company performed an evaluation of the revenue recognition of the

$2,000,000

fee under ASC

606.

It determined that the

$2,000,000

will be recognized over time, based on the term of the contract. It was determined that the most likely outcome is the agreement is extended for

one

additional

two

-year term after the initial

five

-year contract is complete. Consequently, the term to recognize the exclusivity fee is over

seven

years. The Company will allocate the upfront fee evenly to each daily performance obligation of providing exclusivity and recognize the revenue ratably over the

seven

-year period. As each day passes, the Company will recognize the portion of the exclusivity fee allocated to that day. For the

three

and

nine

months ended

September 30, 2020,

the Company recorded revenue of

$71,000

and

$214,000,

respectively, related to the exclusivity fee. The remaining balance of the

$2,000,000

payment of

$1,690,000

was recorded to deferred revenue, with

$286,000

in short-term deferred revenue and

$1,404,000

recorded in long-term deferred revenue.

Backlog of Remaining Customer Performance Obligations

	Remainder of 2020		2021		2022		2023		2024 and beyond		Total
Service revenue	$	310,000	$	958,000	$	561,000	$	298,000	$	38,000	$	2,165,000
Clinical revenue		3,000		13,000		13,000		13,000		175,000		217,000
Exclusivity fee		71,000		286,000		286,000		286,000		761,000		1,690,000
Total	$	384,000	$	1,257,000	$	860,000	$	597,000	$	974,000	$	4,072,000

Revenues are net of normal discounts. Shipping and handling fees billed to customers are included in net revenues, while the related costs are included in cost of revenues.

Fair Value Measurements

In accordance with ASC

820,

“

Fair Value Measurements and Disclosures

,” fair value is defined as the exit price, or the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants as of the measurement date.

The guidance also establishes a hierarchy for inputs used in measuring fair value that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that the most observable inputs be used when available. Observable inputs are inputs that market participants would use in valuing the asset or liability and are developed based on market data obtained from sources independent of the Company. Unobservable inputs are inputs that reflect the Company's assumptions about the factors that market participants would use in valuing the asset or liability. The guidance establishes

three

levels of inputs that

may

be used to measure fair value:

Level

Quoted market prices in active markets for identical assets or liabilities.

Level

Observable market-based inputs or unobservable inputs that are corroborated by market data.

Level

Unobservable inputs which are supported by little or

market activity.

The carrying values of cash and cash equivalents, accounts receivable and accounts payable approximate fair value due to their short duration. The fair value of the Company's derivative obligation liability is classified as Level

within the fair value hierarchy since the valuation model of the derivative obligation is based on unobservable inputs. The derivative obligation is

not

material to the financial statements of the Company. The impairment of goodwill and intangible assets is a non-recurring Level

fair value measurement.

Net Loss per Share

vesting or other contingencies associated with them. As of

September 30, 2020,

all pre-funded warrants previously issued have been exercised and

none

are currently outstanding. The calculation of the basic and diluted earnings per share is the same for all periods presented, as the effect of the potential common stock equivalents noted below is anti-dilutive due to the Company's net loss position for all periods presented. Anti-dilutive securities consisted of the following at

September 30:

	2020		2019
Common stock equivalents of convertible promissory note and accrued interest		6,988,334		6,013,667
Vested Series A warrants		40,441		40,441
Unvested Series A warrants (1)		69,853		69,853
Warrants – other		1,006,190		1,300,091
Stock options		892,149		296,029
Total		8,996,967		7,720,081

___________

(

)

The unvested Series A warrants were subject to vesting based upon the amount of funds actually received by the Company in the

second

close of the

August 2015

financing which never occurred. The warrants will remain outstanding but unvested until they expire in

February 2021.

Reclassifications

Certain prior period amounts have been reclassified to conform to the current period presentation. The reclassifications did

not

have an impact on net loss as previously reported.

XML 19 R9.htm IDEA: XBRL DOCUMENT

Note 3 - Related Party Transactions	9 Months Ended
Note 3 - Related Party Transactions	Sep. 30, 2020
Notes to Financial Statements
Related Party Transactions Disclosure [Text Block]	3. Related Party Transactions Health B anks Biotech (USA) Inc. On November 26, 2019 the Company entered into a joint venture agreement with HealthBanks Biotech (USA) Inc. (the “JV Agreement”) to form a new company called ImmuneCyte, Inc. (“ImmuneCyte”) to commercialize the Company's proprietary cell processing platform, CAR-TXpress™, for use in immune cell banking as well as for cell-based contract development and manufacturing services (CMO/CDMO). Under the terms of the JV Agreement, ImmuneCyte was initially owned 80% by HealthBanks Biotech and 20% by the Company. The Company currently owns 18.79% of the equity of ImmuneCyte. ImmuneCyte will be among the first immune cell banks in the U.S. and offer customers the ability to preserve younger, healthier and uncontaminated immune cells for future potential use in dendritic and chimeric antigen receptor (“CAR-T”) cell therapies in a GMP compliant processing environment. The Company's principal contribution to ImmuneCyte was a supply agreement under which ImmuneCyte will have the exclusive right to purchase the Company's proprietary cell processing equipment in the immune cell banking business and a non-exclusive right to purchase it for other cell-based contract development and manufacturing (“CMO/CDMO”) services at a price equal to 115% of the Company's cost. The Company also contributed to ImmuneCyte intellectual property and trademarks relating to the Company's clinical development assets, which were fully impaired by the Company in 2018 and had no book value. HealthBanks contributed to ImmuneCyte a paid-up, royalty free license to use its proprietary business management system, customer relationship management software, and laboratory information statement, and it will also make available a $1,000,000 unsecured, non-convertible line of credit to ImmuneCyte to provide initial operating capital. Healthbanks is a subsidiary of Boyalife Group, Inc. (USA), the owner of Boyalife Asset Holding II, Inc., which is the largest stockholder of the Company, and is owned by Dr. Xiaochun (Chris) Xu, the Company's Chief Executive Officer and Chairman of our Board of Directors. Between November 26, 2019 and September 30, 2020, ImmuneCyte closed $3,700,000 of equity investments with a private institution and qualified investors. ImmuneCyte issued 643,750 shares of Class A common stock at a price between $5.00 to $16.00 per share, representing a total of 6.05% ownership in the joint venture. As a result of these equity investments in ImmuneCyte, the Company's equity in the joint venture is no longer subject to anti-dilution provisions. After these investments, ImmuneCyte is owned 75.16% by HealthBanks, 18.79% by the Company and 6.05% by the private investors. The Company initially determined that ImmuneCyte would be considered a variable interest entity, as a result of the significant influence the Company has over operations and its' lack of sufficient equity at inception. After the additional investment of $3,700,000, ImmuneCyte's equity at risk was considered sufficient and the Company determined it would no longer be classified as a variable interest entity. The Company's investment in ImmuneCyte will be accounted for under the equity method based on management's conclusion that the Company can exercise significant influence over ImmuneCyte via its equity interest and the related Supply Agreement. The Company recorded the investment initially at the value of the nonfinancial assets contributed of $28,000, which consisted of the book value of certain assets contributed at the time of formation. The Company entered into a supply agreement with ImmuneCyte with an effective date of April 22, 2020. The supply agreement, which related to the supply of COVID- 19 antibody detection kits, has a term of one year from the effective date, thirty ( 30 ) day renewal terms and contains the Company's standard supply contract provisions. The Company paid ImmuneCyte approximately $3,600,000 for kits during the nine months ended September 30, 2020. In August 2020, due to concerns over the consistency of performance of these kits, the Company voluntarily withdrew its application for an Emergency Use Authorization (“EUA”) with respect to the detection kits. After the EUA application was withdrawn, ImmuneCyte agreed to refund their mark-up on the purchased kits. That refund of approximately $800,000 was received in the quarter ended September 30, 2020. Additionally, ImmuneCyte and the Company agreed to work together to attempt to secure a refund from the original manufacturer for the remaining amount the Company paid for kits. If a refund is obtained, it will be recognized when received. For the nine months ended September 30, 2020, the Company recorded a loss to cost of goods sold for the remaining carrying amount of the testing kits in inventory as of September 30, 2020 of approximately $2,800,000. In order to continue to pursue its strategy to sell COVID- 19 antibody detection test kits, the Company entered into a supply agreement in August 2020 with BioHit Healthcare (Hefei) Co., Ltd. for kits to be marketed under the ThermoGenesis brand. For the three and nine months ended September 30, 2020, the Company recorded a loss of $0 and $13,000, respectively, on its equity investment in ImmuneCyte as ImmuneCyte has recorded a cumulative loss since the Company made its investment. At September 30, 2020, the value of the Company's investment in ImmuneCyte will remain at $0. For the three and nine months ended September 30, 2020, ImmuneCyte had net loss of $1,313,000 and $1,422,000, respectively. As of September 30, 2020, its current assets were $2,120,000 and current liabilities were $296,000. Convertible Promissory Note and Revolving Credit Agreement In March 2017, ThermoGenesis Holdings entered into a Credit Agreement with Boyalife Investment Fund II, Inc., which later merged into Boyalife Asset Holding II, Inc. (the “Lender”). The Lender is a wholly owned subsidiary of Boyalife Group Inc., which is owned and controlled by the Company's Chief Executive Officer and Chairman of our Board of Directors. The Credit Agreement, as amended, grants to the Company the right to borrow up to $10,000,000 (the “Loan”) at any time prior to March 6, 2022 ( the “Maturity Date”). In February 2020, the Company and the Lender completed a series of transactions in which the Company completed a draw down for $1,869,000 and the Lender converted a total of $3,000,000 of the outstanding balance of the convertible note into an aggregate of 1,666,670 shares of our common stock in two conversions. As a result of the conversions, the Company recorded a $2,486,000 charge to interest expense for the unamortized portion of the beneficial conversion feature related to the unamortized portion of the beneficial conversion feature of outstanding principal balance that was converted. On April 28, 2020, the Company borrowed an additional $2,418,000 under the Loan. Immediately after that draw down, the outstanding principal balance under the Loan was $10,000,000 and accrued but unpaid interest was $580,000. The principal purpose of the draw down was to provide working capital to fund the Company's purchase of SARS-CoV- 2 (COVID- 19 ) IgM/IgG Antibody Fast Detection Kits from ImmuneCyte. As of September 30, 2020, the outstanding principal balance of the Loan was $10,000,000. The Credit Agreement and the Convertible Promissory Note issued thereunder (the “Note”) provide that the principal and all accrued and unpaid interest under the Loan will be due and payable on the Maturity Date, with payments of interest-only due on the last day of each calendar year. The Loan bears interest at 22% per annum, simple interest. The Company has five business days after the Lender demands payment to pay the interest due before the Loan is considered in default. The Note can be prepaid in whole or in part by the Company at any time without penalty. The Maturity Date of the Note is subject to acceleration at the option of the Lender upon customary events of default, which include; a breach of the Loan documents, termination of operations, or bankruptcy. The Lender's obligation to make advances under the Loan is subject to the Company's representations and warranties in the Credit Agreement continuing to be true at all times and there being no continuing event of default under the Note. The Credit Agreement and Note were amended in April 2018. The amendment granted the Lender the right to convert, at any time, outstanding principal and accrued but unpaid interest into shares of Common Stock at a conversion price of $16.10 per share and if the Company issues shares of Common Stock at a lower price per share, the conversion price of the Note is lowered to the reduced amount. The Company completed two transactions in 2018, lowering the conversion price to $1.80. It was concluded that the conversion option of the draw down in February 2020 of $1,869,000 contained a beneficial conversion feature and the Company recorded a debt discount for the full amount in the quarter ended March 31, 2020. It was also concluded that the conversion option of the draw down in April 2020 of $2,418,000 contained a beneficial conversion feature and the Company recorded a debt discount for the full amount in the quarter ended June 30, 2020. Such discount represented the fair value of the incremental shares up to the proceeds received from the convertible notes. The Company amortized $828,000 and $2,103,000 of debt discount to interest expense for the three and nine months ended September 30, 2020, respectively, and $471,000 and $1,398,000 for the three and nine months ended September 30, 2019, respectively. As of September 30, 2020, the Company had an interest payable balance of $1,519,000 as compared to $1,869,000 at December 31, 2019 related to the Note. Distributor Agreement On August 21, 2017, ThermoGenesis Corp. entered into an International Distributor Agreement with Boyalife W.S.N. Under the terms of the agreement, Boyalife W.S.N. was granted the exclusive right, subject to existing distributors and customers (if any), to develop, sell to, and service a customer base for ThermoGenesis Corp's AXP ® AutoXpress System and BioArchive ® System in the People's Republic of China (excluding Hong Kong and Taiwan), Singapore, Indonesia, and the Philippines (the “Territories”). Boyalife W.S.N. is related to our Chief Executive Officer and Chairman of our Board of Directors, and an affiliate of Boyalife (Hong Kong) Limited. Boyalife W.S.N,'s rights under the agreement include the exclusive right to distribute AXP ® Disposable Blood Processing Sets and use rights to the AXP ® AutoXpress System, BioArchive ® System and other accessories used for the processing of stem cells from cord blood in the Territories. Boyalife W.S.N. is also appointed as the exclusive service provider to provide repairs and preventative maintenance to ThermoGenesis Corp. products in the Territories. The term of the agreement is for three years with ThermoGenesis Corp. having the right to renew the agreement for successive two -year periods at its option. However, ThermoGenesis Corp. has the right to terminate the agreement early if Boyalife W.S.N. fails to meet specified minimum purchase requirements. During the three and nine months ended September 30, 2020, the Company recorded no revenue and for the three and nine months ended September 30, 2019, the Company recorded $214,000 and $794,000, respectively, of revenues from Boyalife related to the aforementioned distributor agreement.

XML 20 R10.htm IDEA: XBRL DOCUMENT

Note 4 - Convertible Promissory Note	9 Months Ended
Note 4 - Convertible Promissory Note	Sep. 30, 2020
Notes to Financial Statements
Debt Disclosure [Text Block]	4. CONVERTIBLE PROMISSORY NOTE On January 29, 2019, the Company agreed to issue and sell an unsecured note payable to an accredited investor (the “Accredited Investor”) for an aggregate of $800,000 face value (the “January 2019 Note”) that, after six months, is convertible into shares of the Company's common stock at a conversion price equal to the lower of (a) $1.80 per share or (b) 90% of the closing sale price of the Company's common stock on the date of conversion (subject to a floor conversion price of $0.50 ). The January 2019 Note bears interest at the rate of twenty-four percent ( 24% ) per annum and is payable quarterly in arrears. Unless sooner converted in the manner described below, all principal under the January 2019 Note, together with all accrued and unpaid interest thereupon, will be due and payable eighteen ( 18 ) months from the date of the issuance of the January 2019 Note. The January 2019 Note may be prepaid without penalty at any time after it becomes convertible (at which time the holder will have the right to convert it before prepayment thereof). On the date that is six months after the issuance of the January 2019 Note, and for so long thereafter as any principal and accrued but unpaid interest under the January 2019 Note remains outstanding, the holder of the January 2019 Note may convert such holder's January 2019 Note, in whole or in part, into a number of shares of the Company's common stock equal to (i) the principal amount being converted, together with any accrued or unpaid interest thereon, divided by (ii) the conversion price in effect at the time of conversion. The January 2019 Note has customary conversion blockers at 4.99% and 9.99% unless otherwise agreed to by the Company and the holder. It was concluded that the conversion option was beneficial. Accordingly, the Company recorded a debt discount in the amount of $800,000, upon stockholder approval of the conversion feature, which occurred on May 30, 2019. The discount represented the fair value of the incremental shares up to the proceeds received from the convertible note. On July 23, 2019, the Company entered into Amendment No. 1 to the January 2019 Note (“Amended Note”). Under the terms of the amendment, the maturity date of the January 2019 Note was extended from July 29, 2020 to July 31, 2022. All other terms of the January 2019 Note remain the same. The Amended Note was accounted for as an extinguishment of the January 2019 Note as the change in the fair value of the embedded conversion option featured in the January 2019 Note immediately before and after the amendment exceeded 10% of the carrying amount of the January 2019 Note. Accordingly, the Company recorded a loss on the constructive extinguishment of this debt in the amount of $840,000 for the year ended December 31, 2019. The fair value of the Amended Note, which amounted to $1,473,000 was recorded as a liability. The Company also evaluated the conversion option embedded in the Amended Note and determined it was beneficial. Accordingly, the Company recorded a debt discount in the amount of $556,000 on the Amended Note for the year ended December 31, 2019. The Company amortized $77,000 of the debt discount for the January 2019 Note to interest expense for the year ended December 31, 2019. The Company utilized a Monte Carlo simulation model to determine the fair value of the Amended Note. During the nine months ended September 30, 2020, the holder converted the remainder of the face value of the note into shares of common stock. For the nine months ended September 30, 2020, $369,000 was converted into 204,445 shares of common stock. Additionally, the unamortized premium for the portion of the note that was converted of $46,000 was recorded to interest income during the nine months ended September 30, 2020. On July 23, 2019, the Company entered into a private placement with the Accredited Investor, pursuant to which the Company issued and sold to such investor an unsecured convertible promissory note in the original principal amount of $1,000,000 (the “July 2019 Note”). Such note is convertible into shares of the Company's common stock at a conversion price equal to the lower of (a) $1.80 per share or (b) 90% of the closing sale price of the Company's common stock on the date of conversion (subject to a floor conversion price of $0.50 ). The July 2019 Note bears interest at the rate of twenty-four percent ( 24% ) per annum and is payable quarterly in arrears. Unless sooner converted in the manner described below, all principal under the July 2019 Note, together with all accrued and unpaid interest thereupon, will be due and payable three years from the date of the issuance on July 31, 2022. The July 2019 Note may be prepaid without penalty at any time after it becomes convertible (at which time the holder will have the right to convert it before prepayment thereof). On the date that is six months after the issuance of the July 2019 Note, the holder may convert the July 2019 Note, in whole or in part, into a number of shares of the Company's common stock equal to (i) the principal amount being converted, together with any accrued or unpaid interest thereon, divided by (ii) the conversion price in effect at the time of conversion. The Company had accounted for the July 2019 Note as a debt instrument until the conversion feature was approved by the Company's stockholders. Accordingly, the Company recorded a beneficial conversion feature in the amount of $694,000, upon stockholder approval of the conversion feature, which occurred on June 4, 2020. The discount represented the fair value of the incremental shares up to the proceeds received from the convertible note. The debt discount will be amortized to interest expense over the term of the July 2019 Note. For the three and nine months ended September 30, 2020, $27,000 and $107,000, respectively, were amortized to interest expense.

XML 21 R11.htm IDEA: XBRL DOCUMENT

Note 5 - Leases

9 Months Ended

Sep. 30, 2020

Notes to Financial Statements

Lessee, Operating Leases [Text Block]

LEASES

The Company leases the Rancho Cordova, California and Gurgaon, India facilities pursuant to operating leases. The Rancho Cordova lease expires in

May 2024.

The Gurgaon lease expires in

September 2023;

however, either party can terminate with

three

months' notice. As such, it was accounted for as a short-term lease.

Operating Leases

Operating lease assets and liabilities are recognized at the lease commencement date. Operating lease liabilities represent the present value of lease payments

not

yet paid. Operating lease assets represent our right to use an underlying asset and are based upon the operating lease liabilities adjusted for prepayments or accrued lease payments, initial direct costs, lease incentives, and impairment of operating lease assets. To determine the present value of lease payments

not

yet paid, we use the Company's cost of capital based on existing debt instruments. Our material leases typically contain rent escalations over the lease term. We recognize expense for these leases on a straight-line basis over the lease term.

The following summarizes the Company's operating leases:

	September 30, 2020
Right-of-use operating lease assets, net	$	765,000
Current lease liability		147,000
Non-current lease liability		648,000

Weighted average remaining lease term		3.7
Discount rate		22	%

Maturities of lease liabilities by year for our operating leases are as follows:

2020 (remaining)	$	76,000
2021		310,000
2022		319,000
2023		328,000
2024		139,000
Thereafter		--
Total lease payments	$	1,172,000
Less: imputed interest		(377,000	)
Present value of operating lease liabilities	$	795,000

Statement of Cash Flows

January 2019,

the Company signed a new amendment to its lease for office space at its corporate headquarters in Rancho Cordova, CA. The amendment was accounted for as a modification and resulted in a right-of-use asset of

$966,000

being recognized as a non-cash addition on the date of the amendment. Cash paid for amounts included in the measurement of operating lease liabilities was

$225,000

for the

nine

months ended

September 30, 2020

and is included in cash flows from operating activities.

Operating Lease Costs

Operating lease costs were

$135,000

and

$343,000

for the

three

and

nine

months ended

September 30, 2020,

respectively. These costs are primarily related to long-term operating leases, but also include immaterial amounts for variable lease costs and short-term leases with terms greater than

days.

Finance Leases

not

and were

not

material for the

three

and

nine

months ended of

September 30, 2020.

XML 22 R12.htm IDEA: XBRL DOCUMENT

Note 6 - Commitments and Contingencies

9 Months Ended

Sep. 30, 2020

Notes to Financial Statements

Commitments and Contingencies Disclosure [Text Block]

COMMITMENTS AND CONTINGENCIES

Financial Covenants

Effective

March 16, 2020,

the Company and CBR Systems, Inc. (“CBR”) entered into a Manufacturing and Supply Amending Agreement

(the “Amendment”). The Amendment amends the Manufacturing and Supply Agreement entered into on

May 15, 2017

by the Company and CBR (the “Original Agreement”). The Amendment, among other things, amends the Original Agreement by reducing from

$2.0

million to

$1.0

million the required amount of cash and short-term investments, net of debt or borrowed funds due in

one

year or less, that the Company must have on hand at the end of any month to avoid being in default under the Original Agreement.

July 13, 2020,

the Company, entered into a Manufacturing and Supply Amending Agreement

with CBR with an effective date of

July 13, 2020 (

the “Amendment”). The Amendment, among other things, revised the amount of certain products to be purchased, pricing of those products and removal of the safety stock requirement. In addition, the Amendment updated the financial requirement to exclude convertible debt from the definition of short-term debt under events or conditions that constitute a default. The Amendment states that the Company's cash balance and short-term investments net of non-convertible debt and borrowed funds that are payable within

one

year must be greater than

$1,000,000

at any month end.

The Company was in compliance with this financial covenant as of

September 30, 2020.

Warranty

The Company offers a warranty on all of its non-disposable products of

one

two

years. The Company warrants disposable products through their expiration date. The Company periodically assesses the adequacy of its recorded warranty liabilities and adjusts the amounts as necessary.

The warranty liability is included in other current liabilities in the unaudited condensed consolidated balance sheets. The change in the warranty liability for the

nine

months ended

September 30, 2020

is summarized in the following table:

Balance at December 31, 2019	$	277,000
Warranties issued during the period		62,000
Settlements made during the period		(171,000	)
Changes in liability for pre-existing warranties during the period		(20,000	)
Balance at September 30, 2020	$	148,000

Contingen

cies and Restricted Cash

In fiscal

2016,

the Company signed an engagement letter with a strategic consulting firm (“Mavericks”). Included in the engagement letter was a success fee due upon the successful conclusion of certain transactions. On

May 4, 2017,

a lawsuit was filed in California Superior Court against the Company and its Chief Executive Officer by the consulting firm, which argued that it was owed a transaction fee of

$1,000,000

under the terms of the engagement letter due to the conversion of the Boyalife debentures in

August 2016.

October 2017,

to streamline the case by providing for the dismissal of claims against the Company's Chief Executive Officer based on alter ego theories and without acknowledging any liability, the Company deposited

$1,000,000

with the Court, which was recorded as restricted cash. The trial completed in

February 2020

with an adverse jury verdict in favor of Mavericks in the total amount of

$1,000,000.

As a result, the Company recorded in other current liabilities a

$1,400,000

loss in general and administrative expenses for the year ended

December 31, 2019.

The loss includes the

$1,000,000

transaction fee and an estimated

$400,000

in interest due. The

$1,000,000

deposited with the court will be used to settle the transaction fee. At the conclusion of the trial,

judgment had been entered as the parties were disputing whether the defense of equitable estoppel should bar entry of judgment and the proper pre-judgment interest start date. In

April 2020,

the Company received notice that equitable estoppel defense was denied by the Court. After that ruling, Mavericks and the Company reached agreement for the interest start date and the total amount of Mavericks' trial-related expenses that must be reimbursed by the Company as result of the verdict. On

May 1, 2020

the parties agreed that the Company would pay Mavericks

$480,000,

representing

$369,000

for interest and

$111,000

for trial-related expenses. Additionally, the Company agreed

not

to contest the jury verdict and allowing the Court to release the

$1,000,000

cash bond deposited by the Company early in the litigation to Mavericks, effectively ending the case.

In the normal course of operations, the Company

may

have disagreements or disputes with customers, employees or vendors. Such potential disputes are seen by management as a normal part of business. As of

September 30, 2020,

except as disclosed, management believes any liability that

may

ultimately result from the resolution of these matters will

not

have a material adverse effect on the Company's consolidated financial position, operating results or cash flows.

XML 23 R13.htm IDEA: XBRL DOCUMENT

Note 7 - Stockholders' Equity

9 Months Ended

Sep. 30, 2020

Notes to Financial Statements

Share-based Payment Arrangement [Text Block]

STOCKHOLDERS' EQUITY

Common Stock

March 25, 2020,

the Company entered into a Securities Purchase Agreement (the “Purchase Agreement”) with

three

institutional and accredited investors (the “Investors”), pursuant to which the Company agreed to issue and sell to the Investors, in a registered direct offering (the “RDO”), an aggregate of

1,000,002

shares of the Company's common stock at an offering price of

$3.50

per share, for gross proceeds of approximately

$3.5

million before the deduction of

$393,000

in placement agent fees and offering expenses. The shares were issued and sold by the Company pursuant to a registration statement on Form S-

(File

No.

333

235509

), which was initially filed with the Securities and Exchange Commission (the “Commission”) on

December 13, 2019

and was declared effective by the Commission on

January 3, 2020,

and the related prospectus supplement filed with the Commission on

March 27, 2020.

The closing of the RDO occurred on

March 27, 2020.

The Purchase Agreement also contains representations, warranties, indemnification and other provisions customary for transactions of this nature. Under the Purchase Agreement, (i) the Company and its subsidiaries were prohibited for a period of

days after the closing (subject to certain exceptions) from issuing, entering into any agreement to issue, or announcing the issuance or the proposed issuance of any shares of the Company's common stock or any other securities that are at any time convertible into, or exercisable or exchangeable for, or otherwise entitle the holder thereof to receive, shares of the Company's common stock and (ii) the Company is prohibited for a period of

twelve

(

) months after the closing (subject to certain exceptions) from effecting or entering into an agreement to effect any issuance by the Company or any of its subsidiaries of the Company's common stock or any other securities that are at any time convertible into, or exercisable or exchangeable for, or otherwise entitle the holder thereof to receive, shares of the Company's common stock involving a Variable Rate Transaction (as defined in the Purchase Agreement).

December 13, 2019,

the Company entered into an At The Market Offering Agreement, by and between the Company and H.C. Wainwright & Co., LLC, as agent (“H.C. Wainwright”) (the “ATM Agreement”), pursuant to which the Company

may

offer and sell, from time to time through H.C. Wainwright, shares of Common Stock, having an aggregate offering price of up to

$4.4

million and on

May 19, 2020

the ATM Agreement was amended to increase the aggregate value of up to

$15,280,313

(the “HCW Shares”). The offer and sale of the HCW Shares is made pursuant to a shelf registration statement on Form S-

and the related prospectus (File

No.

333

235509

). Pursuant to the ATM Agreement, H.C. Wainwright

may

sell the HCW Shares by any method permitted by law deemed to be an “at the market offering” as defined in Rule

415

of the Securities Act of

1933,

including sales made by means of ordinary brokers' transactions, including on The NASDAQ Capital Market, at market prices or as otherwise agreed with H.C. Wainwright. H.C. Wainwright will use commercially reasonable efforts consistent with its normal trading and sales practices to sell the HCW Shares from time to time, based upon instructions from the Company, including any price or size limits or other customary parameters or conditions the Company

may

impose. The Company is

not

obligated to make any sales of the HCW Shares under the ATM Agreement. The offering of HCW Shares pursuant to the ATM Agreement will terminate upon the earliest of (a) the sale of all of the HCW Shares subject to the ATM Agreement, (b) the termination of the ATM Agreement by H.C. Wainwright or the Company, as permitted therein, or (c)

August 9, 2022.

The Company will pay H.C. Wainwright a commission rate equal to

of the aggregate gross proceeds from each sale of HCW Shares and have agreed to provide H.C. Wainwright with customary indemnification and contribution rights. The Company will also reimburse H.C. Wainwright for certain specified expenses in connection with entering into the ATM Agreement. As of

September 30, 2020,

the Company sold a total of

517,740

shares of Common Stock for aggregate gross proceeds of

$2,785,000

at an average selling price of

$5.38

per share, resulting in net proceeds of approximately

$2,473,000

after deducting legal expenses, audit fees, commissions and other transaction costs of approximately

$312,000.

Subsequent to

September 30, 2020,

the Company sold a total of

964,130

shares of Common Stock for aggregate gross proceeds of

$2,771,000

at an average selling price of

$2.87

per share, resulting in net proceeds of approximately

$2,683,000

after deducting commissions and other transaction costs of approximately

$88,000.

Stock Based Compensation

The Company recorded stock-based compensation of

$234,000

and

$615,000

for the

three

and

nine

months ended

September 30, 2020,

and

$253,000

and

$459,000

for the

three

and

nine

months ended

September 30, 2019,

respectively, as comprised of the following:

	Three Months Ended September 30,				Nine Months Ended September 30,
	2020		2019		2020		2019
Cost of revenues	$	3,000	$	1,000	$	5,000	$	2,000
Sales and marketing		65,000		110,000		106,000		166,000
Research and development		36,000		38,000		72,000		75,000
General and administrative		130,000		104,000		432,000		216,000
Total	$	234,000	$	253,000	$	615,000	$	459,000

The following is a summary of option activity for the Company's stock option plans:

	Number of Shares			Weighted- Average Exercise Price		Weighted- Average Remaining Contractual Life		Aggregate Intrinsic Value
Outstanding at December 31, 2019		291,807		$	13.96

Granted		615,500		$	5.92
Forfeited		(15,158	)	$	5.13
Outstanding at September 30, 2020		892,149		$	8.57		8.997	$	--

Vested and expected to vest at September 30, 2020		565,836		$	9.91		8.736	$	--

Exercisable at September 30, 2020		184,137		$	17.05		7.665	$	--

The aggregate intrinsic value is calculated as the difference between the exercise price of the underlying awards and the quoted price of the Company's common stock. There were

options exercised during the

nine

months ended

September 30, 2020.

Warrants

A summary of warrant activity for the

nine

months ended

September 30, 2020

follows:

	Number of Shares			Weighted-Average Exercise Price Per Share
Balance at December 31, 2019		1,716,066		$	25.23
Warrants expired		--			--
Warrants exercised		(599,582	)	$	2.81

Outstanding at September 30, 2020		1,116,484		$	37.27

Exercisable at September 30, 2020		1,046,631		$	34.42

XML 24 R14.htm IDEA: XBRL DOCUMENT

Note 8 - Major Customers and Accounts Receivable	9 Months Ended
Note 8 - Major Customers and Accounts Receivable	Sep. 30, 2020
Notes to Financial Statements
Concentration Risk Disclosure [Text Block]	8 . MAJOR CUSTOMERS AND ACCOUNTS RECEIVABLE The Company had certain customers whose revenue individually represented 10% or more of the Company's total revenue, or whose accounts receivable balances individually represented 10% or more of the Company's total accounts receivable as follows: For the three months ended September 30, 2020 and 2019, one customer accounted for 22% and 27% of revenue, a second customer accounted for 20% and 13% of revenue, while a third customer accounted for 10% and 2% of revenue, respectively. For the nine months ended September 30, 2020 and 2019, one customer accounted for 28% and 29% of revenue, a second customer accounted for 12% and 13% of revenue, while a third customer accounted for 12% and 0% of revenue, respectively. At September 30, 2020, two customers accounted for 59% of accounts receivable. At December 31, 2019, three customers accounted for 53% of accounts receivable.

XML 25 R15.htm IDEA: XBRL DOCUMENT

Note 9 - Subsequent Events	9 Months Ended
Note 9 - Subsequent Events	Sep. 30, 2020
Notes to Financial Statements
Subsequent Events [Text Block]	9 . S UBSEQUENT EVENTS The Company has evaluated events subsequent to the balance sheet date for inclusion in the accompanying consolidated financial statements through the date of issuance and determined that no subsequent events have occurred that would require recognition in the consolidated financial statements or disclosures in the notes thereto except as disclosed above.

XML 26 R16.htm IDEA: XBRL DOCUMENT

Significant Accounting Policies (Policies)

9 Months Ended

Sep. 30, 2020

Accounting Policies [Abstract]

New Accounting Pronouncements, Policy [Policy Text Block]

Recently Issued Accounting Standards

August 2020,

the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”)

2020

“Debt-Debt with Conversion and Other Options (

“

Subtopic

470

”

) and Derivatives and Hedging—Contracts in Entity's Own Equity (

“

Subtopic

815

”

): Accounting for Convertible Instruments and Contracts in an Entity's Own Equity,”

) permits settlement in unregistered shares, (

) whether counterparty rights rank higher than shareholder's rights, and (

may

be applied on a full retrospective of modified retrospective basis. This ASU is effective

January 1, 2022

and interim periods presented. Early adoption of the ASU is permitted by the Company effective

January 1, 2021.

The Company is in the process of assessing the impact of the adoption of the ASU on the Company's financial statements.

December 2019,

FASB issued ASU

2019

“

Income Taxes (

“

Topic

740

”

): Simplifying the Accounting of Income Taxes

” which is intended to simplify various aspects related to accounting for income taxes. ASU

2019

removes certain exceptions to the general principles in Topic

740

and also clarifies and amends existing guidance to improve consistent application. This guidance is effective for fiscal years and interim periods within those fiscal years, beginning after

December 15, 2020,

with early adoption permitted. The Company doesn't expect the adoption of the standard to have a material impact.

June 2016,

the FASB issued

ASU

2016

13,

“

Financial Instruments - Credit Losses (

“

Topic

326

”

The ASU introduces a new accounting model, the Current Expected Credit Losses model (“CECL”), which requires

2016

is effective for annual periods beginning after

December 15, 2022,

including interim reporting periods within those annual reporting periods. We expect that the impact of adoption will

not

have a material impact.

Recently Adopted Accounting Standards

August 2018,

the FASB issued ASU

2018

13,

“

Fair Value Measurement (“Topic

820”

): Disclosure Framework-Changes to the Disclosure Requirements for Fair Value Measurement

.” This ASU eliminates, adds and modifies certain disclosure requirements for fair value measurements as part of its disclosure framework project. The standard was adopted and did

not

have a material impact on the Company's financial statements.

Revenue from Contract with Customer [Policy Text Block]

Revenue Recognition

Revenue is recognized based on the

five

-step process outlined in Accounting Standards Codification (“ASC”)

606.

The following tables summarize the revenues by product line:

	Three Months Ended September 30, 2020
	Device Revenue		Service Revenue		Other Revenue		Total Revenue
AXP	$	1,137,000	$	32,000	$	--	$	1,169,000
BioArchive		337,000		282,000		--		619,000
CAR-TXpress		332,000		22,000		71,000		425,000
Manual Disposables		100,000		--		--		100,000
Other		26,000		--		16,000		42,000
Total	$	1,932,000	$	336,000	$	87,000	$	2,355,000

	Nine Months Ended September 30, 2020
	Device Revenue		Service Revenue		Other Revenue		Total Revenue
AXP	$	4,009,000	$	103,000	$	--	$	4,112,000
BioArchive		675,000		900,000		--		1,575,000
CAR-TXpress		1,035,000		47,000		214,000		1,296,000
Manual Disposables		499,000		--		--		499,000
Other		276,000		--		39,000		315,000
Total	$	6,494,000	$	1,050,000	$	253,000	$	7,797,000

	Three Months Ended September 30, 2019
	Device Revenue		Service Revenue		Other Revenue		Total Revenue
AXP	$	2,255,000	$	51,000	$	--	$	2,306,000
BioArchive		243,000		351,000		--		594,000
Manual Disposables		221,000		--		--		221,000
CAR-TXpress		875,000		10,000		33,000		918,000
Other		--		--		19,000		19,000
Total	$	3,594,000	$	412,000	$	52,000	$	4,058,000

	Nine Months Ended September 30, 2019
	Device Revenue		Service Revenue		Other Revenue		Total Revenue
AXP	$	6,550,000	$	160,000	$	--	$	6,710,000
BioArchive		1,274,000		1,117,000		--		2,391,000
Manual Disposables		764,000		--		--		764,000
CAR-TXpress		1,365,000		6,000		33,000		1,404,000
Other		5,000		11,000		40,000		56,000
Total	$	9,958,000	$	1,294,000	$	73,000	$	11,325,000

Contract Balances

Generally, all sales are contract sales (with either an underlying contract or purchase order). The Company does

not

three

and

nine

months ended

September 30, 2020

that were included in the beginning balance of deferred revenue were

$115,000

and

$547,000,

respectively. Short-term deferred revenues increased from

$620,000

$700,000

and long-term deferred revenues decreased from

$1,901,000

$1,669,000

during the

nine

months ended

September 30, 2020,

respectively.

Exclusivity Fee

August 30, 2019,

the Company entered into a Supply Agreement with Corning Incorporated (the “Supply Agreement”). The Supply Agreement has an initial term of

five

years with automatic

two

-Series

$2,000,000

exclusivity fee, in addition to any amounts payable throughout the Term for the Products.

The Company performed an evaluation of the revenue recognition of the

$2,000,000

fee under ASC

606.

It determined that the

$2,000,000

will be recognized over time, based on the term of the contract. It was determined that the most likely outcome is the agreement is extended for

one

additional

two

-year term after the initial

five

-year contract is complete. Consequently, the term to recognize the exclusivity fee is over

seven

years. The Company will allocate the upfront fee evenly to each daily performance obligation of providing exclusivity and recognize the revenue ratably over the

seven

-year period. As each day passes, the Company will recognize the portion of the exclusivity fee allocated to that day. For the

three

and

nine

months ended

September 30, 2020,

the Company recorded revenue of

$71,000

and

$214,000,

respectively, related to the exclusivity fee. The remaining balance of the

$2,000,000

payment of

$1,690,000

was recorded to deferred revenue, with

$286,000

in short-term deferred revenue and

$1,404,000

recorded in long-term deferred revenue.

Backlog of Remaining Customer Performance Obligations

	Remainder of 2020		2021		2022		2023		2024 and beyond		Total
Service revenue	$	310,000	$	958,000	$	561,000	$	298,000	$	38,000	$	2,165,000
Clinical revenue		3,000		13,000		13,000		13,000		175,000		217,000
Exclusivity fee		71,000		286,000		286,000		286,000		761,000		1,690,000
Total	$	384,000	$	1,257,000	$	860,000	$	597,000	$	974,000	$	4,072,000

Revenues are net of normal discounts. Shipping and handling fees billed to customers are included in net revenues, while the related costs are included in cost of revenues.

Fair Value of Financial Instruments, Policy [Policy Text Block]

Fair Value Measurements

In accordance with ASC

820,

“

Fair Value Measurements and Disclosures

The guidance also establishes a hierarchy for inputs used in measuring fair value that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that the most observable inputs be used when available. Observable inputs are inputs that market participants would use in valuing the asset or liability and are developed based on market data obtained from sources independent of the Company. Unobservable inputs are inputs that reflect the Company's assumptions about the factors that market participants would use in valuing the asset or liability. The guidance establishes

three

levels of inputs that

may

be used to measure fair value:

Level

Quoted market prices in active markets for identical assets or liabilities.

Level

Observable market-based inputs or unobservable inputs that are corroborated by market data.

Level

Unobservable inputs which are supported by little or

market activity.

within the fair value hierarchy since the valuation model of the derivative obligation is based on unobservable inputs. The derivative obligation is

not

material to the financial statements of the Company. The impairment of goodwill and intangible assets is a non-recurring Level

fair value measurement.

Earnings Per Share, Policy [Policy Text Block]

Net Loss per Share

vesting or other contingencies associated with them. As of

September 30, 2020,

all pre-funded warrants previously issued have been exercised and

none

September 30:

	2020		2019
Common stock equivalents of convertible promissory note and accrued interest		6,988,334		6,013,667
Vested Series A warrants		40,441		40,441
Unvested Series A warrants (1)		69,853		69,853
Warrants – other		1,006,190		1,300,091
Stock options		892,149		296,029
Total		8,996,967		7,720,081

___________

(

)

The unvested Series A warrants were subject to vesting based upon the amount of funds actually received by the Company in the

second

close of the

August 2015

financing which never occurred. The warrants will remain outstanding but unvested until they expire in

February 2021.

Reclassification, Comparability Adjustment [Policy Text Block]

Reclassifications

Certain prior period amounts have been reclassified to conform to the current period presentation. The reclassifications did

not

have an impact on net loss as previously reported.

- Definition

Disclosure of accounting policy for revenue from contract with customer.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 17
-URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130561-203045

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 20
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130566-203045

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 18
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130563-203045

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-URI http://asc.fasb.org/topic&trid=49130388

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 20
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130566-203045

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 18
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130563-203045

Reference 7: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section 50
-Paragraph 4
-Subparagraph (e)
-URI http://asc.fasb.org/extlink&oid=84158767&loc=d3e18823-107790

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 20
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130566-203045

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 19
-URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130564-203045

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 20
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130566-203045

+ Details

XML 27 R17.htm IDEA: XBRL DOCUMENT

Note 2 - Summary of Significant Accounting Policies (Tables)

9 Months Ended

Sep. 30, 2020

Notes Tables

Disaggregation of Revenue [Table Text Block]

	Three Months Ended September 30, 2020
	Device Revenue		Service Revenue		Other Revenue		Total Revenue
AXP	$	1,137,000	$	32,000	$	--	$	1,169,000
BioArchive		337,000		282,000		--		619,000
CAR-TXpress		332,000		22,000		71,000		425,000
Manual Disposables		100,000		--		--		100,000
Other		26,000		--		16,000		42,000
Total	$	1,932,000	$	336,000	$	87,000	$	2,355,000

	Nine Months Ended September 30, 2020
	Device Revenue		Service Revenue		Other Revenue		Total Revenue
AXP	$	4,009,000	$	103,000	$	--	$	4,112,000
BioArchive		675,000		900,000		--		1,575,000
CAR-TXpress		1,035,000		47,000		214,000		1,296,000
Manual Disposables		499,000		--		--		499,000
Other		276,000		--		39,000		315,000
Total	$	6,494,000	$	1,050,000	$	253,000	$	7,797,000

	Three Months Ended September 30, 2019
	Device Revenue		Service Revenue		Other Revenue		Total Revenue
AXP	$	2,255,000	$	51,000	$	--	$	2,306,000
BioArchive		243,000		351,000		--		594,000
Manual Disposables		221,000		--		--		221,000
CAR-TXpress		875,000		10,000		33,000		918,000
Other		--		--		19,000		19,000
Total	$	3,594,000	$	412,000	$	52,000	$	4,058,000

	Nine Months Ended September 30, 2019
	Device Revenue		Service Revenue		Other Revenue		Total Revenue
AXP	$	6,550,000	$	160,000	$	--	$	6,710,000
BioArchive		1,274,000		1,117,000		--		2,391,000
Manual Disposables		764,000		--		--		764,000
CAR-TXpress		1,365,000		6,000		33,000		1,404,000
Other		5,000		11,000		40,000		56,000
Total	$	9,958,000	$	1,294,000	$	73,000	$	11,325,000

Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Table Text Block]

	Remainder of 2020		2021		2022		2023		2024 and beyond		Total
Service revenue	$	310,000	$	958,000	$	561,000	$	298,000	$	38,000	$	2,165,000
Clinical revenue		3,000		13,000		13,000		13,000		175,000		217,000
Exclusivity fee		71,000		286,000		286,000		286,000		761,000		1,690,000
Total	$	384,000	$	1,257,000	$	860,000	$	597,000	$	974,000	$	4,072,000

Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]

	2020		2019
Common stock equivalents of convertible promissory note and accrued interest		6,988,334		6,013,667
Vested Series A warrants		40,441		40,441
Unvested Series A warrants (1)		69,853		69,853
Warrants – other		1,006,190		1,300,091
Stock options		892,149		296,029
Total		8,996,967		7,720,081

XML 28 R18.htm IDEA: XBRL DOCUMENT

Note 5 - Leases (Tables)

9 Months Ended

Sep. 30, 2020

Notes Tables

Lease, Cost [Table Text Block]

	September 30, 2020
Right-of-use operating lease assets, net	$	765,000
Current lease liability		147,000
Non-current lease liability		648,000

Weighted average remaining lease term		3.7
Discount rate		22	%

Lessee, Operating Lease, Liability, Maturity [Table Text Block]

2020 (remaining)	$	76,000
2021		310,000
2022		319,000
2023		328,000
2024		139,000
Thereafter		--
Total lease payments	$	1,172,000
Less: imputed interest		(377,000	)
Present value of operating lease liabilities	$	795,000

XML 29 R19.htm IDEA: XBRL DOCUMENT

Note 6 - Commitments and Contingencies (Tables)

9 Months Ended

Sep. 30, 2020

Notes Tables

Schedule of Product Warranty Liability [Table Text Block]

Balance at December 31, 2019	$	277,000
Warranties issued during the period		62,000
Settlements made during the period		(171,000	)
Changes in liability for pre-existing warranties during the period		(20,000	)
Balance at September 30, 2020	$	148,000

XML 30 R20.htm IDEA: XBRL DOCUMENT

Note 7 - Stockholders' Equity (Tables)

9 Months Ended

Sep. 30, 2020

Notes Tables

Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]

	Three Months Ended September 30,				Nine Months Ended September 30,
	2020		2019		2020		2019
Cost of revenues	$	3,000	$	1,000	$	5,000	$	2,000
Sales and marketing		65,000		110,000		106,000		166,000
Research and development		36,000		38,000		72,000		75,000
General and administrative		130,000		104,000		432,000		216,000
Total	$	234,000	$	253,000	$	615,000	$	459,000

Share-based Payment Arrangement, Option, Activity [Table Text Block]

	Number of Shares			Weighted- Average Exercise Price		Weighted- Average Remaining Contractual Life		Aggregate Intrinsic Value
Outstanding at December 31, 2019		291,807		$	13.96

Granted		615,500		$	5.92
Forfeited		(15,158	)	$	5.13
Outstanding at September 30, 2020		892,149		$	8.57		8.997	$	--

Vested and expected to vest at September 30, 2020		565,836		$	9.91		8.736	$	--

Exercisable at September 30, 2020		184,137		$	17.05		7.665	$	--

Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]

	Number of Shares			Weighted-Average Exercise Price Per Share
Balance at December 31, 2019		1,716,066		$	25.23
Warrants expired		--			--
Warrants exercised		(599,582	)	$	2.81

Outstanding at September 30, 2020		1,116,484		$	37.27

Exercisable at September 30, 2020		1,046,631		$	34.42

XML 31 R21.htm IDEA: XBRL DOCUMENT

Note 1 - Description of Business, Basis of Presentation and Going Concern (Details Textual)				3 Months Ended
	Apr. 21, 2020 USD ($)	Jun. 04, 2019 shares	Jan. 01, 2019 USD ($)	Mar. 31, 2019 USD ($)	Sep. 30, 2020 USD ($) shares	Jun. 30, 2020	Apr. 28, 2020 USD ($)	Dec. 31, 2019 USD ($) shares	Nov. 26, 2019 USD ($)	Mar. 31, 2017 USD ($)
Stockholders' Equity Attributable to Noncontrolling Interest, Ending Balance					$ 170,000			$ 530,000
Reorganization of Subsidiary and Related Change in Non-controlling Interest
Common Stock, Shares Authorized (in shares) \| shares		350,000,000			350,000,000			350,000,000
Notes Payable, Current, Total					$ 235,000
Notes Payable, Noncurrent, Total					411,000			1,000,000
Cash and Cash Equivalents, at Carrying Value, Ending Balance					4,436,000			3,157,000
Working Capital					7,056,000
Retained Earnings (Accumulated Deficit), Ending Balance					(250,434,000)			$ (236,932,000)
Paycheck Protection Program CARES Act [Member]
Proceeds from Issuance of Long-term Debt, Total	$ 646,000
Notes Payable, Current, Total					235,000
Notes Payable, Noncurrent, Total					411,000
Boyalife Investment Fund II, Inc. [Member] \| Revolving Credit Facility [Member]
Line of Credit Facility, Maximum Borrowing Capacity					10,000,000					$ 10,000,000
Long-term Line of Credit, Total					$ 10,000,000		$ 10,000,000
Reverse Stock Split [Member]
Stockholders' Equity Note, Stock Split, Conversion Ratio		10
ImmuneCyte [Member]
Equity Method Investment, Ownership Percentage					18.79%				20.00%
Line of Credit Facility, Maximum Borrowing Capacity									$ 1,000,000
ImmuneCyte [Member] \| HealthBanks Biotech [Member]
Equity Method Investment, Ownership Percentage					75.16%				80.00%
Noncontrolling Interest [Member]
Reorganization of Subsidiary and Related Change in Non-controlling Interest			$ 2,843,000	$ 2,843,000
CAR-TXpress [Member]
Noncontrolling Interest, Ownership Percentage by Parent			80.00%		80.00%	80.00%
Minority Interest Acquired Through Exchange			20.00%
Stockholders' Equity Attributable to Noncontrolling Interest, Ending Balance			$ 1,100,000
Noncontrolling Interest, Ownership Percentage by Noncontrolling Owners						20.00%
ThermoGenesis [Member]
Noncontrolling Interest, Ownership Percentage by Parent			100.00%
Ownership in Subsidiary Exchanged			20.00%
Stockholders' Equity Attributable to Noncontrolling Interest, Ending Balance			$ (1,711,000)

XML 32 R22.htm IDEA: XBRL DOCUMENT

Note 2 - Summary of Significant Accounting Policies (Details Textual) - USD ($)		3 Months Ended	9 Months Ended
	Aug. 30, 2019	Sep. 30, 2020	Sep. 30, 2020	Dec. 31, 2019
Contract with Customer, Liability, Revenue Recognized		$ 115,000	$ 547,000
Deferred Revenue, Current, Total		700,000	700,000	$ 620,000
Deferred Revenue, Noncurrent, Total		1,669,000	1,669,000	$ 1,901,000
Exclusivity Fee [Member]
Deferred Revenue, Current, Total		286,000	286,000
Deferred Revenue, Noncurrent, Total		1,404,000	1,404,000
Deferred Revenue, Total		1,690,000	1,690,000
Exclusivity Fee [Member]
Contract with Customer, Liability, Revenue Recognized		$ 71,000	$ 214,000
Exclusivity Fee Recognize Period (Year)			7 years
Supply Agreement [Member]
Supply Agreement, Term (Year)	5 years
Supply Agreement, Renewal Term (Year)	2 years		2 years
Contract with Customer, Liability, Total	$ 2,000,000
Proceeds from Customers			$ 2,000,000

XML 33 R23.htm IDEA: XBRL DOCUMENT

Note 2 - Summary of Significant Accounting Policies - Revenues (Details) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019
Net revenues	$ 2,355,000	$ 4,058,000	$ 7,797,000	$ 11,325,000
Device [Member] \| AXP [Member]
Net revenues	1,169,000	2,306,000	4,112,000	6,710,000
Device [Member] \| BioArchive [Member]
Net revenues	619,000	594,000	1,575,000	2,391,000
Device [Member] \| CAR-TXpress [Member]
Net revenues	425,000	918,000	1,296,000	1,404,000
Device [Member] \| Manual Disposables [Member]
Net revenues	100,000	221,000	499,000	764,000
Device [Member] \| Other Subsegments [Member]
Net revenues	42,000	19,000	315,000	56,000
Device Revenue [Member]
Net revenues	1,932,000	3,594,000	6,494,000	9,958,000
Device Revenue [Member] \| Device [Member] \| AXP [Member]
Net revenues	1,137,000	2,255,000	4,009,000	6,550,000
Device Revenue [Member] \| Device [Member] \| BioArchive [Member]
Net revenues	337,000	243,000	675,000	1,274,000
Device Revenue [Member] \| Device [Member] \| CAR-TXpress [Member]
Net revenues	332,000	875,000	1,035,000	1,365,000
Device Revenue [Member] \| Device [Member] \| Manual Disposables [Member]
Net revenues	100,000	221,000	499,000	764,000
Device Revenue [Member] \| Device [Member] \| Other Subsegments [Member]
Net revenues	26,000		276,000	5,000
Service [Member]
Net revenues	336,000	412,000	1,050,000	1,294,000
Service [Member] \| Device [Member] \| AXP [Member]
Net revenues	32,000	51,000	103,000	160,000
Service [Member] \| Device [Member] \| BioArchive [Member]
Net revenues	282,000	351,000	900,000	1,117,000
Service [Member] \| Device [Member] \| CAR-TXpress [Member]
Net revenues	22,000	10,000	47,000	6,000
Service [Member] \| Device [Member] \| Manual Disposables [Member]
Net revenues
Service [Member] \| Device [Member] \| Other Subsegments [Member]
Net revenues				11,000
Other [Member]
Net revenues	87,000	52,000	253,000	73,000
Other [Member] \| Device [Member] \| AXP [Member]
Net revenues
Other [Member] \| Device [Member] \| BioArchive [Member]
Net revenues
Other [Member] \| Device [Member] \| CAR-TXpress [Member]
Net revenues	71,000	33,000	214,000	33,000
Other [Member] \| Device [Member] \| Manual Disposables [Member]
Net revenues
Other [Member] \| Device [Member] \| Other Subsegments [Member]
Net revenues	$ 16,000	$ 19,000	$ 39,000	$ 40,000

XML 34 R24.htm IDEA: XBRL DOCUMENT

Note 2 - Summary of Significant Accounting Policies - Remaining Performance Obligations (Details)	Sep. 30, 2020 USD ($)
Revenue, Remaining Performance Obligation, Amount	$ 4,072,000
Service [Member]
Revenue, Remaining Performance Obligation, Amount	2,165,000
Clinical Revenue [Member]
Revenue, Remaining Performance Obligation, Amount	217,000
Exclusivity Fee [Member]
Revenue, Remaining Performance Obligation, Amount	$ 1,690,000

XML 35 R25.htm IDEA: XBRL DOCUMENT

Note 2 - Summary of Significant Accounting Policies - Remaining Performance Obligations 2 (Details)	Sep. 30, 2020 USD ($)
Revenue, Remaining Performance Obligation, Amount	$ 4,072,000
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2020-01-01
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction (Year)	91 days
Revenue, Remaining Performance Obligation, Amount	$ 384,000
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2021-01-01
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction (Year)	1 year
Revenue, Remaining Performance Obligation, Amount	$ 1,257,000
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2022-01-01
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction (Year)	1 year
Revenue, Remaining Performance Obligation, Amount	$ 860,000
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2023-01-01
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction (Year)	1 year
Revenue, Remaining Performance Obligation, Amount	$ 597,000
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2024-01-01
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction (Year)	1 year
Revenue, Remaining Performance Obligation, Amount	$ 974,000
Service [Member]
Revenue, Remaining Performance Obligation, Amount	$ 2,165,000
Service [Member] \| Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2020-10-01
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction (Year)	91 days
Revenue, Remaining Performance Obligation, Amount	$ 310,000
Service [Member] \| Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2021-01-01
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction (Year)	1 year
Revenue, Remaining Performance Obligation, Amount	$ 958,000
Service [Member] \| Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2022-01-01
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction (Year)	1 year
Revenue, Remaining Performance Obligation, Amount	$ 561,000
Service [Member] \| Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2023-01-01
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction (Year)	1 year
Revenue, Remaining Performance Obligation, Amount	$ 298,000
Service [Member] \| Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2024-01-01
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction (Year)	1 year
Revenue, Remaining Performance Obligation, Amount	$ 38,000
Clinical Revenue [Member]
Revenue, Remaining Performance Obligation, Amount	$ 217,000
Clinical Revenue [Member] \| Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2020-10-01
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction (Year)	91 days
Revenue, Remaining Performance Obligation, Amount	$ 3,000
Clinical Revenue [Member] \| Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2021-01-01
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction (Year)	1 year
Revenue, Remaining Performance Obligation, Amount	$ 13,000
Clinical Revenue [Member] \| Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2022-01-01
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction (Year)	1 year
Revenue, Remaining Performance Obligation, Amount	$ 13,000
Clinical Revenue [Member] \| Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2023-01-01
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction (Year)	1 year
Revenue, Remaining Performance Obligation, Amount	$ 13,000
Clinical Revenue [Member] \| Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2024-01-01
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction (Year)	1 year
Revenue, Remaining Performance Obligation, Amount	$ 175,000
Exclusivity Fee [Member]
Revenue, Remaining Performance Obligation, Amount	$ 1,690,000
Exclusivity Fee [Member] \| Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2020-10-01
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction (Year)	91 days
Revenue, Remaining Performance Obligation, Amount	$ 71,000
Exclusivity Fee [Member] \| Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2021-01-01
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction (Year)	1 year
Revenue, Remaining Performance Obligation, Amount	$ 286,000
Exclusivity Fee [Member] \| Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2022-01-01
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction (Year)	1 year
Revenue, Remaining Performance Obligation, Amount	$ 286,000
Exclusivity Fee [Member] \| Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2023-01-01
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction (Year)	1 year
Revenue, Remaining Performance Obligation, Amount	$ 286,000
Exclusivity Fee [Member] \| Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2024-01-01
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction (Year)	1 year
Revenue, Remaining Performance Obligation, Amount	$ 761,000

XML 36 R26.htm IDEA: XBRL DOCUMENT

Note 2 - Summary of Significant Accounting Policies - Anti-dilutive Securities (Details) - shares

9 Months Ended

Sep. 30, 2020

Sep. 30, 2019

Anti-dilutive securities (in shares)

8,996,967

7,720,081

Convertible Debt Securities [Member]

Anti-dilutive securities (in shares)

6,988,334

6,013,667

Vested Series A Warrants [Member]

Anti-dilutive securities (in shares)

40,441

Unvested Series A Warrants [Member]

Anti-dilutive securities (in shares)

^[1]

69,853

Warrant, Other [Member]

Anti-dilutive securities (in shares)

1,006,190

1,300,091

Share-based Payment Arrangement, Option [Member]

Anti-dilutive securities (in shares)

892,149

296,029

[1]	The unvested Series A warrants were subject to vesting based upon the amount of funds actually received by the Company in the second close of the August 2015 financing which never occurred. The warrants will remain outstanding but unvested until they expire in February 2021.

XML 37 R27.htm IDEA: XBRL DOCUMENT

Note 3 - Related Party Transactions (Details Textual) - USD ($)				1 Months Ended	3 Months Ended		9 Months Ended		10 Months Ended
	Apr. 28, 2020	Feb. 29, 2020	Aug. 21, 2017	Feb. 29, 2020	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Dec. 31, 2019	Nov. 26, 2019	Dec. 31, 2018	Apr. 16, 2018	Mar. 31, 2017
Income (Loss) from Equity Method Investments, Total							$ (13,000)
Net Income (Loss), Including Portion Attributable to Noncontrolling Interest, Total					(2,609,000)	(2,373,000)	(13,862,000)	(5,895,000)
Assets, Current, Total					12,776,000		12,776,000		$ 12,776,000	$ 9,861,000
Liabilities, Current, Total					5,720,000		5,720,000		5,720,000	6,685,000
Amortization of Accelerated Debt Discount Due to Conversion							2,486,000
Amortization of Debt Discount (Premium)							2,165,000	1,799,000
Conversion of Related Party Convertible Promissory Note Into Common Stock [Member]
Debt Conversion, Original Debt, Amount				$ 3,000,000
Debt Conversion, Converted Instrument, Shares Issued (in shares)				1,666,670
Boyalife Investment Fund II, Inc. [Member] \| Convertible Debt [Member]
Debt Instrument, Convertible, Conversion Price (in dollars per share)												$ 1.80	$ 16.10
Boyalife Investment Fund II, Inc. [Member] \| Revolving Credit Facility [Member]
Line of Credit Facility, Maximum Borrowing Capacity					10,000,000		10,000,000		10,000,000					$ 10,000,000
Proceeds from Long-term Lines of Credit	$ 2,418,000			$ 1,869,000
Amortization of Accelerated Debt Discount Due to Conversion				$ 2,486,000
Long-term Line of Credit, Total	10,000,000				10,000,000		10,000,000		10,000,000
Interest Payable	$ 580,000				$ 1,519,000		$ 1,519,000		$ 1,519,000	$ 1,869,000
Debt Instrument, Interest Rate, Stated Percentage					22.00%		22.00%		22.00%
Debt Instrument, Convertible, Beneficial Conversion Feature		$ 1,869,000
Amortization of Debt Discount (Premium)					$ 828,000	471,000	$ 2,103,000	1,398,000
Boyalife W.S.N. [Member]
Distributor Agreement Term (Year)			3 years
Distributor Agreement, Renewal Term (Year)			2 years
Revenue from Related Parties					0	$ 214,000	0	$ 794,000
COVID-19 Testing Kits [Member]
Inventory Write-down							2,800,000
COVID-19 Testing Kits [Member] \| ImmuneCyte [Member]
Related Party Transaction, Purchases from Related Party							$ 3,600,000
Refund from Related Party Purchases					$ 800,000
ImmuneCyte [Member]
Proceeds from Issuance of Common Stock									$ 3,700,000
ImmuneCyte [Member] \| Common Class A [Member]
Stock Issued During Period, Shares, New Issues (in shares)									643,750
ImmuneCyte [Member] \| Common Class A [Member] \| Minimum [Member]
Shares Issued, Price Per Share (in dollars per share)					$ 5		$ 5		$ 5
ImmuneCyte [Member] \| Common Class A [Member] \| Maximum [Member]
Shares Issued, Price Per Share (in dollars per share)					$ 16		$ 16		$ 16
ImmuneCyte [Member]
Equity Method Investment, Ownership Percentage					18.79%		18.79%		18.79%		20.00%
Joint Venture Purchase, Percent of Company's Cost											115.00%
Line of Credit Facility, Maximum Borrowing Capacity											$ 1,000,000
Equity Method Investment, Aggregate Cost					$ 0		$ 0		$ 0		$ 28,000
Income (Loss) from Equity Method Investments, Total					0		13,000
Net Income (Loss), Including Portion Attributable to Noncontrolling Interest, Total					1,313,000		1,422,000
Assets, Current, Total					2,120,000		2,120,000		2,120,000
Liabilities, Current, Total					$ 296,000		$ 296,000		$ 296,000
ImmuneCyte [Member] \| HealthBanks Biotech [Member]
Equity Method Investment, Ownership Percentage					75.16%		75.16%		75.16%		80.00%
ImmuneCyte [Member] \| Private Institution [Member]
Equity Method Investment, Ownership Percentage					6.05%		6.05%		6.05%

XML 38 R28.htm IDEA: XBRL DOCUMENT

Note 4 - Convertible Promissory Note (Details Textual) - USD ($)				3 Months Ended		9 Months Ended		12 Months Ended
	Jun. 04, 2020	Jul. 23, 2019	Jan. 29, 2019	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019	Dec. 31, 2019	May 30, 2019
Gain (Loss) on Extinguishment of Debt, Total					$ (840,000)		$ (840,000)
Amortization of Debt Discount (Premium)						2,165,000	$ 1,799,000
Conversion of Convertible Promissory Note to Common Stock [Member]
Debt Conversion, Converted Instrument, Amount						$ 369,000
Debt Conversion, Converted Instrument, Shares Issued (in shares)						204,445
Interest Income (Expense), Nonoperating, Net						$ 46,000
Convertible Debt [Member] \| Notes [Member]
Debt Instrument, Convertible, Threshold Percentage of Stock Price Trigger			90.00%
Debt Instrument, Interest Rate, Stated Percentage			24.00%
Debt Instrument, Term (Month)			1 year 180 days
Debt Instrument, Convertible, First Customary Conversion Blockers			4.99%
Debt Instrument, Convertible, Second customary conversion blockers			9.99%
Debt Instrument, Unamortized Discount, Total									$ 800,000
Convertible Debt [Member] \| Notes [Member] \| Maximum [Member]
Debt Instrument, Face Amount			$ 800,000
Debt Instrument, Convertible, Conversion Price (in dollars per share)			$ 1.80
Convertible Debt [Member] \| Notes [Member] \| Minimum [Member]
Debt Instrument, Convertible, Conversion Price (in dollars per share)			$ 0.50
Convertible Debt [Member] \| January 2019 Notes, Amendment No. 1 [Member]
Debt Instrument, Unamortized Discount, Total								$ 556,000
Gain (Loss) on Extinguishment of Debt, Total								840,000
Long-term Debt, Fair Value		$ 1,473,000
Amortization of Debt Discount (Premium)								$ 77,000
Convertible Debt [Member] \| The July 2019 Note [Member]
Debt Instrument, Face Amount		$ 1,000,000
Debt Instrument, Convertible, Threshold Percentage of Stock Price Trigger		90.00%
Debt Instrument, Interest Rate, Stated Percentage		24.00%
Amortization of Debt Discount (Premium)				$ 27,000		$ 107,000
Debt Instrument, Convertible, Beneficial Conversion Feature	$ 694,000
Convertible Debt [Member] \| The July 2019 Note [Member] \| Maximum [Member]
Debt Instrument, Convertible, Conversion Price (in dollars per share)		$ 1.80
Convertible Debt [Member] \| The July 2019 Note [Member] \| Minimum [Member]
Debt Instrument, Convertible, Conversion Price (in dollars per share)		$ 0.50

XML 39 R29.htm IDEA: XBRL DOCUMENT

Note 5 - Leases (Details Textual) - USD ($)	3 Months Ended	9 Months Ended
Note 5 - Leases (Details Textual) - USD ($)	Sep. 30, 2020	Sep. 30, 2020	Dec. 31, 2019	Jan. 01, 2019
Operating Lease, Right-of-Use Asset	$ 765,000	$ 765,000	$ 859,000
Operating Lease, Payments		225,000
Operating Lease, Cost	$ 135,000	$ 343,000
Accounting Standards Update 2016-02 [Member]
Operating Lease, Right-of-Use Asset				$ 966,000

XML 40 R30.htm IDEA: XBRL DOCUMENT

Note 5 - Leases - Lease Information (Details) - USD ($)	Sep. 30, 2020	Dec. 31, 2019
Right-of-use operating lease assets, net	$ 765,000	$ 859,000
Non-current lease liability	$ 648,000	$ 761,000
Weighted average remaining lease term (Year)	3 years 255 days
Discount rate	22.00%
Current Liabilities [Member]
Current lease liability	$ 147,000

XML 41 R31.htm IDEA: XBRL DOCUMENT

Note 5 - Leases - Maturities of Lease Liabilities (Details)	Sep. 30, 2020 USD ($)
2020 (remaining)	$ 76,000
2021	310,000
2022	319,000
2023	328,000
2024	139,000
Thereafter
Total lease payments	1,172,000
Less: imputed interest	(377,000)
Present value of operating lease liabilities	$ 795,000

XML 42 R32.htm IDEA: XBRL DOCUMENT

Note 6 - Commitments and Contingencies (Details Textual) - USD ($)			1 Months Ended		9 Months Ended
	May 01, 2020	May 04, 2017	Feb. 29, 2020	Oct. 31, 2017	Sep. 30, 2020	Jul. 13, 2020	Mar. 17, 2020	Dec. 31, 2019
Short Term Investment Minimum						$ 1,000,000	$ 1,000,000	$ 2,000,000
Litigation Related to Strategic Advisory Services [Member]
Loss Contingency, Damages Sought, Value		$ 1,000,000
Loss Contingency, Negotiation Condition Bond				$ 1,000,000
Loss Contingency, Damages Awarded, Value			$ 1,000,000
Gain (Loss) Related to Litigation Settlement, Total			(1,400,000)
Litigation Settlement, Expense			1,000,000
Litigation Settlement Interest			$ 400,000
Agreement with Plaintiff For Reimbursement of Trial Related Expenses [Member]
Litigation Settlement, Expense	$ 111,000
Litigation Settlement Interest	369,000
Loss Contingency, Damages Awarded, Value	$ 480,000
Minimum [Member]
Period Of Warranty On Products (Year)					1 year
Maximum [Member]
Period Of Warranty On Products (Year)					2 years

XML 43 R33.htm IDEA: XBRL DOCUMENT

Note 6 - Commitments and Contingencies - Changes in Product Liability Included in Accrued Liabilities (Details)	9 Months Ended
	Sep. 30, 2020 USD ($)
Balance	$ 277,000
Warranties issued during the period	62,000
Settlements made during the period	(171,000)
Changes in liability for pre-existing warranties during the period	(20,000)
Balance	$ 148,000

XML 44 R34.htm IDEA: XBRL DOCUMENT

Note 7 - Stockholders' Equity (Details Textual) - USD ($)			1 Months Ended	3 Months Ended		9 Months Ended
	Mar. 27, 2020	Dec. 13, 2019	Nov. 12, 2020	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019	May 19, 2020
Proceeds from Issuance of Common Stock, Net						$ 5,580,000	$ 756,000
Share-based Payment Arrangement, Expense				$ 234,000	$ 253,000	$ 615,000	$ 459,000
Registered Direct Offering [Member]
Stock Issued During Period, Shares, New Issues (in shares)	1,000,002
Shares Issued, Price Per Share (in dollars per share)	$ 3.50
Proceeds from Issuance of Common Stock	$ 3,500,000
Payments of Stock Issuance Costs	$ 393,000
At The Market Offering Agreement [Member]
Stock Issued During Period, Shares, New Issues (in shares)						517,740
Proceeds from Issuance of Common Stock						$ 2,785,000
Payments of Stock Issuance Costs						$ 312,000
Maximum Offering Price for Issuance of Common Stock		$ 4,400,000						$ 15,280,313
Commission as Percentage of Gross Proceeds		3.00%
Shares Issued, Average Price Per Share (in dollars per share)						$ 5.38
Proceeds from Issuance of Common Stock, Net						$ 2,473,000
At The Market Offering Agreement [Member] \| Subsequent Event [Member]
Stock Issued During Period, Shares, New Issues (in shares)			964,130
Proceeds from Issuance of Common Stock			$ 2,771,000
Payments of Stock Issuance Costs			$ 88,000
Shares Issued, Average Price Per Share (in dollars per share)			$ 2.87
Proceeds from Issuance of Common Stock, Net			$ 2,683,000

XML 45 R35.htm IDEA: XBRL DOCUMENT

Note 7 - Stockholders' Equity - Stock-based Compensation (Details) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019
Stock-based compensation	$ 234,000	$ 253,000	$ 615,000	$ 459,000
Cost of Sales [Member]
Stock-based compensation	3,000	1,000	5,000	2,000
Selling and Marketing Expense [Member]
Stock-based compensation	65,000	110,000	106,000	166,000
Research and Development Expense [Member]
Stock-based compensation	36,000	38,000	72,000	75,000
General and Administrative Expense [Member]
Stock-based compensation	$ 130,000	$ 104,000	$ 432,000	$ 216,000

XML 46 R36.htm IDEA: XBRL DOCUMENT

Note 7 - Stockholders' Equity - Option Activity for Stock Option Plans (Details)	9 Months Ended
	Sep. 30, 2020 USD ($) $ / shares shares
Outstanding, options (in shares) \| shares	291,807
Outstanding, weighted average exercise price, options (in dollars per share) \| $ / shares	$ 13.96
Granted, options (in shares) \| shares	615,500
Granted, weighted average exercise price, options (in dollars per share) \| $ / shares	$ 5.92
Forfeited, options (in shares) \| shares	(15,158)
Forfeited, weighted average exercise price, options (in dollars per share) \| $ / shares	$ 5.13
Outstanding, options (in shares) \| shares	892,149
Outstanding, weighted average exercise price, options (in dollars per share) \| $ / shares	$ 8.57
Outstanding, weighted average remaining contractual life, options (Year)	8 years 363 days
Outstanding, aggregate intrinsic value, options \| $
Vested and expected to vest, options (in shares) \| shares	565,836
Vested and expected to vest, weighted average exercise price, options (in dollars per share) \| $ / shares	$ 9.91
Vested and expected to vest, weighted average remaining contractual life, options (Year)	8 years 268 days
Vested and expected to vest, aggregate intrinsic value, options \| $
Exercisable, options (in shares) \| shares	184,137
Exercisable, weighted average exercise price, options (in dollars per share) \| $ / shares	$ 17.05
Exercisable, weighted average remaining contractual life, options (Year)	7 years 242 days
Exercisable, aggregate intrinsic value, options \| $

XML 47 R37.htm IDEA: XBRL DOCUMENT

Note 7 - Stockholders' Equity - Warrant Activity (Details)	9 Months Ended
	Sep. 30, 2020 $ / shares shares
Outstanding (in shares) \| shares	1,716,066
Outstanding, weighted average exercise price (in dollars per share) \| $ / shares	$ 25.23
Warrants expired (in shares) \| shares
Warrants expired, weighted average exercise price (in dollars per share) \| $ / shares
Warrants exercised (in shares) \| shares	(599,582)
Warrants exercised, weighted average exercise price (in dollars per share) \| $ / shares	$ 2.81
Outstanding (in shares) \| shares	1,116,484
Outstanding, weighted average exercise price (in dollars per share) \| $ / shares	$ 37.27
Exercisable (in shares) \| shares	1,046,631
Exercisable, weighted average exercise price (in dollars per share) \| $ / shares	$ 34.42

XML 48 R38.htm IDEA: XBRL DOCUMENT

Note 8 - Major Customers and Accounts Receivable (Details Textual) - Customer Concentration Risk [Member]	3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019	Dec. 31, 2019
Revenue Benchmark [Member] \| Customer 1 [Member]
Concentration Risk, Percentage	22.00%	27.00%	28.00%	29.00%
Revenue Benchmark [Member] \| Customer 2 [Member]
Concentration Risk, Percentage	20.00%	13.00%	12.00%	13.00%
Revenue Benchmark [Member] \| Customer 3 [Member]
Concentration Risk, Percentage	10.00%	2.00%	12.00%	0.00%
Accounts Receivable [Member] \| Two Customers [Member]
Concentration Risk, Percentage			59.00%		53.00%

EXCEL 49 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 50 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 51 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 52 FilingSummary.xml IDEA: XBRL DOCUMENT 3.20.2 html 335 342 1 true 66 0 false 4 false false R1.htm 000 - Document - Document And Entity Information Sheet http://cescatherapeutics.com/20200930/role/statement-document-and-entity-information Document And Entity Information Cover 1 false false R2.htm 001 - Statement - Condensed Consolidated Balance Sheets (Current Period Unaudited) Sheet http://cescatherapeutics.com/20200930/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited Condensed Consolidated Balance Sheets (Current Period Unaudited) Statements 2 false false R3.htm 002 - Statement - Condensed Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals) Sheet http://cescatherapeutics.com/20200930/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited-parentheticals Condensed Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals) Statements 3 false false R4.htm 003 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) Sheet http://cescatherapeutics.com/20200930/role/statement-condensed-consolidated-statements-of-operations-and-comprehensive-loss-unaudited Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) Statements 4 false false R5.htm 004 - Statement - Condensed Consolidated Statements of Equity (Unaudited) Sheet http://cescatherapeutics.com/20200930/role/statement-condensed-consolidated-statements-of-equity-unaudited Condensed Consolidated Statements of Equity (Unaudited) Statements 5 false false R6.htm 005 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited) Sheet http://cescatherapeutics.com/20200930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited Condensed Consolidated Statements of Cash Flows (Unaudited) Statements 6 false false R7.htm 006 - Disclosure - Note 1 - Description of Business, Basis of Presentation and Going Concern Sheet http://cescatherapeutics.com/20200930/role/statement-note-1-description-of-business-basis-of-presentation-and-going-concern Note 1 - Description of Business, Basis of Presentation and Going Concern Notes 7 false false R8.htm 007 - Disclosure - Note 2 - Summary of Significant Accounting Policies Sheet http://cescatherapeutics.com/20200930/role/statement-note-2-summary-of-significant-accounting-policies Note 2 - Summary of Significant Accounting Policies Notes 8 false false R9.htm 008 - Disclosure - Note 3 - Related Party Transactions Sheet http://cescatherapeutics.com/20200930/role/statement-note-3-related-party-transactions Note 3 - Related Party Transactions Notes 9 false false R10.htm 009 - Disclosure - Note 4 - Convertible Promissory Note Sheet http://cescatherapeutics.com/20200930/role/statement-note-4-convertible-promissory-note Note 4 - Convertible Promissory Note Notes 10 false false R11.htm 010 - Disclosure - Note 5 - Leases Sheet http://cescatherapeutics.com/20200930/role/statement-note-5-leases Note 5 - Leases Notes 11 false false R12.htm 011 - Disclosure - Note 6 - Commitments and Contingencies Sheet http://cescatherapeutics.com/20200930/role/statement-note-6-commitments-and-contingencies Note 6 - Commitments and Contingencies Notes 12 false false R13.htm 012 - Disclosure - Note 7 - Stockholders' Equity Sheet http://cescatherapeutics.com/20200930/role/statement-note-7-stockholders-equity Note 7 - Stockholders' Equity Notes 13 false false R14.htm 013 - Disclosure - Note 8 - Major Customers and Accounts Receivable Sheet http://cescatherapeutics.com/20200930/role/statement-note-8-major-customers-and-accounts-receivable Note 8 - Major Customers and Accounts Receivable Notes 14 false false R15.htm 014 - Disclosure - Note 9 - Subsequent Events Sheet http://cescatherapeutics.com/20200930/role/statement-note-9-subsequent-events Note 9 - Subsequent Events Notes 15 false false R16.htm 015 - Disclosure - Significant Accounting Policies (Policies) Sheet http://cescatherapeutics.com/20200930/role/statement-significant-accounting-policies-policies Significant Accounting Policies (Policies) Policies http://cescatherapeutics.com/20200930/role/statement-note-2-summary-of-significant-accounting-policies 16 false false R17.htm 016 - Disclosure - Note 2 - Summary of Significant Accounting Policies (Tables) Sheet http://cescatherapeutics.com/20200930/role/statement-note-2-summary-of-significant-accounting-policies-tables Note 2 - Summary of Significant Accounting Policies (Tables) Tables http://cescatherapeutics.com/20200930/role/statement-note-2-summary-of-significant-accounting-policies 17 false false R18.htm 017 - Disclosure - Note 5 - Leases (Tables) Sheet http://cescatherapeutics.com/20200930/role/statement-note-5-leases-tables Note 5 - Leases (Tables) Tables http://cescatherapeutics.com/20200930/role/statement-note-5-leases 18 false false R19.htm 018 - Disclosure - Note 6 - Commitments and Contingencies (Tables) Sheet http://cescatherapeutics.com/20200930/role/statement-note-6-commitments-and-contingencies-tables Note 6 - Commitments and Contingencies (Tables) Tables http://cescatherapeutics.com/20200930/role/statement-note-6-commitments-and-contingencies 19 false false R20.htm 019 - Disclosure - Note 7 - Stockholders' Equity (Tables) Sheet http://cescatherapeutics.com/20200930/role/statement-note-7-stockholders-equity-tables Note 7 - Stockholders' Equity (Tables) Tables http://cescatherapeutics.com/20200930/role/statement-note-7-stockholders-equity 20 false false R21.htm 020 - Disclosure - Note 1 - Description of Business, Basis of Presentation and Going Concern (Details Textual) Sheet http://cescatherapeutics.com/20200930/role/statement-note-1-description-of-business-basis-of-presentation-and-going-concern-details-textual Note 1 - Description of Business, Basis of Presentation and Going Concern (Details Textual) Details http://cescatherapeutics.com/20200930/role/statement-note-1-description-of-business-basis-of-presentation-and-going-concern 21 false false R22.htm 021 - Disclosure - Note 2 - Summary of Significant Accounting Policies (Details Textual) Sheet http://cescatherapeutics.com/20200930/role/statement-note-2-summary-of-significant-accounting-policies-details-textual Note 2 - Summary of Significant Accounting Policies (Details Textual) Details http://cescatherapeutics.com/20200930/role/statement-note-2-summary-of-significant-accounting-policies-tables 22 false false R23.htm 022 - Disclosure - Note 2 - Summary of Significant Accounting Policies - Revenues (Details) Sheet http://cescatherapeutics.com/20200930/role/statement-note-2-summary-of-significant-accounting-policies-revenues-details Note 2 - Summary of Significant Accounting Policies - Revenues (Details) Details http://cescatherapeutics.com/20200930/role/statement-note-2-summary-of-significant-accounting-policies-tables 23 false false R24.htm 023 - Disclosure - Note 2 - Summary of Significant Accounting Policies - Remaining Performance Obligations (Details) Sheet http://cescatherapeutics.com/20200930/role/statement-note-2-summary-of-significant-accounting-policies-remaining-performance-obligations-details Note 2 - Summary of Significant Accounting Policies - Remaining Performance Obligations (Details) Details 24 false false R25.htm 024 - Disclosure - Note 2 - Summary of Significant Accounting Policies - Remaining Performance Obligations 2 (Details) Sheet http://cescatherapeutics.com/20200930/role/statement-note-2-summary-of-significant-accounting-policies-remaining-performance-obligations-2-details Note 2 - Summary of Significant Accounting Policies - Remaining Performance Obligations 2 (Details) Details 25 false false R26.htm 025 - Disclosure - Note 2 - Summary of Significant Accounting Policies - Anti-dilutive Securities (Details) Sheet http://cescatherapeutics.com/20200930/role/statement-note-2-summary-of-significant-accounting-policies-antidilutive-securities-details Note 2 - Summary of Significant Accounting Policies - Anti-dilutive Securities (Details) Details 26 false false R27.htm 026 - Disclosure - Note 3 - Related Party Transactions (Details Textual) Sheet http://cescatherapeutics.com/20200930/role/statement-note-3-related-party-transactions-details-textual Note 3 - Related Party Transactions (Details Textual) Details http://cescatherapeutics.com/20200930/role/statement-note-3-related-party-transactions 27 false false R28.htm 027 - Disclosure - Note 4 - Convertible Promissory Note (Details Textual) Sheet http://cescatherapeutics.com/20200930/role/statement-note-4-convertible-promissory-note-details-textual Note 4 - Convertible Promissory Note (Details Textual) Details http://cescatherapeutics.com/20200930/role/statement-note-4-convertible-promissory-note 28 false false R29.htm 028 - Disclosure - Note 5 - Leases (Details Textual) Sheet http://cescatherapeutics.com/20200930/role/statement-note-5-leases-details-textual Note 5 - Leases (Details Textual) Details http://cescatherapeutics.com/20200930/role/statement-note-5-leases-tables 29 false false R30.htm 029 - Disclosure - Note 5 - Leases - Lease Information (Details) Sheet http://cescatherapeutics.com/20200930/role/statement-note-5-leases-lease-information-details Note 5 - Leases - Lease Information (Details) Details 30 false false R31.htm 030 - Disclosure - Note 5 - Leases - Maturities of Lease Liabilities (Details) Sheet http://cescatherapeutics.com/20200930/role/statement-note-5-leases-maturities-of-lease-liabilities-details Note 5 - Leases - Maturities of Lease Liabilities (Details) Details 31 false false R32.htm 031 - Disclosure - Note 6 - Commitments and Contingencies (Details Textual) Sheet http://cescatherapeutics.com/20200930/role/statement-note-6-commitments-and-contingencies-details-textual Note 6 - Commitments and Contingencies (Details Textual) Details http://cescatherapeutics.com/20200930/role/statement-note-6-commitments-and-contingencies-tables 32 false false R33.htm 032 - Disclosure - Note 6 - Commitments and Contingencies - Changes in Product Liability Included in Accrued Liabilities (Details) Sheet http://cescatherapeutics.com/20200930/role/statement-note-6-commitments-and-contingencies-changes-in-product-liability-included-in-accrued-liabilities-details Note 6 - Commitments and Contingencies - Changes in Product Liability Included in Accrued Liabilities (Details) Details 33 false false R34.htm 033 - Disclosure - Note 7 - Stockholders' Equity (Details Textual) Sheet http://cescatherapeutics.com/20200930/role/statement-note-7-stockholders-equity-details-textual Note 7 - Stockholders' Equity (Details Textual) Details http://cescatherapeutics.com/20200930/role/statement-note-7-stockholders-equity-tables 34 false false R35.htm 034 - Disclosure - Note 7 - Stockholders' Equity - Stock-based Compensation (Details) Sheet http://cescatherapeutics.com/20200930/role/statement-note-7-stockholders-equity-stockbased-compensation-details Note 7 - Stockholders' Equity - Stock-based Compensation (Details) Details 35 false false R36.htm 035 - Disclosure - Note 7 - Stockholders' Equity - Option Activity for Stock Option Plans (Details) Sheet http://cescatherapeutics.com/20200930/role/statement-note-7-stockholders-equity-option-activity-for-stock-option-plans-details Note 7 - Stockholders' Equity - Option Activity for Stock Option Plans (Details) Details 36 false false R37.htm 036 - Disclosure - Note 7 - Stockholders' Equity - Warrant Activity (Details) Sheet http://cescatherapeutics.com/20200930/role/statement-note-7-stockholders-equity-warrant-activity-details Note 7 - Stockholders' Equity - Warrant Activity (Details) Details 37 false false R38.htm 037 - Disclosure - Note 8 - Major Customers and Accounts Receivable (Details Textual) Sheet http://cescatherapeutics.com/20200930/role/statement-note-8-major-customers-and-accounts-receivable-details-textual Note 8 - Major Customers and Accounts Receivable (Details Textual) Details http://cescatherapeutics.com/20200930/role/statement-note-8-major-customers-and-accounts-receivable 38 false false All Reports Book All Reports thmo-20200930.xml thmo-20200930.xsd thmo-20200930_cal.xml thmo-20200930_def.xml thmo-20200930_lab.xml thmo-20200930_pre.xml http://xbrl.sec.gov/dei/2019-01-31 http://fasb.org/srt/2020-01-31 http://fasb.org/us-gaap/2020-01-31 true true ZIP 54 0001437749-20-023634-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001437749-20-023634-xbrl.zip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end